image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
ab6a760a42658bc9ce805a146a2949577ca54d19d52b33f988209f7235402ea5.png | simple | <table><tr><td> </td><td>AS</td><td>FA</td><td>SS</td><td>AC</td><td>EF</td><td>WO</td><td>CLDQ</td></tr><tr><td>PF</td><td>0.597</td><td>0.762</td><td>0.691</td><td>0.744</td><td>0.636</td><td>0.438</td><td>0.756</td></tr><tr><td>RP</td><td>0.643</td><td>0.717</td><td>0.646</td><td>0.667</td><td>0.614</td><td>0.480</td><td>0.735</td></tr><tr><td>BP</td><td>0.662</td><td>0.763</td><td>0.702</td><td>0.686</td><td>0.660</td><td>0.475</td><td>0.776</td></tr><tr><td>GH</td><td>0.595</td><td>0.614</td><td>0.563</td><td>0.546</td><td>0.586</td><td>0.538</td><td>0.676</td></tr><tr><td>VT</td><td>0.648</td><td>0.846</td><td>0.727</td><td>0.608</td><td>0.798</td><td>0.560</td><td>0.825</td></tr><tr><td>SF</td><td>0.667</td><td>0.799</td><td>0.759</td><td>0.697</td><td>0.726</td><td>0.536</td><td>0.825</td></tr><tr><td>RE</td><td>0.572</td><td>0.702</td><td>0.589</td><td>0.568</td><td>0.666</td><td>0.496</td><td>0.708</td></tr><tr><td>MH</td><td>0.598</td><td>0.778</td><td>0.655</td><td>0.524</td><td>0.824</td><td>0.506</td><td>0.771</td></tr></table> |
e846d7b711f36c6af1b5e1ab78a71b8d488b1d0e84d4a0a0c018c3e5cb57acda.png | simple | <table><tr><td>CNVs</td><td>Copy numbers</td><td>Related genes</td><td>Related pathways</td></tr><tr><td>rs2002594; rs1986617</td><td>1</td><td>FAM162A</td><td>Mitochondrial apoptotic cascades</td></tr><tr><td>rs10517547; rs10517548; rs2122642; rs2345041; rs1823535; rs1823536; rs1470724</td><td>1</td><td>LPHN3</td><td>G-protein-coupled-receptor proteolysis</td></tr><tr><td>rs764223</td><td>1</td><td>PGAM1</td><td>Glycolysis/gluconeogenesis; metabolism of carbohydrates</td></tr><tr><td>rs137964; rs10483201</td><td>1</td><td>GRAP2</td><td>T cell receptor signaling pathway</td></tr><tr><td>rs10491333</td><td>4</td><td>HLA-DQB1</td><td>Antigen processing and presentation</td></tr><tr><td>rs2895201</td><td>4</td><td>SPTLC1</td><td>Sphingolipid metabolism</td></tr><tr><td>rs1988981; rs1321555; rs1358815; rs1964875;</td><td>4</td><td>PRIM2</td><td>Purine and pyrimidine metabolism; telomere maintenance</td></tr><tr><td>rs3797819; rs10515399; rs1896582; rs1366081; rs9326759</td><td>4</td><td>FER</td><td>Adherens junction</td></tr><tr><td>rs342597; rs10507638; rs10507639</td><td>3</td><td>DIAPH3</td><td>Regulation of actin cytoskeleton</td></tr><tr><td>rs10520675; rs10520671; rs7167737; rs1948066; rs10520673; rs965313</td><td>3</td><td>NTRK3</td><td>MAPK pathway</td></tr><tr><td>rs6816712; rs2911940; rs10517654; rs10517655; rs7662187; rs10517658</td><td>3</td><td>PDGFC</td><td>Cytokine-cytokine receptor interaction; Focal adhesion; Gap junction</td></tr><tr><td>rs855858; rs855860; rs10489736</td><td>3</td><td>ROR1</td><td>transmembrane receptor protein tyrosine kinase signaling pathway</td></tr><tr><td>rs2912</td><td>3</td><td>GAB2</td><td>Fc epsilon RI signaling pathway</td></tr><tr><td>rs10491050; rs7092874; rs7904118</td><td>3</td><td>SORCS1</td><td>neuropeptide signaling pathway</td></tr><tr><td>rs10485060; rs9322451; rs1852629</td><td>3</td><td>OPRM1</td><td>Neuroactive ligand-receptor interaction</td></tr><tr><td>rs1060447; rs4919231; rs1932796; rs716838; rs2169462; rs10509722</td><td>3</td><td>HPSE2</td><td>Glycosaminoglycan degradation</td></tr></table> |
2511a5f77900e871a37c5f222e7dda045f555585bebd743a3f925bf7518fd09e.png | simple | <table><tr><td>Gene symbol</td><td>Description</td><td>Position (Mb)</td><td>MiRNA</td><td>Packages</td></tr><tr><td><i>RNF111</i></td><td>Ring Finger Protein 111</td><td>6.32–6.36</td><td>miR-142-3p</td><td>Targetscan</td></tr><tr><td><i>TCF12</i></td><td>transcription factor 12</td><td>6.90–7.00</td><td>miR-142-5p</td><td>MIRDB, TargetscanPicTar</td></tr><tr><td><i>ARPP19</i></td><td>cAMP–regulated phosphoprotein, 19 kDa</td><td>8.23–8.24</td><td>miR-142-5p</td><td>Targentscan</td></tr><tr><td><i>MYO5A</i></td><td>myosin VA (heavy chain 12, myoxin)</td><td>8.24–8.33</td><td>miR-142-3p</td><td>Targentscan</td></tr><tr><td><i>MAPK6</i></td><td>Mitogen–Activated Protein Kinase 6</td><td>8.42– 8.45</td><td>miR-142-5p</td><td>Targentscan</td></tr></table> |
8033eba3598a07097a50c8fe38db2ac03eb56f5eaf90debf3adebf00784bb9bc.png | complex | <table><tr><td rowspan="2">Compounds</td><td colspan="2">Bradykinin <sup>a</sup></td><td colspan="2">Renin substrate tetra-decapeptide <sup>a</sup></td></tr><tr><td>S/N</td><td>Sig. Int.</td><td>S/N</td><td>Sig. Int.</td></tr><tr><td>1</td><td>711</td><td>56530</td><td>551</td><td>47162</td></tr><tr><td>2</td><td>540</td><td>23276</td><td>423</td><td>23276</td></tr><tr><td>3</td><td>547</td><td>61687</td><td>228</td><td>23778</td></tr><tr><td>4</td><td>447</td><td>64184</td><td>205</td><td>50958</td></tr><tr><td>5</td><td>965</td><td>179163</td><td>579</td><td>39417</td></tr><tr><td>6</td><td>612</td><td>73058</td><td>450</td><td>40258</td></tr><tr><td>7</td><td>403</td><td>98986</td><td>586</td><td>132521</td></tr><tr><td>8</td><td>710</td><td>105850</td><td>689</td><td>68272</td></tr><tr><td>9</td><td>148</td><td>254785</td><td>435</td><td>32688</td></tr><tr><td>10</td><td>250</td><td>38696</td><td>411</td><td>59285</td></tr><tr><td>11</td><td>568</td><td>129858</td><td>361</td><td>80878</td></tr><tr><td>12</td><td>524</td><td>157277</td><td>360</td><td>144048</td></tr><tr><td>13</td><td>548</td><td>58187</td><td>620</td><td>105141</td></tr><tr><td>14</td><td>520</td><td>131703</td><td>668</td><td>127967</td></tr><tr><td>15</td><td>612</td><td>17858</td><td>402</td><td>55811</td></tr><tr><td>16</td><td>369</td><td>24724</td><td>463</td><td>65700</td></tr><tr><td>17</td><td>250</td><td>57522</td><td>432</td><td>81912</td></tr><tr><td>18</td><td>332</td><td>101983</td><td>299</td><td>61957</td></tr><tr><td>19</td><td>294</td><td>55402</td><td>200</td><td>13615</td></tr><tr><td>20</td><td>286</td><td>13022</td><td>514</td><td>14110</td></tr><tr><td>21</td><td>244</td><td>53297</td><td>446</td><td>36294</td></tr><tr><td>22</td><td>427</td><td>88683</td><td>642</td><td>101135</td></tr><tr><td>23</td><td>455</td><td>85541</td><td>650</td><td>53205</td></tr><tr><td>24</td><td>328</td><td>11451</td><td>519</td><td>81163</td></tr><tr><td>25</td><td>850</td><td>16992</td><td>574</td><td>85517</td></tr><tr><td>26</td><td>402</td><td>14593</td><td>436</td><td>79334</td></tr><tr><td>27</td><td>370</td><td>26798</td><td>444</td><td>66542</td></tr><tr><td>28</td><td>202</td><td>10398</td><td>221</td><td>13736</td></tr><tr><td>29</td><td>727</td><td>115238</td><td>309</td><td>124664</td></tr><tr><td>30</td><td>708</td><td>10452</td><td>125</td><td>16030</td></tr><tr><td>31</td><td>806</td><td>89386</td><td>66</td><td>18759</td></tr><tr><td>HCCA</td><td>832</td><td>86824</td><td>792</td><td>147702</td></tr></table> |
58f398f6ee0a00bf8770fb1efbfd95ec1accfce37df7c0356e622d638f21f22b.png | simple | <table><tr><td>Variable</td><td>Number</td><td>Percentage</td></tr><tr><td>Intravenous drug users</td><td>20</td><td>5.8</td></tr><tr><td>Surgery</td><td>144</td><td>41.6</td></tr><tr><td>Blood transfusion</td><td>40</td><td>11.6</td></tr><tr><td>Transplantation</td><td>1</td><td>0.3</td></tr><tr><td>History of hepatitis in the family</td><td>186</td><td>53.8</td></tr><tr><td>Uterine curettage</td><td>12</td><td>11.9<sup>a</sup></td></tr><tr><td>Dialysis</td><td>13</td><td>3.8</td></tr><tr><td>Dental manipulation</td><td>292</td><td>84.4</td></tr><tr><td>Tattoo</td><td>54</td><td>15.6</td></tr><tr><td>Ear Piercing</td><td>91</td><td>26.3</td></tr><tr><td>Circumcision</td><td>243</td><td>99.2<sup>b</sup></td></tr><tr><td>High-risk sex</td><td>6</td><td>1.7</td></tr><tr><td>Phlebotomy</td><td>60</td><td>17.3</td></tr></table> |
a98ce093ae9dcefec13920c93c5d6837db621bf6b4b34e3c4d522b9192b7d870.png | complex | <table><tr><td>Variables</td><td colspan="2">Univariate analysis</td><td></td><td colspan="2">Model 1</td><td></td><td colspan="2">Model 2</td></tr><tr><td></td><td>HR (95%CI)</td><td><i>p</i> value</td><td></td><td>HR (95%CI)</td><td><i>p</i> value</td><td></td><td>HR (95%CI)</td><td><i>p</i> value</td></tr><tr><td>Age (years)</td><td>1.1 (1.0-1.1)</td><td>0.011</td><td></td><td>1.0 (1.0-1.1)</td><td>0.191</td><td></td><td>1.0 (1.0-1.1)</td><td>0.195</td></tr><tr><td>Sex (1 = male, 2 = female)</td><td>0.7 (0.4-1.1)</td><td>0.130</td><td></td><td>0.5 (0.3-1.1)</td><td>0.089</td><td></td><td>0.7 (0.3-1.3)</td><td>0.262</td></tr><tr><td>TC (mmol/L)</td><td>1.3 (1.0-1.7)</td><td>0.087</td><td></td><td>1.2 (0.9-1.7)</td><td>0.161</td><td></td><td>1.2 (0.9-1.6)</td><td>0.213</td></tr><tr><td>Elevated WC</td><td>3.1 (1.9-5.3)</td><td>< 0.001</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Elevated TG</td><td>2.3 (1.3-4.0)</td><td>0.004</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Elevated BP</td><td>1.9 (1.1-3.2)</td><td>0.017</td><td></td><td>1.5 (0.8-2.5)</td><td>0.172</td><td></td><td></td><td></td></tr><tr><td>Reduced HDL-C</td><td>1.4 (0.9-2.4)</td><td>0.142</td><td></td><td>1.8 (1.1-3.0)</td><td>0.032</td><td></td><td></td><td></td></tr><tr><td>Smoking</td><td>1.4 (0.9-2.3)</td><td>0.169</td><td></td><td>1.5 (0.8-2.8)</td><td>0.226</td><td></td><td>1.5 (0.8-2.7)</td><td>0.251</td></tr><tr><td>HTGW</td><td>3.8 (2.2-6.5)</td><td>< 0.001</td><td></td><td>3.9 (2.2-7.0)</td><td>< 0.001</td><td></td><td></td><td></td></tr><tr><td>MetS</td><td>3.4 (2.0-5.9)</td><td>< 0.001</td><td></td><td></td><td></td><td></td><td>3.7 (2.1-6.6)</td><td>< 0.001</td></tr></table> |
43efdb13f7b7070e4a3c8feba82a46f30cb8e4e1809a457c781ab48eaeda9aad.png | complex | <table><tr><td> </td><td colspan="2">Perprotocol</td><td colspan="2">Intention to treat</td></tr><tr><td> </td><td>Odds ratio (95% CI)</td><td><i>P</i> value</td><td>Odds ratio (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <60 years old</td><td>1.0 (referent)</td><td> </td><td>1.0 (referent)</td><td> </td></tr><tr><td> ≥60 years old</td><td>1.33 (0.61–2.92)</td><td>0.478</td><td>1.16 (0.55–2.47)</td><td>0.696</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>1.0 (referent)</td><td> </td><td>1.0 (referent)</td><td> </td></tr><tr><td> Female</td><td>1.14 (0.53–2.46)</td><td>0.737</td><td>1.18 (0.57–2.44)</td><td>0.648</td></tr><tr><td>Resident area</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Urban</td><td>1.0 (referent)</td><td> </td><td>1.0 (referent)</td><td> </td></tr><tr><td> Rural</td><td>1.49 (0.65–3.42)</td><td>0.342</td><td>1.12 (0.53–2.37)</td><td>0.775</td></tr><tr><td>Endoscopic finding</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> With peptic ulcer</td><td>1.0 (referent)</td><td> </td><td>1.0 (referent)</td><td> </td></tr><tr><td> Without peptic ulcer</td><td>1.05 (0.48–2.26)</td><td>0.909</td><td>1.05 (0.51–2.16)</td><td>0.900</td></tr><tr><td>Treatment</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> CAR</td><td>1.0 (referent)</td><td> </td><td>1.0 (referent)</td><td> </td></tr><tr><td> LAcR</td><td>2.67 (1.22–5.84)</td><td>0.014*</td><td>2.57 (1.24–5.33)</td><td>0.011*</td></tr></table> |
0d2884efc9475302b77f01b300ca00e895bb66acc643cb9e65039548023e7ca4.png | simple | <table><tr><td> </td><td>σ (MPa)</td><td><i>STD</i></td><td><sub><i>λ</i></sub></td><td><i>STD</i></td></tr><tr><td>SV- Longitudinal</td><td>5.38</td><td>0.6</td><td>1.32</td><td>0.04</td></tr><tr><td>SV- Circumferential</td><td>2.61</td><td>0.67</td><td>1.55</td><td>0.06</td></tr><tr><td>UV- Longitudinal</td><td>1.65</td><td>0.11</td><td>1.33</td><td>0.04</td></tr><tr><td>UV- Circumferential</td><td>0.97</td><td>0.19</td><td>1.90</td><td>0.16</td></tr></table> |
0dfdd110ff0283a2db9a0e580b711d5df8a59223f4340ee75107809e2cd8c107.png | complex | <table><tr><td>Platform</td><td colspan="6">System</td><td colspan="7">Applications</td></tr><tr><td></td><td>IMU</td><td>GPS</td><td>LIDAR</td><td>Camera</td><td>DG payload weights</td><td>Cost</td><td>Large area</td><td>Small area</td><td>Mobility</td><td>Weather limitation</td><td>DG accuracy (3DRMS)</td><td>Cyber city</td><td>Rapid Disaster Relief</td></tr><tr><td>Fixed wing aircraft</td><td>Tactical grade</td><td>Geodetic grade</td><td>Yes</td><td>Digital/film</td><td>> 50 kg</td><td>High</td><td>Yes</td><td>Yes</td><td>Low</td><td>High</td><td>< 20 cm</td><td>Yes</td><td>Low</td></tr><tr><td>Helicopter</td><td>Tactical grade</td><td>Geodetic grade</td><td>Yes</td><td>Digital</td><td>> 50 kg</td><td>High</td><td>No</td><td>Yes</td><td>Low</td><td>High</td><td>< 20 cm</td><td>Yes</td><td>Low</td></tr><tr><td>UAV</td><td>MEMS</td><td>L1 phase</td><td>Yes</td><td>Digital</td><td>< 25 kg</td><td>Low</td><td>No</td><td>Yes</td><td>High</td><td>Low</td><td>< 50 cm</td><td>Yes</td><td>High</td></tr><tr><td>UAV Helicopter</td><td>MEMS</td><td>L1 phase</td><td>Yes</td><td>Digital</td><td>< 10 kg</td><td>Low</td><td>No</td><td>Yes</td><td>High</td><td>Low</td><td>< 50 cm</td><td>Yes</td><td>High</td></tr></table> |
8e3dfd8ae9d185571aa6fdc80f58d59fc7693710d1965ea81cb81606ee0b065c.png | simple | <table><tr><td></td><td>N voxels</td><td>Gray Matter</td><td>White Matter</td><td>CSF</td><td>MD</td><td>axial</td><td>FA</td><td>FW</td><td>radial</td></tr><tr><td>CSF</td><td>117049</td><td>0.1321 ± 0.2485</td><td>0.0044 ± 0.0423</td><td>0.7580 ± 0.2926</td><td>0.0018 ± 0.0009</td><td>0.0022 ± 0.0011</td><td>0.2046 ± 0.1257</td><td>0.4511 ± 0.2221</td><td>0.0015 ± 0.0008</td></tr><tr><td>Gray matter</td><td>256549</td><td>0.7724 ± 0.2988</td><td>0.1024 ± 0.2260</td><td>0.1206 ± 0.2451</td><td>0.0009 ± 0.0004</td><td>0.0011 ± 0.0004</td><td>0.2208 ± 0.1053</td><td>0.2302 ± 0.1050</td><td>0.0008 ± 0.0003</td></tr><tr><td>White matter</td><td>162773</td><td>0.1119 ± 0.2301</td><td>0.8808 ± 0.2417</td><td>0.0055 ± 0.0483</td><td>0.0007 ± 0.0002</td><td>0.0010 ± 0.0003</td><td>0.4226 ± 0.1441</td><td>0.1397 ± 0.0519</td><td>0.0005 ± 0.0002</td></tr><tr><td>Left Hippocampus</td><td>1359</td><td>0.8438 ± 0.2672</td><td>0.0368 ± 0.1349</td><td>0.1176 ± 0.2425</td><td>0.0011 ± 0.0004</td><td>0.0013 ± 0.0005</td><td>0.2265 ± 0.0919</td><td>0.2734 ± 0.1055</td><td>0.0009 ± 0.0003</td></tr><tr><td>Right Hippocampus</td><td>1457</td><td>0.8541 ± 0.2610</td><td>0.0287 ± 0.1135</td><td>0.1153 ± 0.2435</td><td>0.0011 ± 0.0004</td><td>0.0013 ± 0.0005</td><td>0.2248 ± 0.0895</td><td>0.2734 ± 0.1079</td><td>0.0009 ± 0.0004</td></tr><tr><td>Left MOG middle occipital gyrus</td><td>2659</td><td>0.6734 ± 0.3550</td><td>0.1602 ± 0.2997</td><td>0.1601 ± 0.2873</td><td>0.0010 ± 0.0004</td><td>0.0012 ± 0.0005</td><td>0.2101 ± 0.1020</td><td>0.2562 ± 0.1217</td><td>0.0009 ± 0.0004</td></tr><tr><td>Right MOG middle occipital gyrus</td><td>2263</td><td>0.6738 ± 0.3535</td><td>0.1454 ± 0.2868</td><td>0.1650 ± 0.2829</td><td>0.0010 ± 0.0004</td><td>0.0012 ± 0.0005</td><td>0.2145 ± 0.0964</td><td>0.2514 ± 0.1085</td><td>0.0009 ± 0.0003</td></tr><tr><td>Left PCgG posterior cingulate gyrus</td><td>1877</td><td>0.6969 ± 0.3493</td><td>0.0877 ± 0.2133</td><td>0.2120 ± 0.3323</td><td>0.0009 ± 0.0004</td><td>0.0011 ± 0.0004</td><td>0.2052 ± 0.0952</td><td>0.2551 ± 0.1095</td><td>0.0009 ± 0.0003</td></tr><tr><td>Right PCgG posterior cingulate gyrus</td><td>1648</td><td>0.7383 ± 0.3210</td><td>0.1020 ± 0.2264</td><td>0.1571 ± 0.2851</td><td>0.0009 ± 0.0003</td><td>0.0011 ± 0.0004</td><td>0.2109 ± 0.0925</td><td>0.2411 ± 0.1024</td><td>0.0008 ± 0.0003</td></tr><tr><td>Left Cerebellum White Matter</td><td>4948</td><td>0.1392 ± 0.2664</td><td>0.8237 ± 0.3130</td><td>0.0351 ± 0.1613</td><td>0.0007 ± 0.0004</td><td>0.0011 ± 0.0005</td><td>0.4411 ± 0.1507</td><td>0.1454 ± 0.1007</td><td>0.0006 ± 0.0003</td></tr><tr><td>Right Cerebellum White Matter</td><td>4847</td><td>0.1114 ± 0.2261</td><td>0.8635 ± 0.2663</td><td>0.0232 ± 0.1201</td><td>0.0007 ± 0.0003</td><td>0.0011 ± 0.0004</td><td>0.4468 ± 0.1464</td><td>0.1409 ± 0.0853</td><td>0.0005 ± 0.0003</td></tr><tr><td>Left SPL superior parietal lobule</td><td>5225</td><td>0.4955 ± 0.3931</td><td>0.1335 ± 0.2805</td><td>0.3621 ± 0.4095</td><td>0.0012 ± 0.0006</td><td>0.0014 ± 0.0006</td><td>0.1998 ± 0.1109</td><td>0.3220 ± 0.1774</td><td>0.0011 ± 0.0006</td></tr><tr><td>Right SPL superior parietal lobule</td><td>5249</td><td>0.4720 ± 0.3950</td><td>0.1138 ± 0.2588</td><td>0.4024 ± 0.4178</td><td>0.0012 ± 0.0006</td><td>0.0014 ± 0.0006</td><td>0.1946 ± 0.1034</td><td>0.3375 ± 0.1779</td><td>0.0011 ± 0.0006</td></tr><tr><td>Left Pallidum</td><td>559</td><td>0.0347 ± 0.0905</td><td>0.9609 ± 0.0963</td><td>0.0012 ± 0.0059</td><td>0.0007 ± 0.0001</td><td>0.0010 ± 0.0001</td><td>0.4009 ± 0.1427</td><td>0.1375 ± 0.0397</td><td>0.0005 ± 0.0001</td></tr><tr><td>Right Pallidum</td><td>564</td><td>0.0253 ± 0.0744</td><td>0.9700 ± 0.0816</td><td>0.0014 ± 0.0064</td><td>0.0007 ± 0.0001</td><td>0.0010 ± 0.0001</td><td>0.4259 ± 0.1499</td><td>0.1334 ± 0.0401</td><td>0.0005 ± 0.0001</td></tr><tr><td>Left PP planum polare</td><td>893</td><td>0.6095 ± 0.3765</td><td>0.0095 ± 0.0515</td><td>0.3775 ± 0.3801</td><td>0.0012 ± 0.0005</td><td>0.0014 ± 0.0006</td><td>0.1715 ± 0.0639</td><td>0.3357 ± 0.1390</td><td>0.0011 ± 0.0005</td></tr><tr><td>Right PP planum polare</td><td>783</td><td>0.5859 ± 0.3846</td><td>0.0048 ± 0.0288</td><td>0.4054 ± 0.3861</td><td>0.0013 ± 0.0006</td><td>0.0015 ± 0.0007</td><td>0.1688 ± 0.0584</td><td>0.3628 ± 0.1516</td><td>0.0012 ± 0.0005</td></tr></table> |
94f93407cf4152a63b2a7c6d1f8fd9a26a79f9897e39955b793846cc0bae489d.png | complex | <table><tr><td rowspan="2">Factors</td><td colspan="3">ANC</td><td colspan="3">Delivery</td></tr><tr><td colspan="3">N = 315</td><td colspan="3">N = 315</td></tr><tr><td></td><td>AOR (95% CI)</td><td>P-value<sup>*</sup></td><td>P-value<sup>**</sup></td><td>AOR (95% CI)</td><td>P-value<sup>*</sup></td><td>P-value<sup>**</sup></td></tr><tr><td>Age group of women: ref. = Teens</td><td></td><td></td><td><0.001</td><td></td><td></td><td>0.002</td></tr><tr><td>Young adults</td><td>2.12 (1.18,3.79)</td><td>0.01</td><td></td><td>1.54 (0.81,2.93)</td><td>0.2</td><td></td></tr><tr><td>Adults</td><td>3.14 (1.76,5.63)</td><td><0.001</td><td></td><td>2.9 (1.56,5.38)</td><td><0.001</td><td></td></tr><tr><td>Ethnicity of women: ref. = Indigenous Non-Indigenous</td><td>1.77 (1.11,2.83)</td><td>0.02</td><td>0.02</td><td>1.71 (1.04,2.8)</td><td>0.03</td><td>0.03</td></tr><tr><td>Referral status: ref. = Referred Not referred</td><td></td><td></td><td></td><td>3.77 (1.27,11.15)</td><td>0.02</td><td>0.006</td></tr></table> |
a208841c966cab6abf3e19feb4bacf05e2e3660d5e87fc86ef22af07cb66e18d.png | simple | <table><tr><td></td><td>Recipient</td><td>Donor</td></tr><tr><td>Male (%)</td><td>37 (74%)</td><td>36 (72%)</td></tr><tr><td>Female (%)</td><td>13 (26%)</td><td>14 (28%)</td></tr><tr><td>Age (yrs)</td><td>51.3 ± 11.1 (16 - 67)</td><td>53.2 ± 17.2 (19 - 86)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.7 ± 4.73 (16.6 - 42.9)</td><td>24.3 ± 3.3 (16.0- 31.0)</td></tr><tr><td>MELD</td><td>21 ± 10.4 (6 - 40)</td><td></td></tr><tr><td>RRT before TPL (%)</td><td>8 (16%)</td><td></td></tr><tr><td>HRS before TPL (%)</td><td>17 (34%)</td><td></td></tr><tr><td>SAPS II</td><td>30 ± 19 (0 - 91)</td><td></td></tr><tr><td>Creatinine (μmol/l)</td><td>121 ± 117 (40 - 814)</td><td></td></tr><tr><td>Hematocrit (%)</td><td>31.4 ± 7.6 (18.8 - 49.6)</td><td></td></tr><tr><td>Platelets (10<sup>3</sup>/μl)</td><td>106 ± 65 (33 - 324)</td><td></td></tr><tr><td>INR</td><td>1.5 ± 0.6 (0.9 - 4.3)</td><td></td></tr><tr><td>Bilirubin (μmol/l)</td><td>148 ± 198 (5 - 875)</td><td></td></tr><tr><td>Etiology of liver disease</td><td></td><td></td></tr><tr><td> HCV (%)</td><td>17 (34%)</td><td></td></tr><tr><td> HBV (%)</td><td>3 (6%)</td><td></td></tr><tr><td> HCC (%)</td><td>10 (20%)</td><td></td></tr><tr><td> Alcoholic liver cirrhosis (%)</td><td>6 (12%)</td><td></td></tr><tr><td> Cholangiocarcinoma (%)</td><td>2 (4%)</td><td></td></tr><tr><td> Others<sup>1</sup> (%)</td><td>12 (24%)</td><td></td></tr><tr><td>Cadaveric Donor (%)</td><td></td><td>44 (88%)</td></tr><tr><td>Living Donor (%)</td><td></td><td>6 (12%)</td></tr><tr><td>Extended donor graft criteria (%)</td><td></td><td>16 (32%)</td></tr></table> |
1909e8ec8fa321238d89b5b3ffaffa5bab0ff3572d8f612275431d2e2c39f90a.png | complex | <table><tr><td> </td><td colspan="2">No. of points</td></tr><tr><td>Risk factor</td><td>SITS SICH risk score</td><td>Extended risk score</td></tr><tr><td>Aspirin + clopidogrel</td><td>3</td><td>3</td></tr><tr><td>Aspirin monotherapy</td><td>2</td><td>2</td></tr><tr><td>NIHSS ≥13</td><td>2</td><td>2</td></tr><tr><td>NIHSS 7-12</td><td>1</td><td>1</td></tr><tr><td>Blood glucose ≥180 mg/dL</td><td>2</td><td>2</td></tr><tr><td>Age ≥72 y</td><td>1</td><td>1</td></tr><tr><td>Systolic blood pressure ≥146 mm Hg</td><td>1</td><td>1</td></tr><tr><td>Weight ≥95 kg</td><td>1</td><td>1</td></tr><tr><td>Onset-to-treatment time ≥180 min</td><td>1</td><td>1</td></tr><tr><td>History of hypertension</td><td>1</td><td>1</td></tr><tr><td>Total anterior circulation infarct</td><td>N/A</td><td>3</td></tr><tr><td>Maximal total points</td><td>12</td><td>15*</td></tr></table> |
002f6ac944299a46ab1e94ec1c99f5c9cd7a27237f9fdc25f1b8e09b1110b163.png | complex | <table><tr><td rowspan="2">Variable</td><td colspan="2">Level of knowledge</td><td rowspan="2">COR (95% CI)</td><td rowspan="2">AOR (95% CI)</td></tr><tr><td>Adequate</td><td>Inadequate</td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 15–24</td><td>53 (57%)</td><td>40 (43%)</td><td><i>4.711 (2.022, 10.976)</i></td><td>1.253 (0.364, 4.319)</td></tr><tr><td> 25–35</td><td>115 (64.2%)</td><td>64 (35.8%)</td><td><i>6.389 (2.870, 14.221)</i></td><td>2.740 (1.000, 7.502)</td></tr><tr><td> 36–45</td><td>31 (54.4%)</td><td>26 (45.6%)</td><td><i>4.239 (1.715, 10.476)</i></td><td>1.950 (0.678, 5.606)</td></tr><tr><td> >45</td><td>9 (22%)</td><td>32 (78%)</td><td>1.00</td><td>1.00</td></tr><tr><td>Marital status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Married</td><td>190 (59.6%)</td><td>129 (40.4%)</td><td>1.00</td><td>1.00</td></tr><tr><td> Single</td><td>6 (31.6%)</td><td>13 (68.4%)</td><td><i>0.313 (0.116, 0.846)</i></td><td>0.548 (0.104, 2.893)</td></tr><tr><td> Widowed</td><td>2 (20%)</td><td>8 (80%)</td><td><i>0.170 (0.035, 0.812)</i></td><td>0.498 (0.054, 4.580)</td></tr><tr><td> Divorced</td><td>10 (45.5%)</td><td>12 (54.5%)</td><td>0.566 (0.237, 1.348)</td><td>0.685 (0.169, 2.768)</td></tr><tr><td>Educational status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Illiterate</td><td>87 (40.1%)</td><td>130 (59.9%)</td><td>1.00</td><td>1.00</td></tr><tr><td> Primary (1–8)</td><td>32 (57.1%)</td><td>24 (42.9%)</td><td><i>1.992 (1.099, 3.612)</i></td><td><i>5.384 (2.008, 14.435</i>)<sup><i>∗</i></sup></td></tr><tr><td> Secondary and above</td><td>89 (91.6%)</td><td>8 (8.4%)</td><td><i>16.624 (7.676, 36)</i></td><td><i>11.769 (3.527, 39.275</i>)<sup><i>∗</i></sup></td></tr><tr><td>Occupational status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Housewife</td><td>123 (50.8%)</td><td>119 (49.2%)</td><td>1.00</td><td>1.00</td></tr><tr><td>Government emp<sup><i>∗</i></sup></td><td>61 (98.4%)</td><td>1 (1.6%)</td><td><i>59.016 (8.051, 432.587)</i></td><td>5.037 (0.516, 49.207)</td></tr><tr><td> Private employee</td><td>5 (41.7%)</td><td>7 (58.3%)</td><td>0.691 (0.213, 2.238)</td><td>0.245 (0.036, 1.680)</td></tr><tr><td> Daily laborer</td><td>10 (28.6%)</td><td>25 (71.4%)</td><td><i>0.387 (0.178, 0.840)</i></td><td><i>0.208 (0.054, 0.810</i>)<sup><i>∗</i></sup></td></tr><tr><td> Merchant</td><td>9 (64.3%)</td><td>5 (35.7%)</td><td>1.741 (0.567, 5.347)</td><td>0.441 (0.113, 1.728)</td></tr><tr><td> Farmer</td><td>2 (40%)</td><td>3 (60%)</td><td>0.644 (0.243, 3.952)</td><td>0.379 (0.186, 1.962)</td></tr><tr><td>Number of children</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 1-2</td><td>149 (63.1%)</td><td>87 (36.9%)</td><td>1.00</td><td>1.00</td></tr><tr><td> 3-4</td><td>55 (46.6%)</td><td>63 (53.4%)</td><td><i>0.510 (0.326, 0.798)</i></td><td>1.141 (0.560, 2.322)</td></tr><tr><td> >4</td><td>4 (25%)</td><td>12 (75%)</td><td><i>0.195 (0.061, 0.622)</i></td><td>0.609 (0.138, 2.688)</td></tr><tr><td>Information about diarrhea</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No information</td><td>6 (12.8%)</td><td>41 (87.2%)</td><td><i>0.088 (0.036, 0.213)</i></td><td><i>0.139 (0.054, 0.354</i>)<sup><i>∗</i></sup></td></tr><tr><td> Have information</td><td>202 (62.5%)</td><td>121 (37.5%)</td><td>1.00</td><td>1.00</td></tr></table> |
a5162ee77a6b42d28d3df1d309a4652f5689c6f288b1b0e690313ab895f19c5a.png | complex | <table><tr><td rowspan="2"></td><td>IL-1</td><td>IL-6</td><td>TNF-α</td><td>IL-10</td><td>TGF-β1</td></tr><tr><td colspan="5">pg/mg</td></tr><tr><td>NC</td><td>10.3 ± 1.2 *</td><td>12.5 ± 2.1 *</td><td>20.7 ± 2.3 *</td><td>265.8 ± 17.9</td><td>16.4 ± 1.8</td></tr><tr><td>SS24</td><td>92.6 ± 4.5</td><td>1275.6 ± 18.3</td><td>80.4 ± 3.4</td><td>235.8 ± 4.1</td><td>12.8 ± 1.6</td></tr><tr><td>SA24</td><td>44.3 ± 2.6 <sup>#</sup></td><td>662.3 ± 13.5 <sup>#</sup></td><td>42.9 ± 1.9 <sup>#</sup></td><td>367.8 ± 9.2 <sup>#</sup></td><td>55.3 ± 2.6 <sup>#</sup></td></tr><tr><td>SS48</td><td>83.2 ± 5.4</td><td>834.3 ± 17.3</td><td>67.8 ± 3.6</td><td>214.2 ± 5.6</td><td>16.6 ± 5.6</td></tr><tr><td>SA48</td><td>32.3 ± 2.3 <sup>#</sup></td><td>385.4 ± 12.8 <sup>#</sup></td><td>38.8 ± 3.2 <sup>#</sup></td><td>229.4 ± 7.7</td><td>22.4 ± 3.4</td></tr></table> |
7e44d073201f65a4fb00b65e8f860671fa8b5b87427882f2e0784e99177c672e.png | complex | <table><tr><td>Treatment</td><td>Flume number</td><td>Field name</td></tr><tr><td>Sustainable intensification</td><td>6</td><td>Golden Rove</td></tr><tr><td rowspan="2">Increased use of legumes</td><td>8</td><td>Higher Wyke Moor and Middle Wyke Moor (reseeding in 2013)</td></tr><tr><td>11</td><td>Dairy East</td></tr><tr><td rowspan="2">Planned reseeding</td><td>10</td><td>Lower Wheaty</td></tr><tr><td>15</td><td>Longlands East (reseeding in 2013)</td></tr></table> |
b5c26992ea8abefba4ab097d94b16db1a2f43d222a27d46ef5d343f2fcbf8b29.png | simple | <table><tr><td>Characteristics</td><td>Count (%)</td></tr><tr><td>Sociodemographic</td><td> </td></tr><tr><td> Gender</td><td> </td></tr><tr><td>Male</td><td>98 (65.3)</td></tr><tr><td>Female</td><td>52 (34.7)</td></tr><tr><td> Age (years)</td><td> </td></tr><tr><td>20–30</td><td>80 (53.3)</td></tr><tr><td>31–40</td><td>48 (32.0)</td></tr><tr><td>41–50</td><td>22 (14.7)</td></tr><tr><td> Education level</td><td> </td></tr><tr><td>Vocational school</td><td>58 (38.7)</td></tr><tr><td>Diploma or equivalent</td><td>62 (41.3)</td></tr><tr><td>Bachelor degree or higher</td><td>30 (20.0)</td></tr><tr><td> Monthly income (Baht)</td><td> </td></tr><tr><td><9000</td><td>96 (64.0)</td></tr><tr><td>≥9000</td><td>54 (36.0)</td></tr><tr><td>Behavioral</td><td> </td></tr><tr><td> Smoke cigarettes</td><td> </td></tr><tr><td>No</td><td>70 (46.7)</td></tr><tr><td>Yes</td><td>80 (53.3)</td></tr><tr><td> Drink alcohol</td><td> </td></tr><tr><td>No</td><td>86 (57.3)</td></tr><tr><td>Yes</td><td>64 (42.7)</td></tr></table> |
e2615be9ada0aa4ca0c92f4a685ee175c237987fa073ef611ddffc4a347183eb.png | complex | <table><tr><td>Variable</td><td colspan="3"><i>PIK3CA </i>mutations (n = 113)</td><td colspan="3"><i>PIK3CA </i>amplification (n = 131)</td></tr><tr><td></td><td>Yes</td><td>No</td><td><i>P</i></td><td>Yes</td><td>No</td><td><i>P</i></td></tr><tr><td>No.of patients</td><td>8</td><td>105</td><td></td><td>88</td><td>43</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td>5</td><td>82</td><td>0.57</td><td>68</td><td>34</td><td>0.82</td></tr><tr><td> Female</td><td>3</td><td>23</td><td></td><td>20</td><td>9</td><td></td></tr><tr><td>Age, years</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mean</td><td>55.5</td><td>59.1</td><td>0.47</td><td>58.6</td><td>61.4</td><td>0.25</td></tr><tr><td> SD</td><td>19.8</td><td>12.7</td><td></td><td>13.3</td><td>12.1</td><td></td></tr><tr><td>Tumor localization</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> gastric cardia</td><td>0</td><td>26</td><td>0.98</td><td>23</td><td>12</td><td>0.66</td></tr><tr><td> gastric body</td><td>5</td><td>24</td><td></td><td>22</td><td>12</td><td></td></tr><tr><td> gastric antrum</td><td>3</td><td>55</td><td></td><td>43</td><td>19</td><td></td></tr><tr><td>Tumor size (cm<sup>3</sup>)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> ≤ 3</td><td>3</td><td>35</td><td>0.68</td><td>29</td><td>14</td><td>0.88</td></tr><tr><td> 3-5</td><td>3</td><td>35</td><td></td><td>32</td><td>15</td><td></td></tr><tr><td> > 5</td><td>2</td><td>35</td><td></td><td>27</td><td>14</td><td></td></tr><tr><td>Differentiation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> well/moderate</td><td>1</td><td>44</td><td>0.21</td><td>33</td><td>23</td><td>0.08</td></tr><tr><td> poor/undifferentiation</td><td>7</td><td>61</td><td></td><td>55</td><td>20</td><td></td></tr><tr><td>Tumor invasion</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> T1</td><td>2</td><td>14</td><td>0.96</td><td>9</td><td>5</td><td>0.59</td></tr><tr><td> T2</td><td>0</td><td>17</td><td></td><td>15</td><td>8</td><td></td></tr><tr><td> T3</td><td>6</td><td>72</td><td></td><td>62</td><td>30</td><td></td></tr><tr><td> T4</td><td>0</td><td>2</td><td></td><td>2</td><td>0</td><td></td></tr><tr><td>TNM stage</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> I</td><td>2</td><td>27</td><td>0.91</td><td>20</td><td>10</td><td>0.86</td></tr><tr><td> II</td><td>1</td><td>14</td><td></td><td>15</td><td>6</td><td></td></tr><tr><td> III</td><td>5</td><td>58</td><td></td><td>49</td><td>25</td><td></td></tr><tr><td> IV</td><td>0</td><td>6</td><td></td><td>4</td><td>2</td><td></td></tr><tr><td>Residual tumor</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>1</td><td>12</td><td>1.00</td><td>12</td><td>2</td><td>0.10</td></tr><tr><td> No</td><td>7</td><td>93</td><td></td><td>76</td><td>41</td><td></td></tr><tr><td>Lymph node metastasis (LNM)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>5</td><td>65</td><td>1.00</td><td>57</td><td>24</td><td>0.32</td></tr><tr><td> No</td><td>3</td><td>40</td><td></td><td>31</td><td>19</td><td></td></tr><tr><td>No. of LNM</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> N0</td><td>3</td><td>40</td><td>0.63</td><td>31</td><td>19</td><td>0.20</td></tr><tr><td> N1 (1-6)</td><td>4</td><td>36</td><td></td><td>32</td><td>16</td><td></td></tr><tr><td> N2 (7-15)</td><td>1</td><td>23</td><td></td><td>20</td><td>7</td><td></td></tr><tr><td> N3 (≥ 16)</td><td>0</td><td>6</td><td></td><td>5</td><td>1</td><td></td></tr><tr><td>Survival status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Dead</td><td>3</td><td>53</td><td>0.73</td><td>51</td><td>15</td><td>0.01*</td></tr><tr><td> Alive</td><td>5</td><td>52</td><td></td><td>37</td><td>28</td><td></td></tr></table> |
1c17c2ea151d2c646b33db8266d461a3995c51413504838d9a12b98d404f3d1a.png | simple | <table><tr><td></td><td></td><td>Parametric</td><td>Nonparametric</td></tr><tr><td>Misacylation</td><td></td><td></td><td></td></tr><tr><td></td><td>COVE</td><td>68*</td><td>55</td></tr><tr><td></td><td>resCOVE</td><td>64</td><td>64</td></tr><tr><td></td><td>Spacer</td><td>55</td><td>64</td></tr><tr><td></td><td>Usage</td><td>38</td><td>48</td></tr><tr><td>COVERes COVE</td><td></td><td></td><td></td></tr><tr><td></td><td>Spacer</td><td>46</td><td>46</td></tr><tr><td></td><td></td><td>64</td><td>73*</td></tr><tr><td></td><td>Usage</td><td>67</td><td>62</td></tr><tr><td></td><td></td><td>57</td><td>52</td></tr><tr><td>Spacer</td><td>Usage</td><td>55</td><td>55</td></tr><tr><td>Processing</td><td>Misacylation</td><td></td><td>82*/46</td></tr><tr><td></td><td>COVE</td><td></td><td>82*/82*</td></tr><tr><td></td><td>res COVE</td><td></td><td>55/55</td></tr><tr><td></td><td>Mis-COVE</td><td>82*/46</td><td>64/55</td></tr><tr><td></td><td>Mis-res COVE</td><td>73*/55</td><td>64/55</td></tr><tr><td></td><td>Mis-Usage</td><td>55/20</td><td>64/30</td></tr><tr><td></td><td>COVE-Usage</td><td>55/90*</td><td>55/80*</td></tr><tr><td></td><td>Res COVE-Usage</td><td>46/80*</td><td>46/70</td></tr></table> |
a45c37e33058ebf82522814c0ece62f49f789789919f674ff905b9a195fcf997.png | simple | <table><tr><td> Age/sex</td><td>Comorbidity</td><td>Site</td><td>Culture source</td><td>Therapy</td><td>Outcome</td></tr><tr><td>75/F</td><td>Syringomyelia</td><td>L leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>80/F</td><td>None</td><td>R leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived (skin graft)</td></tr><tr><td>49/F</td><td>None</td><td>L ankle</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>75/M</td><td>None</td><td>R leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>71/M</td><td>None</td><td>L foot</td><td>Skin/bulla</td><td>Antibiotics, debridement</td><td>Survived (skin graft)</td></tr><tr><td>59/M</td><td>Not stated</td><td>R leg</td><td>Skin/blister</td><td>Antibiotics, debridement</td><td>Died</td></tr><tr><td>64/F</td><td>Diabetes mellitus</td><td>Both legs</td><td>Tissue</td><td>Antibiotics</td><td>Died</td></tr><tr><td>65/F</td><td>Rheumatoid arthritis</td><td>R arm</td><td>Blood/tissue</td><td>Antibiotics, amputation</td><td>Died</td></tr><tr><td>52/M</td><td>Diabetes mellitus</td><td>R leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>52/M</td><td>Diabetes mellitus</td><td>R leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>59/M</td><td>Hairy-cell leukemia</td><td>L leg</td><td>Blood/tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>58/M</td><td>Cirrhosis</td><td>L leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Died</td></tr><tr><td>49/F</td><td>Rheumatoid arthritis</td><td>R leg</td><td>Blood/skin</td><td>Antibiotics</td><td>Died</td></tr><tr><td>48/M</td><td>None</td><td>R leg</td><td>Tissue</td><td>Antibiotics, debridement</td><td>Survived</td></tr><tr><td>77/F</td><td>Rheumatoid arthritis</td><td>R leg</td><td>Tissue/blood</td><td>Antibiotics</td><td>Died</td></tr><tr><td>2/M</td><td>Vascular/lymphatic malformation</td><td>Perineum</td><td>Tissue/stool</td><td>Antibiotics, debridement</td><td>Survived</td></tr></table> |
637a6dc81162c285552953fbad6b3d1706491c111e2e6e1d01f9baa062404bc2.png | complex | <table><tr><td>Outcome</td><td colspan="4">All births</td></tr><tr><td></td><td><i>n</i></td><td>Rate</td><td>OR (95% CI)</td><td>AOR<sup>a</sup> (95% CI)</td></tr><tr><td colspan="5">Umbilical artery pH < 7.10</td></tr><tr><td> Occiput posterior</td><td>56</td><td>5.5</td><td>1.48 (1.12–1.96)</td><td>1.28 (0.93–1.74)</td></tr><tr><td> Occiput anterior</td><td>733</td><td>3.8</td><td>reference</td><td>reference</td></tr><tr><td colspan="5">Metabolic acidaemia</td></tr><tr><td> Occiput posterior</td><td>2</td><td>0.2</td><td>1.15 (0.28–4.80)</td><td>0.64 (0.08–5.04)</td></tr><tr><td> Occiput anterior</td><td>33</td><td>0.2</td><td>reference</td><td>reference</td></tr><tr><td colspan="5">Apgar score < 7 at 5 min</td></tr><tr><td> Occiput posterior</td><td>20</td><td>1.5</td><td>2.18 (1.37–3.47)</td><td>1.84 (1.11–3.05)</td></tr><tr><td> Occiput anterior</td><td>188</td><td>0.7</td><td>reference</td><td>reference</td></tr><tr><td colspan="5">Neonatal care</td></tr><tr><td> Occiput posterior</td><td>38</td><td>2.9</td><td>1.87 (1.33–2.62)</td><td>1.68 (1.17–2.42)</td></tr><tr><td> Occiput anterior</td><td>420</td><td>1.6</td><td>reference</td><td>reference</td></tr><tr><td colspan="5">Composite morbidity<sup>b</sup></td></tr><tr><td> Occiput posterior</td><td>47</td><td>3.6</td><td>1.87 (1.38–2.54)</td><td>1.66 (1.19–2.31)</td></tr><tr><td> Occiput anterior</td><td>520</td><td>2.0</td><td>reference</td><td>reference</td></tr></table> |
a96298098c08dbab3dafb5154396a269dc0b908c335542cfb44f71f61f712da0.png | complex | <table><tr><td rowspan="2">Ages (years)</td><td>Mild/NVI</td><td colspan="2">Low vision</td><td colspan="3">Blindness</td><td rowspan="2">Total VI (%)</td></tr><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>6–18</td><td>20.8</td><td>1.8</td><td>0.3</td><td>0.8)</td><td>1.5</td><td>0.0</td><td>4.3</td></tr><tr><td>19–35</td><td>18.8</td><td>2.5</td><td>0.0</td><td>0.8)</td><td>1.3</td><td>1.8</td><td>6.3</td></tr><tr><td>36–59</td><td>15.5</td><td>5.0</td><td>0.0</td><td>1.0)</td><td>2.5</td><td>1.0</td><td>9.5</td></tr><tr><td>≥ 60</td><td>9.3</td><td>7.8</td><td>0.3</td><td>1.8)</td><td>4.3</td><td>1.8</td><td>15.8</td></tr><tr><td>Total</td><td>64.3</td><td>17.0</td><td>0.5</td><td>4.3</td><td>9.5</td><td>4.5</td><td>35.8</td></tr></table> |
a5fc90b839b1269cebe1653f7f3775a8e48fa30234c464c3148c50d5bcc25edc.png | complex | <table><tr><td>Material</td><td>Scaffold Preparation</td><td>Shape and Structure of the Scaffold</td><td>Mechanical Properties of the Scaffold</td><td>Ref.</td></tr><tr><td>Collagen</td><td rowspan="3">Freeze drying</td><td>Sponges L = 11, 23 or 51 mm94% porosity, pore size = 62 μm</td><td>For L = 23 mm spec. EM = 0.02 MPaLinear Stiffness = 0.05 N/mmMaximum Stress = 0.005 MPa</td><td>[38,39]</td></tr><tr><td>Collagen/Chondroitin Sulfate</td><td>Sponge pore size = 53 μm</td><td>Linear Stiffness = 0.025 N/mm</td><td>[87]</td></tr><tr><td>Collagen/Chondroitin Sulfate</td><td>Isotropic sponge pore size = 87 μmAnisotropic pore sizes = 55, 152, 243 μm</td><td>ND</td><td>[51,55]</td></tr><tr><td>Collagen</td><td>Extrusion</td><td>EDC Crosslinked fiber diameter = 215 μmEDC/EDGE Crosslink diameter = 137 μm</td><td>Fiber diameter 215 μm → EM = 19.3 MPaFiber diameter 137 μm → EM = 46.2 MPa</td><td>[52,53]</td></tr><tr><td>Collagen</td><td rowspan="2">ELAC</td><td>Collagen thread diameter = 50–100 μm</td><td>ND</td><td>[33]</td></tr><tr><td>Collagen</td><td>Woven collagen scaffold with 81% of porosity</td><td>Stiffness = 23.8 N/mm</td><td>[34]</td></tr><tr><td>PLGA</td><td rowspan="6">Electrospinning</td><td>Random nanofibers = 568 nmAligned fibers = 320, 680 and 1800 nm</td><td>Random nanofibers → EM = 107 MPaAligned fibers → EM = 341–510 MPa</td><td>[105,106]</td></tr><tr><td>PLLA</td><td>Aligned nanofiber diameter = 430 nmRandom nanofiber diameter = 450 nm</td><td>Aligned nanofibers → Stiffness = 3.48 N/mm; EM = 22.76 MPaRandom nanofibers → Stiffness = 0.07 N/mm; EM = 0.63 MPa</td><td>[30]</td></tr><tr><td>PLDLLA</td><td>Crimped fiber diameter = 880 nmAmplitude = 5.2 μmWavelength = 46 μm</td><td>Crimped fiber Modulus = 3 MPa</td><td>[54]</td></tr><tr><td>PEEUR</td><td>Aligned or random fiberdiameters <1 μm, 1–2 μm or >2 μm</td><td>EM = 4.2–9.2 MPa</td><td>[45,46]</td></tr><tr><td>PCL</td><td>Yarned made of twisted aligned fibers (200 μm diameter)</td><td>UTS = 17 MPaEM = 30 MPa</td><td>[35]</td></tr><tr><td>P(LLA-CL)/Collagen</td><td>Fiber diameter = 643 nmFinal yarn thickness = 150 μmPore size = 28.5 μm</td><td>Yarns EM = 2 MPaUltimate deformation = 250%</td><td>[107]</td></tr><tr><td>PLGA</td><td rowspan="3">Knitting</td><td>Scaffold with 3 yarns. 20 filaments/yarn25 μm diameter of filament + electrospun nanofibers</td><td>Initial failure load = 56.3 NInitial Elastic Stiffness = 5.80 N/mmInitial toe region Stiffness = 0.34 N/mm</td><td>[36]</td></tr><tr><td>Silk</td><td>Combined knitted silk fibers and silk sponge pores size from 20 to 100 μm</td><td>Maximum Tensile Load = 252 NTensile Stiffness = 40 N/mm</td><td>[37]</td></tr><tr><td>Silk/Collagen</td><td>Combined knitted silk scaffold and freeze dryed collagen sponge</td><td>Failure force = 21.65 N</td><td>[97]</td></tr></table> |
37049550b9607c9e6a41ec3afeb97cb59a8d36efbca9d93b505f99a66b755f0a.png | complex | <table><tr><td>Demographic characteristics</td><td>Sampled frequency, <i>n</i> (%)</td><td>Weight misperception frequency, <i>n</i> (%)</td></tr><tr><td colspan="3">Sex<sup>a</sup></td></tr><tr><td> Female</td><td>2003 (44.5)</td><td>426 (21.4)</td></tr><tr><td> Male</td><td>2380 (55.5)</td><td>900 (39.1)</td></tr><tr><td colspan="3">Race/ethnicity<sup>b</sup></td></tr><tr><td> American Indian/Alaskan Native</td><td>50 (0.6)</td><td>17 (30.7)</td></tr><tr><td> Asian</td><td>111 (2.2)</td><td>33 (20.8)</td></tr><tr><td> Hispanic/Latino</td><td>1672 (25.3)</td><td>457 (28.3)</td></tr><tr><td> Multiple Race/Ethnicities Non-Hispanic</td><td>223 (5.1)</td><td>67 (23.3)</td></tr><tr><td> Native Hawaiian/other Pacific Islander</td><td>29 (0.6)</td><td>8 (37.2)</td></tr><tr><td> Non-Hispanic black or African American</td><td>479 (14.5)</td><td>202 (41.0)</td></tr><tr><td> Non-Hispanic white</td><td>1819 (51.8)</td><td>542 (31.0)</td></tr><tr><td colspan="3">Grade in school<sup>c</sup></td></tr><tr><td> 9th</td><td>1120 (26.4)</td><td>376 (35.6)</td></tr><tr><td> 10th</td><td>1129 (26.6)</td><td>357 (30.7)</td></tr><tr><td> 11th</td><td>1152 (24.3)</td><td>330 (30.2)</td></tr><tr><td> 12th</td><td>982 (22.7)</td><td>263 (27.7)</td></tr></table> |
566b4857a6446e18d3e132fbfe46679cf41156cbeb955474287d7628400eaadc.png | complex | <table><tr><td rowspan="2">Factors</td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td>Hazard ratio (95% CI)</td><td><i>P</i> value</td><td>Hazard ratio (95% CI)</td><td><i>P</i> value</td></tr><tr><td>DDA1</td><td>2.747 (1.405–5.372)</td><td>0.003</td><td></td><td>0.005</td></tr><tr><td>Gender</td><td>0.578 (0.267–1.248)</td><td>0.163</td><td></td><td>0.345</td></tr><tr><td>Age</td><td>1.586 (0.851–2.958)</td><td>0.147</td><td></td><td>0.309</td></tr><tr><td>Type</td><td>0.847 (0.462–1.552)</td><td>0.59</td><td></td><td>0.844</td></tr><tr><td>Tumour size</td><td>2.185 (1.189–4.015)</td><td>0.012</td><td></td><td>0.012</td></tr><tr><td>Positive LN number</td><td>2.094 (1.112–3.944)</td><td>0.022</td><td></td><td><0.001</td></tr><tr><td>AJCC stage</td><td>4.42 (2.257–8.656)</td><td><0.001</td><td>4.281 (2.186–8.384)</td><td><0.001</td></tr><tr><td>Histological grade</td><td>1.142 (0.574–2.272)</td><td>0.706</td><td></td><td>0.996</td></tr></table> |
b28ba28726d00d2c7c1db28d7c2be2a92b0a6484f195136d06998d0365698255.png | simple | <table><tr><td></td><td>Men (n = 58)</td><td>Women (n = 65)</td><td>ANOVA</td><td><i>F</i></td><td><i>p</i></td></tr><tr><td>Bench press</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pre</td><td>68.7 ± 16.0§</td><td>29.2 ± 6.3</td><td>Group</td><td>378.14</td><td>< 0.001</td></tr><tr><td>Post</td><td>79.8 ± 15.4<sup>§*</sup></td><td>36.9 ± 6.9<sup>*</sup></td><td>Time</td><td>820.58</td><td>< 0.001</td></tr><tr><td>Δ%</td><td>+16.2</td><td>+26.4</td><td>Interaction</td><td>27.42</td><td>< 0.001</td></tr><tr><td>Arm curl</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pre</td><td>40.0 ± 7.0<sup>§</sup></td><td>21.7 ± 3.8</td><td>Group</td><td>358.12</td><td>< 0.001</td></tr><tr><td>Post</td><td>45.5 ± 6.8<sup>§*</sup></td><td>26.6 ± 4.1<sup>*</sup></td><td>Time</td><td>547.01</td><td>< 0.001</td></tr><tr><td>Δ%</td><td>+13.8</td><td>+22.6</td><td>Interaction</td><td>2.29</td><td>0.132</td></tr></table> |
d5ca076dd19f65dc48935f07e96bfff873ded8386a7bbee0b92b78798b9f81b7.png | simple | <table><tr><td>Task</td><td>Group description</td><td>Activity of group 1 higher that group 2</td><td>Activity of group 1 low that group 2</td><td>Reference</td></tr><tr><td>Tactile stimulation</td><td>PD patients (1) vs. healthy control volunteers</td><td>R. primary sensory, R. motor cortex, R. supplementary motor area, B. caudate, B. precuneus, B. occipital visual cortex, L. and M. temporal gyrus</td><td></td><td>(23)</td></tr><tr><td>Time perception task</td><td>PD patients (1) vs. healthy control volunteers and medical patients (2)</td><td>Precuneus (after long stimuli)</td><td></td><td>(26)</td></tr><tr><td>Gambling</td><td>Non-Pathological gamblers whit PD (1) vs. Pathological gamblers with PD (2)</td><td>B. anterior cingulate cortex, M. and S. frontal gyri, precuneus, R. I. parietal lobule, ventral striatum</td><td></td><td>(24)</td></tr><tr><td>Imaginary gait</td><td>PD patients experiencing freezing (1) vs. PDs not experiencing freezing (2)</td><td><i>R. globus</i> pallidus, R. supplementary motor area, R. mesencephalic locomotor region, R. cerebellum, B. anterior insula, B. ventral striatum, B. pre-supplementary motor area, L. sub-thalamic nucleaus</td><td></td><td>(28, 29)</td></tr><tr><td>Hand movement</td><td>PD patients with (1) and without (2) mirror movements syndrome</td><td>R. dorsolateral prefrontal cortex, M. prefrontal cortex, Pre-supplementary motor area, Occipital Cortex</td><td><i>B. insula</i>, B. posterior cingulate cortex, L inferior frontal cortex</td><td>(27)</td></tr><tr><td>Balloon analog risk task</td><td>PD patients with an impulse-control disorder (1) vs. PD patients without and impulse-control disorder (2)</td><td>R. ventral striatum</td><td></td><td>(25)</td></tr><tr><td>Speech</td><td>PD patients (1) vs. healthy control volunteers</td><td>Primary orofacial sensorimotor cortex</td><td></td><td>(20)</td></tr><tr><td>Saccade</td><td>PD patients (1) vs. healthy control volunteers</td><td>Frontal and supplementary eye fields</td><td>L. and R. cerebellum contralateral motor cortex</td><td>(22)</td></tr><tr><td>Finger tapping</td><td>PD patients (1) vs. healthy control volunteers</td><td>Putamen, supplementary motor area</td><td>R. prefrontal cortex, R. caudate</td><td>(21)</td></tr></table> |
2cb20b9e8e2d9a817fb7331e9dbe92fe350d81c4f26033d0ae812358ef7ba7d5.png | complex | <table><tr><td colspan="4">Motor nerve conduction</td></tr><tr><td>Nerve</td><td>Latency</td><td>Amplitude</td><td>Conduction velocity</td></tr><tr><td>Median R (wrist)</td><td>8.9 ms</td><td>1.3 mV</td><td> </td></tr><tr><td>Median R (elbow)</td><td>18.5 ms</td><td>0.8 mV</td><td>24 m/s</td></tr><tr><td>Ulnar R (wrist)</td><td>4.4 ms</td><td>6.9 mV</td><td> </td></tr><tr><td>Ulnar R (below elbow)</td><td>10.4 ms</td><td>5.7 mV</td><td>38 m/s</td></tr><tr><td>Ulnar R (above elbow)</td><td>13.4 ms</td><td>3.3 mV</td><td>33 m/s</td></tr><tr><td>Tibial R (ankle)</td><td>6.2 ms</td><td>3.4 mV</td><td> </td></tr><tr><td>Tibial R (popliteal fossa)</td><td>23.1 ms</td><td>0.7 mV</td><td>24 m/s</td></tr></table> |
8d61aa2c014ac5e098d184d82b3bb5a7ed708e8850c5cbd6a46f921fcb7f1600.png | complex | <table><tr><td></td><td>R-cases (<i>n</i> = 20)</td><td>6mo-cases (<i>n</i> = 19)<sup>a</sup></td><td>TST+ (<i>n</i> = 9)</td><td>TST− (<i>n</i> = 18)</td></tr><tr><td>Median age, years (range)</td><td>31.5 (17–65)</td><td>30 (18–69)</td><td>42 (20–65)</td><td>22.5 (16–51)</td></tr><tr><td>Female sex, <i>n</i> (%)</td><td>5 (25)</td><td>6 (23)</td><td>8 (89)</td><td>14 (78)</td></tr><tr><td>FflV + , <i>n</i> (%)</td><td>1 (5)</td><td>1 (5)</td><td>0</td><td>0</td></tr><tr><td colspan="5">Smear grade<sup>b</sup></td></tr><tr><td>3, <i>n</i> (%)</td><td>7 (35)</td><td>4 (21.1)</td><td>N/A</td><td>N/A</td></tr><tr><td>2, <i>n</i> (%)</td><td>6 (30)</td><td>6 (31.6)</td><td>N/A</td><td>N/A</td></tr><tr><td>l, <i>n</i> (%)</td><td>6 (30)</td><td>7 (36.8)</td><td>N/A</td><td>N/A</td></tr><tr><td>neg, <i>n</i> (%)</td><td>1 (5)</td><td>2 (10.5)</td><td>N/A</td><td>N/A</td></tr><tr><td colspan="5">Chest X-ray grade<sup>c</sup></td></tr><tr><td>3, <i>n</i> (%)</td><td>14 (70)</td><td>14 (73.7)</td><td>N/A</td><td>N/A</td></tr><tr><td>2, <i>n</i> (%)</td><td>5 (25)</td><td>5 (26.3)</td><td>N/A</td><td>N/A</td></tr><tr><td>l, <i>n</i> TO</td><td>1 (5)</td><td>0</td><td>N/A</td><td>N/A</td></tr></table> |
88b36a23e66931081c344444c3fb40df93c2deb2edc939161eb7be321a4cf4e1.png | complex | <table><tr><td></td><td colspan="6">No. of abnormalities</td></tr><tr><td>Abnormality</td><td>Arctic</td><td>Innoko</td><td>Kenai</td><td>Tetlin</td><td>Yukon Delta</td><td>Total</td></tr><tr><td colspan="7">Eye abnormality</td></tr><tr><td> Anophthalmia (missing eye)</td><td>0</td><td>2</td><td>12</td><td>6</td><td>0</td><td>20</td></tr><tr><td> Unpigmented iris (black eye)</td><td>0</td><td>15</td><td>118</td><td>20</td><td>1</td><td>154</td></tr><tr><td> Microphthalmia (small eye)</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>2</td></tr><tr><td> Othera</td><td>0</td><td>2</td><td>6</td><td>2</td><td>0</td><td>10</td></tr><tr><td colspan="7">Skeletal injuryb</td></tr><tr><td> Brachydactyly (short digits)</td><td>2</td><td>0</td><td>7</td><td>0</td><td>2</td><td>11</td></tr><tr><td> Ectrodactyly (missing digits)</td><td>1</td><td>1</td><td>4</td><td>3</td><td>0</td><td>9</td></tr><tr><td> Ectromelia (partial limb)</td><td>0</td><td>0</td><td>44</td><td>6</td><td>0</td><td>50</td></tr><tr><td> Limb crushed</td><td>0</td><td>0</td><td>14</td><td>1</td><td>2</td><td>17</td></tr><tr><td> Otherc</td><td>0</td><td>2</td><td>2</td><td>0</td><td>0</td><td>4</td></tr><tr><td colspan="7">Skeletal malformation</td></tr><tr><td> Amelia (missing limb)</td><td>0</td><td>1</td><td>31</td><td>3</td><td>0</td><td>35</td></tr><tr><td> Anteversion (twisted long bones)</td><td>0</td><td>0</td><td>9</td><td>0</td><td>0</td><td>9</td></tr><tr><td> Brachygnathia (short jaw)</td><td>1</td><td>4</td><td>6</td><td>0</td><td>0</td><td>11</td></tr><tr><td> Microcephaly (shrunken head or blunt snout)</td><td>0</td><td>0</td><td>4</td><td>0</td><td>0</td><td>4</td></tr><tr><td> Micromelia (shrunken limb or limb element)</td><td>5</td><td>3</td><td>126</td><td>17</td><td>3</td><td>154</td></tr><tr><td> Polymelia (extra limb)</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td></tr><tr><td> Polydactyly (extra digits)</td><td>2</td><td>0</td><td>2</td><td>0</td><td>0</td><td>4</td></tr><tr><td> Scoliosis or lordosis (curved spine)</td><td>0</td><td>0</td><td>2</td><td>0</td><td>0</td><td>2</td></tr><tr><td> Cutaneous fusion (skin webbing)</td><td>0</td><td>0</td><td>3</td><td>0</td><td>0</td><td>3</td></tr><tr><td> Syndactyly (digits fused)</td><td>0</td><td>0</td><td>11</td><td>2</td><td>0</td><td>13</td></tr><tr><td> Taumelia (bone bridge or triangle)</td><td>0</td><td>0</td><td>4</td><td>0</td><td>0</td><td>4</td></tr><tr><td colspan="7">Skeletal unknown origin</td></tr><tr><td> Kinked tail</td><td>0</td><td>0</td><td>3</td><td>0</td><td>0</td><td>3</td></tr><tr><td> Brachydactyly (short digits)</td><td>0</td><td>1</td><td>27</td><td>1</td><td>2</td><td>31</td></tr><tr><td> Ectrodactyly (missing digits)</td><td>0</td><td>0</td><td>26</td><td>3</td><td>0</td><td>29</td></tr><tr><td> Ectromelia (partial limb)</td><td>7</td><td>12</td><td>90</td><td>14</td><td>2</td><td>125</td></tr><tr><td> Otherd</td><td>0</td><td>2</td><td>5</td><td>0</td><td>0</td><td>7</td></tr><tr><td colspan="7">Overall</td></tr><tr><td> Eye total</td><td>0</td><td>19</td><td>137</td><td>29</td><td>1</td><td>186</td></tr><tr><td> Injury total</td><td>3</td><td>3</td><td>71</td><td>10</td><td>4</td><td>91</td></tr><tr><td> Malformation total</td><td>8</td><td>8</td><td>199</td><td>22</td><td>3</td><td>240</td></tr><tr><td> Unknown origin total</td><td>7</td><td>15</td><td>151</td><td>18</td><td>4</td><td>195</td></tr><tr><td>Total abnormalities</td><td>18</td><td>45</td><td>558</td><td>79</td><td>12</td><td>712</td></tr><tr><td>Total abnormal individuals</td><td>12</td><td>39</td><td>450</td><td>68</td><td>7</td><td>576</td></tr><tr><td>Total individuals examined</td><td>615</td><td>1,309</td><td>5,716</td><td>1,146</td><td>482</td><td>9,268</td></tr><tr><td>Percent individuals abnormal</td><td>2.0%</td><td>3.0%</td><td>7.9%</td><td>5.9%</td><td>1.5%</td><td>6.2%</td></tr></table> |
642db7628587a733ed3fe500cc1d5f713eca9b980cd2af18dedbe1a000c5984c.png | complex | <table><tr><td rowspan="2">Source</td><td colspan="3">Minerals</td><td colspan="5">Vitamins</td></tr><tr><td>Fe (%)</td><td>Na (%)</td><td>Se (%)</td><td>Riboflavin (%)</td><td>Thiamin (%)</td><td>B12 (%)</td><td>Niacin (%)</td><td>Folic acid (%)</td></tr><tr><td>Red meat<sup>*</sup></td><td>14.5</td><td>13.9</td><td>25.5</td><td>16.4</td><td>5.4</td><td>50.6</td><td>32.6</td><td>4.4</td></tr><tr><td>White meat</td><td>2.9</td><td>4.5</td><td>5.2</td><td>5.5</td><td>1.5</td><td>4.1</td><td>11.5</td><td>4.6</td></tr><tr><td>Cereals </td><td>6.39</td><td>6.89</td><td>8.4</td><td>4.8</td><td>10.2</td><td>0</td><td>4.1</td><td>21.6</td></tr><tr><td>Legumes</td><td>2.7</td><td>0.9</td><td>0.3</td><td>0.8</td><td>1.2</td><td>0</td><td>0.29</td><td>7.1</td></tr><tr><td>Fish and seafood</td><td>4.4</td><td>5.2</td><td>35.1</td><td>2.3</td><td>1.0</td><td>35.1</td><td>13.9</td><td>1.7</td></tr><tr><td>White bread</td><td>56.6</td><td>52.1</td><td>41.8</td><td>60.7</td><td>73.3</td><td>10.2</td><td>33.9</td><td>47.9</td></tr><tr><td>Vegetables</td><td>12.4</td><td>16.5</td><td>1.4</td><td>9.5</td><td>7.4</td><td>0</td><td>3.6</td><td>16.2</td></tr></table> |
a45fb7f3c79f88c8532b79cffb19ce4456e5d823861d9668b33b65c6aa68824e.png | complex | <table><tr><td></td><td colspan="4">pCR prediction(n = 488)</td></tr><tr><td>Prediction evaluation*</td><td>PPV (SD)</td><td>NPV (SD)</td><td>Sensitivity (SD)</td><td>Specificity (SD)</td></tr><tr><td>Unsupervised clustering</td><td></td><td></td><td></td><td></td></tr><tr><td>BRmet50</td><td>93(14)</td><td>34(3)</td><td>58(3)</td><td>83(0.6)</td></tr><tr><td>PMID18271932Sig33</td><td>92(3)</td><td>32(5)</td><td>53(6)</td><td>83(6)</td></tr><tr><td colspan="2">Anthracycline-taxane Centroid</td><td></td><td></td><td></td></tr><tr><td>BRmet50</td><td>89(6)</td><td>27(0.6)</td><td>40(5)</td><td>83(6)</td></tr><tr><td>PMID18271932Sig33</td><td>77(4)</td><td>20(3)</td><td>29(1)</td><td>67(0.5)</td></tr></table> |
c8f338df17f2aab37fb1e201b8f6350242d962be64308e1f769dc8d57f67faba.png | simple | <table><tr><td>SNP ID</td><td>Chr 16 position sequence</td><td>Sequence</td><td>Type</td><td>Amino acid change</td></tr><tr><td>rs200158701</td><td>70680854(+)</td><td>CCATGC/TCCCGG</td><td>mis</td><td>PS</td></tr><tr><td>rs192337001</td><td>70680866(+)</td><td>GCTTCA/CCCTGG</td><td>mis</td><td>TP</td></tr><tr><td>rs139133476</td><td>70688459(+)</td><td>CCTTGG/CCGTGG</td><td>mis</td><td>AG</td></tr><tr><td>rs142890682</td><td>70688461(+)</td><td>TTGGCG/ATGGCC</td><td>mis</td><td>MV</td></tr><tr><td>rs118062333</td><td>70690511(+)</td><td>AACACT/CACTTC</td><td>mis</td><td>HY</td></tr><tr><td>rs200597979</td><td>70690960(+)</td><td>GGGCCA/GCCCAT</td><td>mis</td><td>HR</td></tr><tr><td>rs8046424</td><td>70690989(+)</td><td>AGGTGC/GAGACG</td><td>mis</td><td>QE</td></tr><tr><td>rs187166563</td><td>70693576(+)</td><td>CCCAGA/GGCCAA</td><td>mis</td><td>EG</td></tr><tr><td>rs142214904</td><td>70693626(+)</td><td>GCTTCC/TGGGTC</td><td>mis</td><td>RW</td></tr><tr><td>rs7206509</td><td>70693945(+)</td><td>GCCAAG/CTCCTC</td><td>mis</td><td>TS</td></tr><tr><td>rs201277640</td><td>70693984(+)</td><td>GTATGC/TGGCCA</td><td>mis</td><td>AV</td></tr><tr><td>rs202122982</td><td>70694001(+)</td><td>TGTACC/TCTCCG</td><td>mis</td><td>PS</td></tr><tr><td>rs148286339</td><td>70694011(+)</td><td>GCCCCC/TGTGGT</td><td>mis</td><td>PL</td></tr><tr><td>rs141513638</td><td>70694056(+)</td><td>GAGGCC/TGGTCA</td><td>mis</td><td>PL</td></tr><tr><td>rs112639369</td><td>70694073(+)</td><td>AGGGCG/AAGGGC</td><td>mis</td><td>KE</td></tr><tr><td>rs1444643201</td><td>70694076(+)</td><td>GCGAGG/AGCCTC</td><td>mis</td><td>SG</td></tr><tr><td>rs367851338</td><td>70693627(+)</td><td>CTTCCA/GGGTCA</td><td>mis</td><td>QR</td></tr><tr><td>rs368143418</td><td>70690933(+)</td><td>TGAGTC/TGGTGC</td><td>mis</td><td>SL</td></tr><tr><td>rs374665339</td><td>70690963(+)</td><td>CCACCC/TATCCT</td><td>mis</td><td>PL</td></tr><tr><td>rs368923655</td><td>70691023(+)</td><td>CCTCAC/TGGTGA</td><td>mis</td><td>TM</td></tr><tr><td>rs368367274</td><td>70693597(+)</td><td>GGTGCA/GGCCCA</td><td>mis</td><td>QR</td></tr><tr><td>rs200891924</td><td>70693560(+)</td><td>TGTCCC/ATCTTG</td><td>mis</td><td>IL</td></tr><tr><td>rs372998917</td><td>70694041(+)</td><td>CTCCAC/TGGGCT</td><td>mis</td><td>TM</td></tr><tr><td>rs370436386</td><td>70690927(+)</td><td>TGCCAC/TTGAGT</td><td>mis</td><td>TL</td></tr><tr><td>rs144427482</td><td>70690571(+)</td><td>CCAACG/ATCACC</td><td>mis</td><td>IV</td></tr><tr><td>rs201108464</td><td>70693569(+)</td><td>TGAATG/ACCCCA</td><td>mis</td><td>TA</td></tr><tr><td>rs144144426</td><td>70690541(+)</td><td>GTGTGC/TCTTAC</td><td>mis</td><td>PS</td></tr><tr><td>rs377411431</td><td>70690885(+)</td><td>CGAGCG/TGGAGC</td><td>mis</td><td>RL</td></tr><tr><td>rs369011177</td><td>70680875(+)</td><td>GGCTGC/TGCTGT</td><td>mis</td><td>RC</td></tr><tr><td>rs145782768</td><td>70693979(+)</td><td>TTGCAG/CTATGC</td><td>mis</td><td>HQ</td></tr><tr><td>rs201784459</td><td>70694005(+)</td><td>CCCTCC/TGCCCC</td><td>mis</td><td>PL</td></tr><tr><td>rs200488835</td><td>70693655(+)</td><td>TCCTGC/GTGTAA</td><td>mis</td><td>CW</td></tr><tr><td>rs3813904</td><td>70680744(+)</td><td>TGACTG/CAGTGA</td><td>ese</td><td></td></tr><tr><td>rs3813905</td><td>70680850(+)</td><td>ACCACC/GATGCC</td><td>ese</td><td></td></tr><tr><td>rs4985556</td><td>70694000(+)</td><td>CTGTAC/ACCTCC</td><td>ese</td><td></td></tr></table> |
f41d9718c98a01ba275ff51a6abfea57ab68b73d44d3f94413a05bea76814250.png | complex | <table><tr><td rowspan="2">Groups</td><td>Total cholesterol </td><td>LDL-C</td><td>HDL-C</td><td>TG</td><td>HbA1c</td><td>FBG</td></tr><tr><td><i>r </i>Pearson</td><td><i>r </i>Pearson</td><td><i>r </i>Pearson</td><td><i>r </i>Pearson</td><td><i>r </i>Pearson</td><td><i>r </i>Pearson</td></tr><tr><td>Ox-LDL of normoalbuminurics</td><td>−0.07</td><td>−0.085</td><td>−0.25</td><td>−0.21</td><td>−0.024</td><td>−0.220</td></tr><tr><td>Ox-LDL of microalbuminurics</td><td>−0.086</td><td>−0.2</td><td>−0.28</td><td>0.28</td><td>−0.379</td><td>0.36</td></tr><tr><td>Ox-LDL of macroalbuminurics</td><td>−0.148</td><td>0.066</td><td>0.001</td><td>−0.139</td><td>−0.136</td><td>−0.129</td></tr><tr><td>Ox-LDL of first degree relatives</td><td> −0.26</td><td>0.21</td><td>−0.029</td><td>0.26</td><td>0.03</td><td>−0.093</td></tr><tr><td>Ox-LDL of control group</td><td>0.49</td><td>0.33</td><td>0.092</td><td>0.05</td><td>0.057</td><td>−0.37</td></tr></table> |
563e267b35a2b55907de85900b91fd35753e25ba53bb7132bf4aaa4011b9ff5f.png | simple | <table><tr><td> </td><td>Survivors(<i>n</i> = 90)</td><td>Former prisoners(<i>n</i> = 83)</td><td><i>Statistics</i></td><td>Descendants of survivors(<i>n</i> = 97)</td><td>Descendants of former prisoners(<i>n</i> = 90)</td><td><i>Statistics</i></td></tr><tr><td>Gender % <i>(n)</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>28.9 (26)</td><td>90.2 (74)</td><td><i>χ</i><sup><i>2</i></sup>(1,172) = 66.4***</td><td>43.3 (42)</td><td>50.5 (46)</td><td>n.s.</td></tr><tr><td>Female</td><td>71.1 (64)</td><td>9.8 (8)</td><td> </td><td>56.7 (55)</td><td>49.5 (45)</td><td> </td></tr><tr><td>Age</td><td>51.6 (10.3, 30–77)</td><td>53.9 (7.9, 34–81)</td><td>n.s.</td><td>21.1 (5.9, 13–31)</td><td>21.6 (5.8, 13–31)</td><td> </td></tr><tr><td>Marital Status % <i>(n)</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Single</td><td>4.5 (4)</td><td>1.2 (1)</td><td>n.s.</td><td>91.8 (89)</td><td>85.7 (78)</td><td>n.s.</td></tr><tr><td>Married</td><td>38.9 (35)</td><td>82.9 (68)</td><td><i>χ</i><sup><i>2</i></sup>(3,172) = 34.6***</td><td>6.2 (6)</td><td>13.2 (12)</td><td>n.s.</td></tr><tr><td>Divorced/ Separated</td><td>3.3 (3)</td><td>4.9 (4)</td><td>n.s.</td><td>2.0 (2)</td><td>1.1 (1)</td><td>n.s.</td></tr><tr><td>Widowed</td><td>53.3 (48)</td><td>11.0 (9)</td><td><i>χ</i><sup><i>2</i></sup>(3,172) = 34.7***</td><td>-</td><td>-</td><td> </td></tr><tr><td>Number of children <i>M (SD, range)</i></td><td>6.0 (2.76, 1–13)</td><td>6.8 (2.63, 2–16)</td><td><i>U</i> = 2971.5*</td><td>0.3 (1.03, 0–5)</td><td>0.3 (0.92, 0–6)</td><td>n.s.</td></tr><tr><td>Years of Schooling <i>M (SD, range)</i></td><td>5.2 (3.48, 0–14)</td><td>3.7 (3.28, 0–14)</td><td><i>U</i> = 2811.5**</td><td>6.71 (3.18, 0–16)</td><td>5.42 (3.02, 0–17)</td><td><i>U</i> = 3251.0**</td></tr><tr><td>Highest degree obtained % <i>(n)</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No degree</td><td>48.9 (44)</td><td>61.0 (50)</td><td>n.s.</td><td>39.2 (38)</td><td>58.2 (53)</td><td><i>χ</i><sup><i>2</i></sup>(2,188) = 6.8**</td></tr><tr><td>Primary School</td><td>46.7 (42)</td><td>35.4 (29)</td><td>n.s.</td><td>45.4 (44)</td><td>34.1 (31)</td><td>n.s.</td></tr><tr><td>Secondary School</td><td>4.4 (4)</td><td>3.6 (3)</td><td>n.s.</td><td>15.4 (15)</td><td>7.7 (7)</td><td>n.s.</td></tr><tr><td>Possessions % <i>(n)</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>House</td><td>93.3 (84)</td><td>98.8 (81)</td><td>n.s.</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Agricultural Field</td><td>80.0 (72)</td><td>96.3 (79)</td><td><i>χ</i><sup><i>2</i></sup>(1,172) = 10.7***</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Monthly Income <i>M (SD, range)</i></td><td>2922.2 (6849.5, 0–41.000)</td><td>3695.1 (6051.6, 0–35.000)</td><td>n.s.</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Social Integration</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Number of friends <i>M (SD, range)</i></td><td>4.3 (4.0, 0–20)</td><td>4.9 (3.7, 0–20)</td><td>n.s.</td><td>4.3 (4.5, 0–25)</td><td>4.6 (3.6, 0–20)</td><td>n.s.</td></tr><tr><td>Community activities % <i>(n)</i></td><td>94.4 (85)</td><td>92.7 (76)</td><td>n.s.</td><td>n.a</td><td>n.a.</td><td> </td></tr><tr><td>Memberships in cooperatives <i>M (SD, range)</i></td><td>.7 (.8, 0–3)</td><td>.7 (.9, 0–5)</td><td>n.s.</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Family members lost in 1994 <i>M (SD, range)</i></td><td>14 (1.6, 0–70)</td><td>3 (.4, 0–24)</td><td><i>U</i> = 1032.5***</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Displacement due to genocide % <i>(n)</i></td><td>98.9 (89)</td><td>82.9 (68)</td><td><i>U</i> = 13.7***</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Destination of displacement % <i>(n)</i></td><td> </td><td> </td><td> </td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Same district</td><td>75.5 (68)</td><td>15.9 (13)</td><td><i>χ</i><sup><i>2</i></sup>(1,172) = 61.4***</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Other district (Bugesera, Kibuye)</td><td>23.3 (21)</td><td>59.8 (49)</td><td><i>χ</i><sup><i>2</i></sup>(1,172) = 23.6***</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Foreign country (DRC)</td><td>-</td><td>7.3 (6)</td><td><i>χ</i><sup><i>2</i></sup>(1,172) = 6.8**</td><td>n.a.</td><td>n.a.</td><td> </td></tr><tr><td>Years spent in prison <i>M (SD, range)</i></td><td>n.a.</td><td>8.5 (4.4, .2-15.7)</td><td> </td><td>n.a.</td><td>n.a.</td><td> </td></tr></table> |
eba539bee38f1eb538c25b683833873476807032134086b155854e72a8bcda4a.png | simple | <table><tr><td>SSA</td><td>ST</td><td>t<sub>1</sub>(h)</td><td>μ<sub>e</sub></td><td>STD</td><td>ξ</td><td>STD</td><td>γ</td><td>t<sub>1</sub>(h)</td><td>μ<sub>e</sub></td><td>STD<sup>a</sup></td><td>ξ</td><td>STD</td><td>γ</td></tr><tr><td>3.37</td><td>53.95</td><td>6</td><td>−3.12</td><td>−0.05</td><td>−31.92</td><td>−0.04</td><td>48.93</td><td>36</td><td>−2.38</td><td>1.79</td><td>−24.26</td><td>1.81</td><td>51.69</td></tr><tr><td></td><td>46.09</td><td></td><td>−3.35</td><td>−0.67</td><td>−34.44</td><td>−0.66</td><td>49.41</td><td></td><td>−2.55</td><td>1.31</td><td>−26.23</td><td>1.32</td><td>50.39</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.44</td><td>−0.81</td><td>−35.29</td><td>−0.81</td><td>46.25</td><td></td><td>−2.72</td><td>0.98</td><td>−27.88</td><td>0.98</td><td>47.87</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.14</td><td>−0.39</td><td>−32.20</td><td>−0.38</td><td>39.87</td><td></td><td>−2.84</td><td>0.35</td><td>−29.13</td><td>0.36</td><td>45.02</td></tr><tr><td>3.73</td><td>53.95</td><td></td><td>−3.21</td><td>−0.61</td><td>−32.94</td><td>−0.60</td><td>47.53</td><td></td><td>−2.52</td><td>1.12</td><td>−25.86</td><td>1.11</td><td>50.20</td></tr><tr><td></td><td>46.09</td><td></td><td>−3.06</td><td>−0.31</td><td>−31.41</td><td>−0.31</td><td>46.38</td><td></td><td>−2.70</td><td>0.59</td><td>−27.72</td><td>0.58</td><td>47.55</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.27</td><td>−0.51</td><td>−33.58</td><td>−0.51</td><td>46.58</td><td></td><td>−2.77</td><td>0.74</td><td>−28.42</td><td>0.74</td><td>47.85</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.44</td><td>−0.70</td><td>−35.27</td><td>−0.69</td><td>44.72</td><td></td><td>−2.94</td><td>0.53</td><td>−30.22</td><td>0.53</td><td>45.27</td></tr><tr><td>4.44</td><td>53.95</td><td></td><td>−3.22</td><td>−0.34</td><td>−33.02</td><td>−0.34</td><td>49.32</td><td></td><td>−2.72</td><td>0.89</td><td>−27.92</td><td>0.89</td><td>49.70</td></tr><tr><td></td><td>46.09</td><td></td><td>−3.32</td><td>−1.01</td><td>−32.92</td><td>−0.76</td><td>48.91</td><td></td><td>−2.31</td><td>1.49</td><td>−23.76</td><td>1.45</td><td>48.48</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.48</td><td>−0.90</td><td>−35.71</td><td>−0.90</td><td>49.18</td><td></td><td>−2.54</td><td>1.44</td><td>−26.04</td><td>1.43</td><td>46.55</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.37</td><td>−0.62</td><td>−34.56</td><td>−0.62</td><td>44.43</td><td></td><td>−2.61</td><td>1.27</td><td>−26.82</td><td>1.25</td><td>44.71</td></tr><tr><td>3.37</td><td>53.95</td><td>12</td><td>−3.21</td><td>−0.29</td><td>−32.98</td><td>−0.30</td><td>52.01</td><td>48</td><td>−3.85</td><td>−1.88</td><td>−39.67</td><td>−1.91</td><td>47.25</td></tr><tr><td></td><td>46.09</td><td></td><td>−3.25</td><td>−0.44</td><td>−33.40</td><td>−0.41</td><td>50.09</td><td></td><td>−3.81</td><td>−1.82</td><td>−38.90</td><td>−1.74</td><td>44.89</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.33</td><td>−0.54</td><td>−34.17</td><td>−0.54</td><td>47.59</td><td></td><td>−3.72</td><td>−1.50</td><td>−38.14</td><td>−1.50</td><td>44.06</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.22</td><td>−0.60</td><td>−33.12</td><td>−0.61</td><td>47.74</td><td></td><td>−3.67</td><td>−1.70</td><td>−37.61</td><td>−1.69</td><td>43.98</td></tr><tr><td>3.73</td><td>53.95</td><td></td><td>−2.94</td><td>0.06</td><td>−30.19</td><td>0.06</td><td>53.88</td><td></td><td>−3.23</td><td>−0.66</td><td>−33.19</td><td>−0.66</td><td>48.11</td></tr><tr><td></td><td>46.09</td><td></td><td>−2.99</td><td>−0.13</td><td>−30.69</td><td>−0.13</td><td>49.52</td><td></td><td>−3.20</td><td>−0.66</td><td>−32.86</td><td>−0.66</td><td>46.40</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.20</td><td>−0.32</td><td>−32.80</td><td>−0.32</td><td>50.05</td><td></td><td>−3.32</td><td>−0.62</td><td>−34.09</td><td>−0.63</td><td>43.18</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.13</td><td>0.06</td><td>−32.18</td><td>0.06</td><td>45.05</td><td></td><td>−3.85</td><td>−1.72</td><td>−39.51</td><td>−1.71</td><td>41.96</td></tr><tr><td>4.44</td><td>53.95</td><td></td><td>−3.35</td><td>−0.66</td><td>−34.36</td><td>−0.66</td><td>51.21</td><td></td><td>−3.10</td><td>−0.05</td><td>−31.83</td><td>−0.05</td><td>46.33</td></tr><tr><td></td><td>46.09</td><td></td><td>−3.09</td><td>−0.45</td><td>−31.77</td><td>−0.48</td><td>51.94</td><td></td><td>−2.92</td><td>−0.01</td><td>−29.94</td><td>−0.04</td><td>45.21</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.49</td><td>−0.93</td><td>−35.82</td><td>−0.93</td><td>49.04</td><td></td><td>−3.26</td><td>−0.37</td><td>−33.47</td><td>−0.36</td><td>43.56</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.13</td><td>−0.03</td><td>−32.10</td><td>−0.02</td><td>46.65</td><td></td><td>−3.37</td><td>−0.63</td><td>−34.62</td><td>−0.63</td><td>42.30</td></tr><tr><td>3.37</td><td>53.95</td><td>24</td><td>−2.70</td><td>0.98</td><td>−27.68</td><td>0.98</td><td>49.02</td><td>72</td><td>−3.31</td><td>−0.54</td><td>−34.01</td><td>−0.55</td><td>46.95</td></tr><tr><td></td><td>46.09</td><td></td><td>−2.48</td><td>1.49</td><td>−25.47</td><td>1.50</td><td>46.44</td><td></td><td>−3.03</td><td>0.12</td><td>−31.71</td><td>0.00</td><td>45.34</td></tr><tr><td></td><td>42.78</td><td></td><td>−2.41</td><td>1.74</td><td>−24.79</td><td>1.73</td><td>44.92</td><td></td><td>−3.06</td><td>0.14</td><td>−31.39</td><td>0.13</td><td>44.44</td></tr><tr><td></td><td>36.07</td><td></td><td>−2.38</td><td>1.49</td><td>−24.48</td><td>1.48</td><td>44.03</td><td></td><td>−2.64</td><td>0.85</td><td>−27.11</td><td>0.85</td><td>44.18</td></tr><tr><td>3.73</td><td>53.95</td><td></td><td>−2.95</td><td>0.05</td><td>−30.26</td><td>0.05</td><td>50.16</td><td></td><td>−2.95</td><td>0.05</td><td>−30.25</td><td>0.05</td><td>45.17</td></tr><tr><td></td><td>46.09</td><td></td><td>−2.67</td><td>0.66</td><td>−27.41</td><td>0.66</td><td>47.68</td><td></td><td>−2.99</td><td>−0.14</td><td>−30.71</td><td>−0.14</td><td>44.97</td></tr><tr><td></td><td>42.78</td><td></td><td>−3.07</td><td>−0.01</td><td>−31.54</td><td>−0.01</td><td>46.01</td><td></td><td>−2.78</td><td>0.72</td><td>−28.47</td><td>0.73</td><td>44.21</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.06</td><td>0.24</td><td>−31.39</td><td>0.24</td><td>44.18</td><td></td><td>−2.52</td><td>1.58</td><td>−25.87</td><td>1.58</td><td>42.71</td></tr><tr><td>4.44</td><td>53.95</td><td></td><td>−2.79</td><td>0.73</td><td>−28.62</td><td>0.72</td><td>49.98</td><td></td><td>−3.31</td><td>−0.58</td><td>−33.99</td><td>−0.57</td><td>45.78</td></tr><tr><td></td><td>46.09</td><td></td><td>−2.85</td><td>0.15</td><td>−29.61</td><td>0.04</td><td>47.20</td><td></td><td>−2.98</td><td>−0.16</td><td>−30.59</td><td>−0.20</td><td>45.65</td></tr><tr><td></td><td>42.78</td><td></td><td>−2.97</td><td>0.36</td><td>−30.51</td><td>0.35</td><td>45.17</td><td></td><td>−2.96</td><td>0.40</td><td>−30.32</td><td>0.40</td><td>44.97</td></tr><tr><td></td><td>36.07</td><td></td><td>−3.15</td><td>−0.08</td><td>−32.31</td><td>−0.07</td><td>45.21</td><td></td><td>−3.08</td><td>0.09</td><td>−31.64</td><td>0.09</td><td>44.60</td></tr></table> |
052f5788b8f24869a2850e1d6e9fac1d83e6b15612b2103bebe80cdd5cb8a7f4.png | simple | <table><tr><td></td><td>ABFAB</td><td>FBC</td><td>FPH</td><td>Total</td></tr><tr><td>Women who stopped breastfeeding before 6 months</td><td>n = 65</td><td>n = 7</td><td>n = 14</td><td>n = 86</td></tr><tr><td>Stopped bf before mastitis</td><td>5</td><td>1</td><td>2</td><td>8</td></tr><tr><td>Stopped within 3 wks</td><td>29</td><td>2</td><td>5</td><td>36*</td></tr><tr><td>Stopped between 3 and 26 wks</td><td>31</td><td>4</td><td>7</td><td>42</td></tr><tr><td>Women breastfeeding at 6 months</td><td>n = 70</td><td>n = 19</td><td>n = 31</td><td>n = 120</td></tr><tr><td>Mastitis in previous 3 wks</td><td>2</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Mastitis > 3 wks earlier</td><td>68</td><td>19</td><td>31</td><td>118</td></tr><tr><td>Total women with mastitis</td><td></td><td></td><td></td><td>206</td></tr></table> |
3646d7c795e184da4148f18c3ff8046272010a472a993df2af9be8ab292814d3.png | complex | <table><tr><td></td><td>Patients</td><td>Controls</td><td>OR*</td><td>95%CI</td><td>OR**</td><td>95%CI</td></tr><tr><td colspan="7">rs117813469</td></tr><tr><td> GG</td><td>186</td><td>198</td><td></td><td></td><td></td><td></td></tr><tr><td> GC/CC</td><td>28</td><td>15</td><td>2.25</td><td>(1.14-4.46)</td><td>2.12</td><td>(1.09-4.14)</td></tr><tr><td colspan="7">rs130005507</td></tr><tr><td> CC</td><td>160</td><td>158</td><td></td><td></td><td></td><td></td></tr><tr><td> CG/GG</td><td>54</td><td>55</td><td>0.98</td><td>(0.63-1.53)</td><td>0.97</td><td>(0.63-1.5)</td></tr><tr><td colspan="7">rs11305133</td></tr><tr><td> AA</td><td>191</td><td>197</td><td></td><td></td><td></td><td></td></tr><tr><td> AG/GG</td><td>23</td><td>16</td><td>1.67</td><td>(0.84-3.34)</td><td>1.54</td><td>(0.79-3.02)</td></tr><tr><td colspan="7">rs150877473</td></tr><tr><td> CC</td><td>188</td><td>192</td><td></td><td></td><td></td><td></td></tr><tr><td> CG/GG</td><td>26</td><td>21</td><td>1.49</td><td>(0.79-2.81)</td><td>1.34</td><td>(0.72-2.49)</td></tr><tr><td colspan="7">rs188801636</td></tr><tr><td> AA</td><td>190</td><td>191</td><td></td><td></td><td></td><td></td></tr><tr><td> AG/GG</td><td>23</td><td>19</td><td>1.40</td><td>(0.72-2.72)</td><td>1.28</td><td>(0.67-2.45)</td></tr><tr><td colspan="7">rs77111769</td></tr><tr><td> TT</td><td>184</td><td>194</td><td></td><td></td><td></td><td></td></tr><tr><td> TC/CC</td><td>30</td><td>19</td><td>1.82</td><td>(0.98-3.41)</td><td>1.74</td><td>(0.94-3.23)</td></tr><tr><td colspan="7">rs142764723</td></tr><tr><td> TT</td><td>189</td><td>189</td><td></td><td></td><td></td><td></td></tr><tr><td> TC/CC</td><td>25</td><td>24</td><td>2.53</td><td>(1.33-4.82)</td><td>2.32</td><td>(1.24-4.34)</td></tr><tr><td colspan="7">rs149306391</td></tr><tr><td> GG</td><td>188</td><td>193</td><td></td><td></td><td></td><td></td></tr><tr><td> GC/CC</td><td>26</td><td>20</td><td>1.58</td><td>(0.83-3.02)</td><td>1.44</td><td>(0.77-2.71)</td></tr><tr><td colspan="7">rs373417600</td></tr><tr><td> GG</td><td>199</td><td>202</td><td></td><td></td><td></td><td></td></tr><tr><td> GC/CC</td><td>15</td><td>11</td><td>1.58</td><td>(0.69-3.64)</td><td>1.47</td><td>(0.65-3.29)</td></tr></table> |
6a8d2828d9e7d00e12a7059fb53253c67fd2d531c90266b08e00e280dfccae21.png | simple | <table><tr><td></td><td>Pencil</td><td>Oil-pastel</td><td>Gouache</td><td><i>F</i><sup>(2,98)</sup></td></tr><tr><td></td><td>(M/SD)</td><td>(M/SD)</td><td>(M/SD)</td><td></td></tr><tr><td>RSA</td><td>6.23 (± 1.07)</td><td>5.90 (± 0.98)</td><td>6.01 (± 1.09)</td><td>3.58<sup>∗</sup></td></tr><tr><td>ΔRSA</td><td>-0.11 (± 0.57)</td><td>-0.49 (± 0.62)</td><td>-0.33 (± 0.65)</td><td>5.97<sup>∗∗</sup></td></tr><tr><td>CSI</td><td>2.85 (± 0.14)</td><td>3.04 (± 0.13)</td><td>2.83 (± 0.13)</td><td>0.017</td></tr><tr><td>ΔCSI</td><td>-0.29 (± 1.02)</td><td>0.08 (± 1.06)</td><td>-0.15 (± 0.85)</td><td>7.41<sup>∗∗</sup></td></tr></table> |
69035cec5af991caff3f85c0fef1045b3b7e50472b9adffe537ca5f600d11224.png | simple | <table><tr><td>Protein ID</td><td>Orthologs</td><td>Potential functions</td></tr><tr><td>Wolco1| 166770</td><td>STE20</td><td>Growth, virulence, and sclerotial formation</td></tr><tr><td>Wolco1| 43954</td><td>STE11</td><td>Growth, virulence, and sclerotial formation</td></tr><tr><td>Wolco1| 150169</td><td>STE7</td><td>Growth, virulence, and sclerotial formation</td></tr><tr><td>Wolco1| 75024</td><td>MKK2</td><td>Regulate MAPK signaling pathway</td></tr><tr><td>Wolco1| 144702</td><td>PBS2</td><td>Regulate MAPK signaling pathway</td></tr><tr><td>Wolco1| 135363</td><td>BCK1</td><td>Regulate MAPK signaling pathway</td></tr><tr><td>Wolco1| 121529</td><td>CLA4</td><td>Pathogenicity, mycelial growth and conidial morphology</td></tr></table> |
7c9c890d2795eee22c44942bb1d093b7317890e32860b2064085cf37c25ab724.png | simple | <table><tr><td> </td><td>Group A<sup>†</sup>(n = 255)</td><td>Group B<sup>‡</sup>(n = 41)</td><td>p-value</td></tr><tr><td>Mean sUA level (mg/dL)</td><td>4.69 ± 1.08</td><td>7.61 ± 0.95</td><td>< 0.001</td></tr><tr><td>F/U time (months)</td><td>73.0 ± 42.2</td><td>62.0 ± 46.8</td><td>0.134</td></tr><tr><td>Initial eGFR (mL/min/1.73 m<sup>2</sup>)</td><td>82.0 ± 19.6</td><td>52.2 ± 27.4</td><td>< 0.001</td></tr><tr><td>Final eGFR (mL/min/1.73 m<sup>2</sup>)</td><td>75.6 ± 27.9</td><td>48.3 ± 31.7</td><td>< 0.001</td></tr><tr><td>ΔeGFR (mL/min/1.73 m<sup>2</sup>/yr)</td><td>−0.29 ± 4.22</td><td>−1.87 ± 3.30</td><td>0.026</td></tr><tr><td>ΔeGFR (%/yr)</td><td>−0.72 ± 6.03</td><td>−6.23 ± 9.84</td><td>0.001</td></tr><tr><td>ESRD progression, n (%)</td><td>14 (5.4%)</td><td>14 (34.1%)</td><td>< 0.001</td></tr></table> |
8b348ae8b1b777e848c7eb91106ccebfa5cf70a5c9f9e4d55f3d309a420b0056.png | complex | <table><tr><td rowspan="2">HPV type</td><td colspan="2">Baseline (<i>n</i> = 1759)</td><td colspan="2">Follow-up (<i>n</i> = 85)</td></tr><tr><td><i>N</i></td><td>Prevalence (%)</td><td><i>N</i></td><td>Persistence (%)</td></tr><tr><td>Any type</td><td>152</td><td>8.64</td><td>29/85</td><td>34.12</td></tr><tr><td>High-risk</td><td>131</td><td>7.45</td><td>25/73</td><td>34.25</td></tr><tr><td> HPV16</td><td>33</td><td>1.88</td><td>7/17</td><td>41.18</td></tr><tr><td> HPV18</td><td>16</td><td>0.91</td><td>5/8</td><td>62.50</td></tr><tr><td> HPV26</td><td>3</td><td>0.17</td><td>0/0</td><td>-</td></tr><tr><td> HPV31</td><td>5</td><td>0.28</td><td>0/0</td><td>-</td></tr><tr><td> HPV33</td><td>10</td><td>0.57</td><td>1/4</td><td>25.00</td></tr><tr><td> HPV39</td><td>15</td><td>0.85</td><td>1/7</td><td>14.29</td></tr><tr><td> HPV45</td><td>2</td><td>0.11</td><td>0/2</td><td>0.00</td></tr><tr><td> HPV51</td><td>3</td><td>0.17</td><td>1/2</td><td>50.00</td></tr><tr><td> HPV52</td><td>29</td><td>1.65</td><td>2/13</td><td>15.38</td></tr><tr><td> HPV56</td><td>2</td><td>0.11</td><td>1/1</td><td>100.00</td></tr><tr><td> HPV58</td><td>19</td><td>1.08</td><td>7/15</td><td>46.67</td></tr><tr><td> HPV59</td><td>2</td><td>0.11</td><td>2/2</td><td>100.00</td></tr><tr><td> HPV66</td><td>1</td><td>0.06</td><td>0/1</td><td>0.00</td></tr><tr><td> HPV68</td><td>7</td><td>0.40</td><td>0/4</td><td>0.00</td></tr><tr><td>Low-risk</td><td>29</td><td>1.65</td><td>4/16</td><td>25.00</td></tr><tr><td> HPV6</td><td>9</td><td>0.51</td><td>0/6</td><td>0.00</td></tr><tr><td> HPV11</td><td>1</td><td>0.06</td><td>0/0</td><td>-</td></tr><tr><td> HPV40</td><td>1</td><td>0.06</td><td>0/0</td><td>-</td></tr><tr><td> HPV53</td><td>1</td><td>0.06</td><td>0/1</td><td>0.00</td></tr><tr><td> HPV55</td><td>2</td><td>0.11</td><td>0/0</td><td>-</td></tr><tr><td> HPV61</td><td>13</td><td>0.74</td><td>4/8</td><td>50.00</td></tr><tr><td> HPV82</td><td>4</td><td>0.23</td><td>0/1</td><td>0.00</td></tr></table> |
599eccd4e92c96d38a535c3c4542ac9239b49b9345a844f4d30ad261a3207a0e.png | complex | <table><tr><td>Individual subject characteristics</td><td>Prognostic factors</td><td></td></tr><tr><td></td><td>Age</td><td>Confirmatory</td></tr><tr><td></td><td>Gender</td><td>Exploratory</td></tr><tr><td></td><td>Height, weight, body mass index</td><td>Exploratory</td></tr><tr><td></td><td>Ethnicity/race</td><td>Exploratory</td></tr><tr><td colspan="3">Lifestyle factors</td></tr><tr><td></td><td>Participation in sports activities or physical fitness level</td><td>Exploratory</td></tr><tr><td></td><td>Smoking</td><td>Exploratory</td></tr><tr><td></td><td>Alcohol use</td><td>Exploratory</td></tr><tr><td colspan="3">Sociodemographic characteristics</td></tr><tr><td></td><td>Marital status</td><td>Exploratory</td></tr><tr><td></td><td>Level of education</td><td>Exploratory</td></tr><tr><td></td><td>Income</td><td>Exploratory</td></tr><tr><td></td><td>Employment status</td><td>Exploratory</td></tr><tr><td colspan="3">Nature and severity of the low back pain</td></tr><tr><td></td><td>Duration of the low back pain</td><td>Confirmatory</td></tr><tr><td></td><td>Non-specific</td><td>Exploratory</td></tr><tr><td></td><td>Radiation</td><td>Exploratory</td></tr><tr><td></td><td>Previous low back pain treatment received</td><td>Exploratory</td></tr><tr><td colspan="3">Comorbidities, e.g., diabetes, heart disease</td></tr><tr><td rowspan="3"></td><td>Presence of comorbidities</td><td>Exploratory</td></tr><tr><td>Number of comorbidities</td><td>Exploratory</td></tr><tr><td>Category of comorbidities</td><td>Exploratory</td></tr><tr><td> Type of treatment</td><td>Manipulation, mobilization, combination</td><td></td></tr><tr><td> Psychosocial factors</td><td>e.g., Back Depression Inventory, Fear Avoidance Beliefs Questionnaire</td><td>Confirmatory</td></tr><tr><td>Treatment preference/ expectation</td><td>e.g., preference for treatment, previous experience with treatment, expectation to final improvement, self-efficacy scale/beliefs</td><td>Confirmatory</td></tr></table> |
bf79e5230e27ba89b20107a4990b5d1cde206cee0fc7834a6e06362ebb781c03.png | complex | <table><tr><td>Systems</td><td>Plot area (m<sup>2</sup>)</td><td>Gradient (°)</td><td>Aspect</td><td>Agro type (by Chinese system)</td><td>Bulk density (g cm<sup>−3</sup>)</td><td>pH</td><td>OM (g kg<sup>−1</sup>)</td><td>TN (g kg<sup>−1</sup>)</td><td>AN (g kg<sup>−1</sup>)</td><td>TP (g kg<sup>−1</sup>)</td><td>AP (g kg<sup>−1</sup>)</td></tr><tr><td>S1</td><td>56</td><td>6.3</td><td>NE36°</td><td rowspan="3">Purple soil</td><td>1.26</td><td>7.81</td><td>29.12</td><td>1.38</td><td>0.104</td><td>0.78</td><td>0.022</td></tr><tr><td>S2</td><td>54</td><td>4.7</td><td>NE98°</td><td>1.31</td><td>7.78</td><td>25.36</td><td>1.44</td><td>0.118</td><td>0.78</td><td>0.015</td></tr><tr><td>S3</td><td>52</td><td>5.8</td><td>NE60°</td><td>1.48</td><td>6.11</td><td>39.66</td><td>2.44</td><td>0.166</td><td>0.36</td><td>0.001</td></tr></table> |
643298bc18e3a0f00727bd49828afa6697ec7b56576bd71d95b85e0279e1dcac.png | simple | <table><tr><td></td><td>B</td><td>SE</td><td>Significance</td></tr><tr><td>(Constant)</td><td>−0.57</td><td>0.05</td><td></td></tr><tr><td>City of residence</td><td>0.25</td><td>0.06</td><td>0.000*</td></tr><tr><td>Smoker(s) present in the home</td><td>0.12</td><td>0.07</td><td>0.073</td></tr></table> |
58e42727741c5fc90aa109083b40670346939d542eecfeeca1416e21ca6d9deb.png | complex | <table><tr><td rowspan="2">Year</td><td rowspan="2">No. of Samples</td><td rowspan="2">No. of Positive</td><td rowspan="2">Positive Rate (%)</td><td colspan="3">Influenza A Virus</td><td rowspan="2">Influenza B Virus</td></tr><tr><td>H1N1</td><td>H3N2</td><td>pdm H1N1</td></tr><tr><td>2006</td><td>1290</td><td>145</td><td>11.24</td><td>103 (71.03%)</td><td>6 (4.14%)</td><td>0 (0%)</td><td>36 (24.83%)</td></tr><tr><td>2007</td><td>1223</td><td>113</td><td>9.24</td><td>2 (1.77%)</td><td>109 (96.46%)</td><td>0 (0%)</td><td>2 (1.77%)</td></tr><tr><td>2008</td><td>1230</td><td>56</td><td>4.56</td><td>31 (55.36%)</td><td>19 (33.93%)</td><td>0 (0%)</td><td>6 (10.71%)</td></tr><tr><td>2009</td><td>2359</td><td>401</td><td>17.00</td><td>37 (9.23%)</td><td>129 (32.17%)</td><td>209 (52.12%)</td><td>26 (6.48%)</td></tr><tr><td>2010</td><td>1821</td><td>128</td><td>7.03</td><td>0 (0%)</td><td>31 (24.22%)</td><td>49 (38.28%)</td><td>48 (37.50%)</td></tr><tr><td>2011</td><td>864</td><td>26</td><td>3.01</td><td>0 (0%)</td><td>3 (11.54%)</td><td>11 (42.31%)</td><td>12 (46.15%)</td></tr><tr><td>2012</td><td>866</td><td>24</td><td>2.77</td><td>0 (0%)</td><td>6 (25.00%)</td><td>0 (0%)</td><td>18 (75.00%)</td></tr><tr><td>2013</td><td>1658</td><td>69</td><td>4.16</td><td>0 (0%)</td><td>18 (26.09%)</td><td>33 (47.83%)</td><td>18 (26.09%)</td></tr><tr><td>2014</td><td>1983</td><td>186</td><td>9.38</td><td>0 (0%)</td><td>95 (51.08%)</td><td>60 (32.26%)</td><td>31 (16.67%)</td></tr><tr><td>Total</td><td>13,294</td><td>1148</td><td>8.64</td><td>173 (15.07%)</td><td>416 (36.24%)</td><td>362 (31.53%)</td><td>197 (17.16%)</td></tr></table> |
763f28988f8d671b242c1522a410a769bbb86ef50ef4dc9668d33ba12edd7068.png | simple | <table><tr><td></td><td>Total, n= 1781</td><td>Wild-type <i>KRAS</i>, n= 1416</td><td>Mutant <i>KRAS</i>, n= 365</td><td>P</td></tr><tr><td>No. of associated alterations</td><td></td><td></td><td></td><td></td></tr><tr><td> Median (range)</td><td>0 (0-9)</td><td>0(0-9)</td><td>1(1-9)</td><td><0.0001</td></tr><tr><td> >2</td><td>118</td><td>81(6%)</td><td>37 (10%)</td><td>0.0025</td></tr><tr><td>Type of associated alterations</td><td></td><td></td><td></td><td></td></tr><tr><td> PI3KCA</td><td>162/1386 (12%)</td><td>118/1203 (10%)</td><td>44/183 (24%)</td><td><0.0001</td></tr><tr><td> P53</td><td>184/510 (36%)</td><td>155/427 (36%)</td><td>29/83 (35%)</td><td>0.87</td></tr><tr><td> PTEN</td><td>132/1040 (13%)</td><td>111/881 (13%)</td><td>21/159 (13%)</td><td>0.83</td></tr><tr><td> BRAF</td><td>77/1370 (6%)</td><td>76/1139 (7%)</td><td>1/231 (0.4%)</td><td>0.0002</td></tr><tr><td> EGFR</td><td>54/1205 (5%)</td><td>49/1022 (5%)</td><td>5/183 (3%)*</td><td>0.21</td></tr><tr><td> MET</td><td>41/951(4%)</td><td>32/786 (4%)</td><td>9/165 (5.5%)</td><td>0.43</td></tr></table> |
43f85e59472e23bb5bf407049cf64438e3c653957561252e125e645f680f847e.png | complex | <table><tr><td rowspan="2">Tumor Response as per RECIST v1.1</td><td>Arm A, <i>N</i> = 3</td><td>Arm B, <i>N</i> = 5</td></tr><tr><td>Number of patients</td><td>Number of patients</td></tr><tr><td>CR</td><td>0</td><td>0</td></tr><tr><td>PR</td><td>0</td><td>0</td></tr><tr><td>SD</td><td>1</td><td>2</td></tr><tr><td>PD</td><td>2</td><td>3</td></tr></table> |
de0faa79dbcf7e8985d2eee38ded9875d967b30b6eeb05f295f3fbed4817235a.png | simple | <table><tr><td>Number of eligible patients</td><td>420</td><td>Type of procedure</td></tr><tr><td>Primary procedures</td><td>196</td><td>Aesthetic</td></tr><tr><td><i>n</i> = 378</td><td>131</td><td>Aesthetic and functional</td></tr><tr><td></td><td>51</td><td>Functional</td></tr><tr><td>Revision procedures</td><td>31</td><td>Aesthetic</td></tr><tr><td><i>n</i> = 42</td><td>9</td><td>Aesthetic and functional</td></tr><tr><td></td><td>2</td><td>Functional</td></tr></table> |
b794f34c2276014168e3eba3b280481fc01cb399a605d34ae3df9b61fddc5eae.png | complex | <table><tr><td rowspan="2">Incubation medium [Fe] (mM)</td><td colspan="2">Measured MR relaxation times</td><td colspan="2">Cell function assays</td></tr><tr><td><i>T</i><sub>1</sub> (ms)</td><td><i>T</i><sub>2</sub> (ms)</td><td>Viability (%)</td><td>Proliferation (%)</td></tr><tr><td>0</td><td>2166 ± 135</td><td>85.7 ± 9.0</td><td>100 ± 14</td><td>100 ± 18</td></tr><tr><td>0.0036</td><td>1263 ± 193</td><td>16.1 ± 2.6</td><td>96 ± 19</td><td>92 ± 8</td></tr><tr><td>0.009</td><td>828 ± 127</td><td>12.6 ± 0.6</td><td>96 ± 15</td><td>96 ± 19</td></tr><tr><td>0.018</td><td>613 ± 65</td><td>11.3 ± 0.6</td><td>95 ± 13</td><td>89 ± 12</td></tr><tr><td>0.036</td><td>630 ± 60</td><td>10.9 ± 0.5</td><td>86 ± 16</td><td>84 ± 15</td></tr></table> |
e4ea7f48434798783f64766449c6ba70aabe8c613aaf523472d6f66a87e2eb59.png | simple | <table><tr><td></td><td>No.</td><td>%</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> Male</td><td>59</td><td>54.13</td></tr><tr><td> Female</td><td>50</td><td>45.87</td></tr><tr><td>Chemotherapy</td><td></td><td></td></tr><tr><td> Gemcitabine alone</td><td>41</td><td>37.61</td></tr><tr><td> Gemcitabine combined with other drugs*</td><td>68</td><td>62.39</td></tr><tr><td>Primary pancreas tumor</td><td></td><td></td></tr><tr><td> Head</td><td>50</td><td>45.87</td></tr><tr><td> Body or tail</td><td>35</td><td>32.11</td></tr><tr><td> Unknown</td><td>24</td><td>22.02</td></tr><tr><td>Stage of disease</td><td></td><td></td></tr><tr><td> Locally advanced</td><td>10</td><td>9.17</td></tr><tr><td> Metastatic</td><td>70</td><td>64.22</td></tr><tr><td> Unknown</td><td>29</td><td>26.61</td></tr><tr><td>Distant metastasis</td><td></td><td></td></tr><tr><td> Liver</td><td>50</td><td>71.43</td></tr><tr><td> Lung</td><td>2</td><td>2.86</td></tr><tr><td> bone</td><td>4</td><td>5.71</td></tr><tr><td> Abdomen</td><td>5</td><td>7.14</td></tr></table> |
96c58a2e05c0abda624f057eca277c8d1d6dbfdeb61951498067069ae2dbd20e.png | complex | <table><tr><td>Characteristic</td><td></td><td>Number (<i>n</i>)</td><td>Percentage (%)</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>155</td><td>55</td></tr><tr><td>Female</td><td>127</td><td>45</td></tr><tr><td rowspan="2">Gestational age (weeks)</td><td>28–36</td><td>115</td><td>41</td></tr><tr><td>≥37–42</td><td>168</td><td>59</td></tr><tr><td rowspan="5">Postnatal age at measurement</td><td>≤24 h</td><td>9</td><td>3</td></tr><tr><td>2 days</td><td>54</td><td>19</td></tr><tr><td>3 days</td><td>84</td><td>30</td></tr><tr><td>4 days</td><td>73</td><td>25</td></tr><tr><td>5–10 days</td><td>58</td><td>21</td></tr></table> |
03742c6ae71558770725399ebce166fe97a1cc073a8b397847d2ac94b3fefbbf.png | complex | <table><tr><td rowspan="2">Ash sample</td><td colspan="5">Fraction</td><td rowspan="2">Total</td><td rowspan="2">Total independent measurment</td></tr><tr><td>Water soluble</td><td>Acid soluble/exchangeable</td><td>Reducible</td><td>Oxidizable</td><td>Entrapped in parent matter</td></tr><tr><td>A</td><td>0.0008</td><td>0.004</td><td>0.01</td><td>0.201</td><td>0.359</td><td>0.575</td><td>0.499</td></tr><tr><td>B</td><td>0.0007</td><td>0.005</td><td>0.02</td><td>0.159</td><td>0.365</td><td>0.550</td><td>0.520</td></tr><tr><td>C</td><td>0.0016</td><td>0.004</td><td>0.01</td><td>0.146</td><td>0.257</td><td>0.419</td><td>0.441</td></tr><tr><td>D</td><td>0.0016</td><td>0.004</td><td>0.01</td><td>0.187</td><td>0.335</td><td>0.538</td><td>0.442</td></tr><tr><td>Blank</td><td>0.00008</td><td>0.0001</td><td>0.0008</td><td>0.0001</td><td>0.0003</td><td></td><td>0.0014</td></tr><tr><td>Average</td><td>0.0012</td><td>0.004</td><td>0.0125</td><td>0.173</td><td>0.329</td><td>0.520</td><td>0.471</td></tr><tr><td>SD</td><td>0.0004</td><td>0.001</td><td>0.005</td><td>0.025</td><td>0.049</td><td></td><td>0.046</td></tr><tr><td>Percent of Total Tl</td><td>0.23</td><td>0.77</td><td>2.4</td><td>33.27</td><td>63.27</td><td></td><td></td></tr></table> |
6b9b89bdb6892532107600973423ebe4178a13891a8dc77fe4472812e2141a48.png | simple | <table><tr><td>Variable</td><td>Adjusted odds ratio (95% CI)</td><td>SE</td></tr><tr><td>CGPA</td><td>15.27 [6.28, 27.11]<sup><i>∗∗∗</i></sup></td><td>0.88</td></tr><tr><td>Age <30 years</td><td>0.31 [0.06, 1.63]</td><td>0.85</td></tr><tr><td>Male gender</td><td>1.13 [0.50, 2.55]</td><td>0.42</td></tr><tr><td>Home residence (ref = rural)</td><td> </td><td> </td></tr><tr><td> Semiurban</td><td>1.49 [0.41, 5.37]</td><td>0.65</td></tr><tr><td> City/urban</td><td>1.44 [0.38, 5.42]</td><td>0.68</td></tr><tr><td>Father highly educated </td><td>0.56 [0.21, 1.49]</td><td>0.49</td></tr><tr><td>Mother highly education</td><td>1.23 [0.55, 2.76]</td><td>0.41</td></tr><tr><td>Entered nursing with WASSCE </td><td>0.32 [0.04, 2.63]</td><td>1.08</td></tr><tr><td>Nursing was a first career of choice</td><td>0.50 [0.21, 1.19]</td><td>0.45</td></tr><tr><td>Read science in formal school</td><td>1.2 [0.5, 2.6]</td><td>0.40</td></tr></table> |
c82458e7963c5b5e5a5d30b2651fc8dee50b893dc079c05752090ebcb5a05b41.png | simple | <table><tr><td>Gene names</td><td>RS</td><td>Gene names</td><td>RS</td><td>Gene names</td><td>RS</td></tr><tr><td>KRT19</td><td>1.6</td><td>PTGES2</td><td>0.4</td><td>BCL7C</td><td>0.2</td></tr><tr><td>BARD1</td><td>1.6</td><td>PREX2</td><td>0.4</td><td>ZNF18</td><td>0.2</td></tr><tr><td>MST1R</td><td>1.5</td><td>USP1</td><td>0.4</td><td>PGLS</td><td>0.2</td></tr><tr><td>S100A14</td><td>1.2</td><td>EHF</td><td>0.4</td><td>CNTN4</td><td>0.2</td></tr><tr><td>LGALS1</td><td>1.2</td><td>ADM</td><td>0.4</td><td>BACH1</td><td>0.2</td></tr><tr><td>RNF168</td><td>1.1</td><td>GRM4</td><td>0.4</td><td>ZFPL1</td><td>0.2</td></tr><tr><td>TFF1</td><td>1</td><td>SHFM1</td><td>0.4</td><td>MAGED2</td><td>0.1</td></tr><tr><td>SPEN</td><td>1</td><td>EMP3</td><td>0.4</td><td>TMEM43</td><td>0.1</td></tr><tr><td>WDR18</td><td>0.9</td><td>PTGES</td><td>0.3</td><td>GALNT5</td><td>0.1</td></tr><tr><td>RRAS</td><td>0.9</td><td>TRAF1</td><td>0.3</td><td>HMX1</td><td>0.1</td></tr><tr><td>PLEK2</td><td>0.8</td><td>NAMPT</td><td>0.3</td><td>RASSF6</td><td>0.1</td></tr><tr><td>CD248</td><td>0.8</td><td>BCL2L12</td><td>0.3</td><td>PFN1</td><td>0.1</td></tr><tr><td>RHBDL2</td><td>0.8</td><td>MAML1</td><td>0.3</td><td>SLC16A7</td><td>0.1</td></tr><tr><td>CAPN5</td><td>0.7</td><td>USP24</td><td>0.3</td><td>ZBTB40</td><td>0.1</td></tr><tr><td>S100A16</td><td>0.7</td><td>AMHR2</td><td>0.3</td><td>MAGED4</td><td>0.1</td></tr><tr><td>CDC6</td><td>0.6</td><td>PSMG3</td><td>0.3</td><td>PIF1</td><td>0.1</td></tr><tr><td>ENDOG</td><td>0.6</td><td>NFE2L2</td><td>0.3</td><td>MBTPS1</td><td>0.1</td></tr><tr><td>GNG2</td><td>0.6</td><td>RAPH1</td><td>0.3</td><td>HDAC4</td><td>0.1</td></tr><tr><td>CLDN18</td><td>0.6</td><td>TSHZ2</td><td>0.2</td><td>VASN</td><td>0.1</td></tr><tr><td>RNF169</td><td>0.5</td><td>RNF146</td><td>0.2</td><td>PSME3</td><td>0.1</td></tr><tr><td>NR3C1</td><td>0.5</td><td>NFIL3</td><td>0.2</td><td>AMN</td><td>0.1</td></tr><tr><td>TMC8</td><td>0.5</td><td>SPINK1</td><td>0.2</td><td>ERCC1</td><td>0.1</td></tr><tr><td>AKT1S1</td><td>0.5</td><td>OSTM1</td><td>0.2</td><td>BRD9</td><td>0.1</td></tr><tr><td>KLK10</td><td>0.5</td><td>ESRRG</td><td>0.2</td><td>B4GALNT1</td><td>0.1</td></tr><tr><td>SLC2A1</td><td>0.5</td><td>XRCC3</td><td>0.2</td><td>PLEKHG5</td><td>0.1</td></tr><tr><td>ANTXR1</td><td>0.4</td><td>SLC4A7</td><td>0.2</td><td>ARHGAP33</td><td>0.1</td></tr><tr><td>CHSY1</td><td>0.4</td><td>DPH1</td><td>0.2</td><td>CYP24A1</td><td>0.1</td></tr><tr><td>ELAC1</td><td>0.4</td><td></td><td></td><td></td><td></td></tr></table> |
adbb04ef5956e742cab0ffb40adf8c2a71e269bc373ef950751315ba02587913.png | complex | <table><tr><td></td><td colspan="2">SNP-database region</td><td></td><td></td></tr><tr><td>Scan-statistic region</td><td>Inter-gene</td><td>Within-gene</td><td>Regions detected only by scan statistic</td><td>Total no. regions</td></tr><tr><td>Non-gene scan statistic</td><td>33 (8)<sup>a</sup></td><td>0</td><td>72 (12)</td><td>105 (20)</td></tr><tr><td>Gene scan statistic</td><td>10 (7)</td><td>38 (17)</td><td>87 (20)</td><td>135 (44)</td></tr><tr><td>Total</td><td>43 (15)</td><td>38 (17)</td><td>159 (32)</td><td>240 (64)</td></tr></table> |
ebb370375814fc09449cebacbd5fa0242e6084ca67c5f80994b8ef23b0830b53.png | complex | <table><tr><td>Reference</td><td>Country</td><td>Study design</td><td>Sample size</td><td>Data source/sample type</td><td colspan="2">Results</td></tr><tr><td rowspan="3">[30]</td><td rowspan="3">China</td><td rowspan="3">The 5th Chinese National Nutrition and Health Survey (2010–2012)</td><td rowspan="3">2111</td><td rowspan="3">Questionnaire of dietary Mn intake</td><td>Men</td><td>A decreased risk of MetS with higher Mn intake.</td></tr><tr><td>Women</td><td>An increased risk of MetS with higher Mn intake.</td></tr><tr><td>MetS components</td><td>Mn intake was inversely associated with abdominal obesity and hypertriacylglycerolaemia in men, but positively associated with low HDL-cholesterol in both men and women.</td></tr><tr><td rowspan="2">[31]</td><td rowspan="2">Korea</td><td rowspan="2">The Korea National Health and Nutrition Examination Survey (2007–2008)</td><td rowspan="2">5136</td><td rowspan="2">Questionnaire of dietary Mn intake</td><td>Men</td><td>No difference</td></tr><tr><td>Women/MetS components</td><td>The women subjects with high blood pressure showed significantly lower intake of Mn than did control subjects.</td></tr><tr><td rowspan="2">[32]</td><td rowspan="2">China</td><td rowspan="2">Cross-sectional study</td><td rowspan="2">Cases: 221 Controls: 329</td><td rowspan="2">Questionnaire of dietary Mn intake</td><td>Men/women</td><td>A lower risk of developing MetS in the second, third, and highest quintiles of Mn intake with respect to the lowest quintile after adjusting age, sex, and energy intake.</td></tr><tr><td>MetS components</td><td>Daily intake of Mn was decreased with the increasing number of MetS components.</td></tr><tr><td>[5]</td><td>Poland</td><td>Cross-sectional study</td><td>313 (men aged 50–75 years)</td><td>Serum (Mn level)</td><td colspan="2">Significant positive correlations (Mn–BMI, Mn–abdominal circumference, Mn–waist-to-hip ratio, Mn–insulin, Mn–HOMA-IR), but no correlation with MetS.</td></tr><tr><td rowspan="2">[33]</td><td rowspan="2">Korea</td><td rowspan="2">The Korea National Health and Nutrition Examination Survey (2008)</td><td rowspan="2">1405</td><td>Whole blood (Mn level)</td><td colspan="2">No difference</td></tr><tr><td>Urine (Mn level)</td><td colspan="2">No difference</td></tr></table> |
3c950692aabca1421775793445d1b9f1ee1370c495db218d31cc0b239c1c956b.png | simple | <table><tr><td>Theme</td><td>Number of mode-sensitive* items of total number of items</td><td>Median (and maximum)odds ratio among mode-sensitive items</td></tr><tr><td><i>Health behaviour</i></td><td></td><td></td></tr><tr><td>Medicine</td><td>0/3</td><td>-</td></tr><tr><td>Smoking habits</td><td>0/1</td><td>-</td></tr><tr><td><i>Self assessments</i></td><td></td><td></td></tr><tr><td>Self-esteem</td><td>8/9</td><td>1.57 (2.57)</td></tr><tr><td>Well-being</td><td>9/11</td><td>1.55 (2.20)</td></tr><tr><td>Depression</td><td>3/6</td><td>2.12 (2.21)</td></tr><tr><td>Stress</td><td>12/15</td><td>1.67 (2.44)</td></tr></table> |
01ca6ef05de6969f22c167f644c0a988150c11f69cda0378f41cedcb8570a567.png | complex | <table><tr><td></td><td>Total</td><td>No education</td><td>Primary</td><td>Secondary</td><td>Some college or more</td><td>Ratio: No ed vs. Some college or more</td></tr><tr><td colspan="7">Diabetes</td></tr><tr><td> 1998</td><td>3.72 (3.62, 3.83)</td><td>3.88 (3.65,4.12)</td><td>3.99 (3.84,4.14)</td><td>2.81 (2.48,3.13)</td><td>2.86 (2.52,3.20)</td><td>1.30</td></tr><tr><td> 2003</td><td>4.52 (4.41, 4.64)</td><td>5.22 (4.93, 5.51)</td><td>4.70 (4.56, 4.85)</td><td>3.70 (3.43, 3.97)</td><td>3.47 (3.16, 3.79)</td><td>1.30</td></tr><tr><td> 2008</td><td>5.54 (5.43, 5.65)</td><td>6.30 (5.99, 6.60)</td><td>5.93 (5.78. 6.09)</td><td>4.64 (4.40, 4.89)</td><td>4.12 (3.83, 4.40)</td><td>1.34</td></tr><tr><td> 2013</td><td>6.76 (6.39, 7.13)</td><td>8.11 (7.03, 9.19)</td><td>7.70 (7.10, 8.30)</td><td>5.46 (4.71, 6.21)</td><td>4.58 (3.73, 5.42)</td><td>1.48</td></tr><tr><td> overall change</td><td>3.04</td><td>4.23</td><td>3.71</td><td>2.65</td><td>1.72</td><td></td></tr><tr><td colspan="7">Hypertension</td></tr><tr><td> 1998</td><td>19.94 (19.68, 20.20)</td><td>23.97 (23.33, 24.62)</td><td>20.33 (20.03,20.63)</td><td>15.70 (15.08, 16.31)</td><td>13.80 (13.14, 14.46)</td><td>1.44</td></tr><tr><td> 2003</td><td>21.36 (21.12, 21.60)</td><td>25.36 (24.67, 26.04)</td><td>22.57 (22.28, 22.86)</td><td>16.18 (15.67, 16.70)</td><td>15.81 (15.22, 16.39)</td><td>1.35</td></tr><tr><td> 2008</td><td>22.10 (21.88, 22.33)</td><td>26.22 (25.55, 26.89)</td><td>23.73 (23.44, 24.03)</td><td>18.12 (17.71, 18.53)</td><td>16.71 (16.20, 17.22)</td><td>1.32</td></tr><tr><td> 2013</td><td>22.54 (21.93, 23.16)</td><td>25.28 (23.46, 27.10)</td><td>24.96 (23.96, 25.96)</td><td>19.81 (18.57, 21.04)</td><td>19.10 (17.62, 20.58)</td><td>1.18</td></tr><tr><td> overall change</td><td>2.60</td><td>1.31</td><td>4.63</td><td>4.11</td><td>5.30</td><td></td></tr><tr><td colspan="7">Heart problems</td></tr><tr><td> 1998</td><td>6.95 (6.78, 7.11)</td><td>8.26 (7.88,8.63)</td><td>7.07 (6.87,7.27)</td><td>5.60 (5.17,6.04)</td><td>4.24 (3.84,4.65)</td><td>1.64</td></tr><tr><td> 2003</td><td>6.13 (5.99, 6.26)</td><td>7.03 (6.70, 7.36)</td><td>6.50 (6.33, 6.68)</td><td>4.39 (4.10, 4.69)</td><td>4.53 (4.18, 4.89)</td><td>1.35</td></tr><tr><td> 2008</td><td>5.82 (5.70, 5.94)</td><td>6.76 (6.44, 7.09)</td><td>6.26 (6.10, 6.42)</td><td>4.60 (4.36, 4.84)</td><td>4.10 (3.83, 4.38)</td><td>1.42</td></tr><tr><td> 2013</td><td>4.20 (3.87, 4.53)</td><td>4.82 (4.00, 5.63)</td><td>4.70 (4.18, 5.23)</td><td>3.38 (2.71, 4.05)</td><td>3.43 (2.55, 4.31)</td><td>1.22</td></tr><tr><td> overall change</td><td>−2.75</td><td>−3.44</td><td>−2.37</td><td>−2.22</td><td>−0.81</td><td></td></tr></table> |
ed9aeec297a9ef3b747f930b8fe3cfbed7e00e8ca0e3333c6264111908e5d351.png | complex | <table><tr><td> </td><td colspan="4">Risk of bias</td><td colspan="3">Applicability concerns concerns</td></tr><tr><td>First author, year</td><td>Patient selection</td><td>Index test</td><td>Reference standard</td><td>Flow and timing</td><td>Patient selection</td><td>Index test</td><td>Reference standard</td></tr><tr><td>Beldame, 2011 [23]</td><td>?</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Boeree, 1991 [24]</td><td>-</td><td>?</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Decker, 1988 [33]</td><td>?</td><td>+</td><td>?</td><td>-</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Harilainen, 1987 [25]</td><td>+</td><td>?</td><td>?</td><td>-</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Katz, 1986 [26]</td><td>-</td><td>+</td><td>?</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Lee, 1988 [27]</td><td>-</td><td>+</td><td>?</td><td>-</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Lucie, 1984 [28]</td><td>-</td><td>+</td><td>?</td><td>-</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Mulligan, 2011 [29]</td><td>+</td><td>+</td><td>?</td><td>?</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Noyes, 1980 [30]</td><td>-</td><td>?</td><td>+</td><td>-</td><td>?</td><td>+</td><td>+</td></tr><tr><td>Richter, 1996 [34]</td><td>-</td><td>+</td><td>?</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Schwartz, 1997 [35]</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Tonino, 1986 [31]</td><td>-</td><td>+</td><td>?</td><td>?</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Wagemakers, 2010 [19]</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Wong, 1999 [32]</td><td>+</td><td>?</td><td>?</td><td>+</td><td>+</td><td>+</td><td>+</td></tr></table> |
530157c1a3be3e6a31db27e656665615eee0510c2808d205b2d53102651e6ad8.png | complex | <table><tr><td>Tumor stage</td><td><i>N</i></td><td>(%)</td></tr><tr><td>Non-invasive carcinoma</td><td>24</td><td>8.7</td></tr><tr><td colspan="3"><i>Invasive carcinoma</i></td></tr><tr><td>T1</td><td>176</td><td>61.9</td></tr><tr><td>T2</td><td>63</td><td>22.1</td></tr><tr><td>T3</td><td>9</td><td>3.0</td></tr><tr><td>T4</td><td>8</td><td>3.0</td></tr><tr><td>Unknown</td><td>4</td><td>1.3</td></tr><tr><td colspan="3"><i>Nodal status</i></td></tr><tr><td>N0</td><td>187</td><td>65.8</td></tr><tr><td>≥N1</td><td>93</td><td>32.7</td></tr><tr><td>Unknown</td><td>4</td><td>1.5</td></tr><tr><td>Metastases/recurrence</td><td>29</td><td>10.4</td></tr><tr><td colspan="3"><i>Treatment</i></td></tr><tr><td colspan="3"><i>Surgery</i></td></tr><tr><td>BET</td><td>224</td><td>78.9</td></tr><tr><td>Mastectomy</td><td>55</td><td>19.4</td></tr><tr><td>No surgery</td><td>5</td><td>1.7</td></tr><tr><td>SN biopsy</td><td>128</td><td>45.2</td></tr><tr><td>Axillary lymph node dissection</td><td>117</td><td>41.5</td></tr><tr><td colspan="3"><i>Chemotherapy</i></td></tr><tr><td>Neoadjuvant</td><td>24</td><td>8.4</td></tr><tr><td>Adjuvant</td><td>122</td><td>42.8</td></tr><tr><td>Irradiation</td><td>233</td><td>81.9</td></tr><tr><td>Hormonal therapy</td><td>218</td><td>76.9</td></tr><tr><td colspan="3"><i>Relationship</i></td></tr><tr><td>Single</td><td>16</td><td>5.7</td></tr><tr><td>Married/living with partner</td><td>172</td><td>60.5</td></tr><tr><td>Divorced/widowed</td><td>79</td><td>27.8</td></tr><tr><td>Unknown</td><td>17</td><td>6</td></tr><tr><td colspan="3"><i>Education</i></td></tr><tr><td>Compulsory</td><td>121</td><td>42.2</td></tr><tr><td>Post-compulsory</td><td>149</td><td>52.8</td></tr><tr><td>University level</td><td>14</td><td>5.0</td></tr><tr><td colspan="3"><i>Employment</i></td></tr><tr><td>Employed</td><td>77</td><td>27.1</td></tr><tr><td>Retired</td><td>86</td><td>30.3</td></tr><tr><td>Homemaker/unemployed</td><td>88</td><td>31.0</td></tr><tr><td>Unknown</td><td>33</td><td>11.6</td></tr></table> |
2fe866da159656645f1457b16c67b4381ce93a5cb7fde6992901519cacfe9fd4.png | complex | <table><tr><td>Primers</td><td>5′–3′ sequence (bp)</td><td></td></tr><tr><td colspan="3">Primers for 3′-RACE PCR</td></tr><tr><td>Kiss1-F</td><td>CGCCACAAGCGGCCAAGAAG</td><td></td></tr><tr><td>Kiss2-F</td><td>AGGGCCACATTTCCTGCCGACT</td><td></td></tr><tr><td colspan="3">Primers for 5′-RACE PCR</td></tr><tr><td>Kiss1-R</td><td>CCCGCTTCTTGGCCGCTTGT</td><td></td></tr><tr><td>Kiss2-R</td><td>CCGAACGGATTGCGGTTGAATTTG</td><td></td></tr><tr><td colspan="3">Primers for qPCR</td></tr><tr><td><i>Kiss1</i>-F</td><td>GGTCTCTTAGGTACACCCCGT</td><td>This study</td></tr><tr><td><i>Kiss1</i>-R</td><td>ACAGCTCCTCGCTCATTTG</td><td></td></tr><tr><td><i>Kiss2</i>-F</td><td>ACGGACGACTCAGGTTCTCT</td><td>This study</td></tr><tr><td><i>Kiss2</i>-R</td><td>GCCCTCGATTTCACTGTCTT</td><td></td></tr><tr><td><i>actin</i>-F</td><td>AGTATTTGCGCTCGGGTG</td><td>Aroua et al. (27)</td></tr><tr><td><i>actin</i>-R</td><td>CAGCCTTCCTTCCTGGGT</td><td></td></tr><tr><td><i>lhβ</i>-F</td><td>TCACCTCCTTGTTTCTGCTG</td><td>Aroua et al. (27)</td></tr><tr><td><i>lhβ</i>-R</td><td>TAGCTTGGGTCCTTGGTGATG</td><td></td></tr><tr><td><i>fshβ</i>-F</td><td>TCTCGCCAACATCTCCATC</td><td>Aroua et al. (27)</td></tr><tr><td><i>fshβ</i>-R</td><td>AGAATCCTGGGTGAAGCACA</td><td></td></tr><tr><td><i>gnrh-r1a</i>-F</td><td>TGGTCATGAGTTGCTGCTACA</td><td>Penaranda et al. (25)</td></tr><tr><td><i>gnrh-r1a</i>-R</td><td>AGACACCCCTCTCCGTCTTT</td><td></td></tr><tr><td><i>gnrh-r1b</i>-F</td><td>TCGTCACGCTCTACGTTGTC</td><td>Penaranda et al. (25)</td></tr><tr><td><i>gnrh-r1b</i>-R</td><td>AGGCAGGACTCTCCACCTTT</td><td></td></tr><tr><td><i>gnrh-r2</i>-F</td><td>TCACCTTCTCCTGCCTCTTC</td><td>Penaranda et al. (25)</td></tr><tr><td><i>gnrh-r2</i>-R</td><td>TTGGAAGATGCCTTCCCTTT</td><td></td></tr></table> |
edb80137ed988cabeaac52890a9029ba836e734ee694fef764cbcc7d1ec8e3b2.png | simple | <table><tr><td>Accession ID</td><td>Amplicon Size</td><td>Primers used</td></tr><tr><td>α ENaC-wt</td><td>325 bp</td><td>Sense: 5'-TCATGCTGCTACGCCGGTTCC-3'</td></tr><tr><td></td><td></td><td>Antisense:5'-TCCATCAGTTTACAAGGGAG-3'</td></tr><tr><td>α ENaC a</td><td>266 bp</td><td>Sense: 5'-CAGAGCTCCTGGGGGCGCCTT-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-TCCTTCTGTCACGATGGTCA-3'</td></tr><tr><td>α ENaC-b</td><td>278 bp</td><td>Sense: 5'-GGATGATGGTGGCTTCAACT-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-ACACCCAGGAGCTCTGCTTT-3'</td></tr><tr><td>α ENaC-c</td><td>59 bp</td><td>Sense: 5'-GCTCCTGGGTGTGATCAACTA-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3'</td></tr><tr><td></td><td>59 bp</td><td>Sense: 5'-GGATGATGGTGGCTTCAACT-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3'</td></tr><tr><td>α ENaC-d</td><td>99 bp</td><td>Sense: 5'-CCACGCGTCCGAAGAAAC-3'</td></tr><tr><td></td><td></td><td>Antisense:5'-AAAGAAGGTGGTGGGGATGT-3'</td></tr><tr><td></td><td>99 bp</td><td>Sense: 5'-CCACGCGTCCGAAGAAACTG-3'</td></tr><tr><td></td><td></td><td>Antisense:5'-TAAAGAAGGTGGTGGGGATG-5'</td></tr><tr><td>CK479583</td><td>767 bp</td><td>Sense: 5'-GCCCCAGCAGGGCATGACCC-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-CTAGAGTAGCATAGGCAGGT-3'</td></tr><tr><td>CK475461</td><td>814 bp</td><td>Sense: 5'-TCCAAGTATACACAGCAGGT-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-TACAGGAGTCAGGCTGTGAG-3'</td></tr><tr><td>CK364785</td><td>764 bp</td><td>Sense: 5'-GGGGCTATTGCTATTATAAA-3'</td></tr><tr><td></td><td></td><td>Antisense:5'-CCACACAGAGGGCTCGGCGGG-3'</td></tr><tr><td>CK475819</td><td>748 bp</td><td>Sense: 5'-GATTCCCGGGATCTTGGA-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-AGGCTGACCATCGTGACAG-3'</td></tr><tr><td>CB690980</td><td>376 bp</td><td>Sense: 5'-CCACGCGTCCGAAGAAAC-3'</td></tr><tr><td></td><td></td><td>Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3'</td></tr><tr><td>Pgk</td><td>263 bp</td><td>Sense: 5'-GCTGCAGAACTCAAATCTCT-3'</td></tr><tr><td></td><td></td><td>Antisense:5'-TGTGTGCAGTCCCAAAAGCA-3'</td></tr></table> |
e848a99bfd5e6afe3ec9a80aae8a7aadf011d081ea63755825161cd1f7c40fca.png | simple | <table><tr><td>Powders Prepared with Different Process Control Agents</td><td>Crystallite Size (nm)</td><td>Lattice Constant (Å)</td><td>Strain (%)</td></tr><tr><td>None</td><td>11.8</td><td>3.1636</td><td>0.688</td></tr><tr><td>Ethanol</td><td>24.2</td><td>3.1549</td><td>0.483</td></tr><tr><td>Stearic acid</td><td>14.7</td><td>3.1648</td><td>0.590</td></tr></table> |
5ff12fd072b6ba73afdf9c871ff317d28c53fd77b711178c59b12db0230e7915.png | simple | <table><tr><td>Region</td><td>States</td><td>Frequency</td><td>IAQ Practice Indexb</td><td>Schools with index ≥ 70 (%)</td></tr><tr><td>1</td><td>Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont</td><td>25</td><td>71.8</td><td>64</td></tr><tr><td>2</td><td>New Jersey, New York, Puerto Rico,c U.S. Virgin Islandsc</td><td>28</td><td>71.9</td><td>57</td></tr><tr><td>3</td><td>Delaware, Maryland, Pennsylvania, Virginia, West Virginia, District of Columbia</td><td>21</td><td>77.0</td><td>71</td></tr><tr><td>4</td><td>Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee</td><td>46</td><td>64.4</td><td>41</td></tr><tr><td>5</td><td>Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin</td><td>87</td><td>73.0</td><td>60</td></tr><tr><td>6</td><td>Arkansas, Louisiana, New Mexico, Oklahoma, Texas</td><td>40</td><td>70.7</td><td>60</td></tr><tr><td>7</td><td>Iowa, Kansas, Missouri, Nebraska</td><td>15</td><td>66.7</td><td>53</td></tr><tr><td>8</td><td>Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming</td><td>13</td><td>66.3</td><td>54</td></tr><tr><td>9</td><td>Arizona, California, Hawaii, Nevada, Pacific Islands,c Tribal Nations subject to U.S. law</td><td>27</td><td>70.1</td><td>56</td></tr><tr><td>10</td><td>Alaska, Idaho, Oregon, Washington</td><td>16</td><td>77.1</td><td>81</td></tr></table> |
3f20548b64bc1132ce1cb62251541c28fd36b7d6c00c82cc64db87e0f0ca78a4.png | simple | <table><tr><td>Zone</td><td>2008 NBS* Est. U5sfrom 2002 Census</td><td>U5s Registered</td><td>LLINs delivered†</td><td>LLINS issued‡ (%)</td><td>U5s not receiving an LLIN**</td></tr><tr><td>Tanga</td><td>288,185</td><td>N/A††</td><td>402,448</td><td>380,458(94.5)</td><td>0‡‡</td></tr><tr><td>South</td><td>333,571</td><td>403,594</td><td>469,644</td><td>435,112 (92.6)</td><td>3,456</td></tr><tr><td>Lake</td><td>1,457,439</td><td>1,925,372</td><td>2,107,000</td><td>2,047,889 (97.2)</td><td>65,618</td></tr><tr><td>West Lake</td><td>1,609,747</td><td>1,691,854</td><td>1,745,682</td><td>1,662,302 (95.2)</td><td>155,523</td></tr><tr><td>South West</td><td>782,563</td><td>766,291</td><td>793,696</td><td>789,586 (99.4)</td><td>68,859</td></tr><tr><td>Southern Highlands</td><td>464,119</td><td>514,414</td><td>562,112</td><td>554,433 (98.6)</td><td>22,922</td></tr><tr><td>Central</td><td>844,157</td><td>984,985</td><td>1,065,748</td><td>1,052,750 (98.7)</td><td>92,397</td></tr><tr><td>Northern</td><td>476,131</td><td>540,785</td><td>586,720</td><td>567,348 (96.6)</td><td>43,190</td></tr><tr><td>Coast</td><td>966,171</td><td>1,153,715</td><td>1,311,987</td><td>1,263,560 (96.3)</td><td>N/A</td></tr><tr><td>Total</td><td>7,222,083</td><td>7.981,010</td><td>9,045,037</td><td>8,753,438 (96.7)</td><td>451,965</td></tr></table> |
dafd2ca98ad9d1ab89951971db1cf68f8b1fc08271304ef5d003cf8eda53082d.png | complex | <table><tr><td rowspan="2">County</td><td colspan="2">Pre-treatment</td><td colspan="2">Post-treatment</td></tr><tr><td>Number of schools</td><td>Number of children</td><td>Number of schools</td><td>Number of children</td></tr><tr><td>Bomet</td><td>1</td><td>108</td><td>1</td><td>103</td></tr><tr><td>Bungoma</td><td>1</td><td>108</td><td>1</td><td>105</td></tr><tr><td>Busia</td><td>2</td><td>214</td><td>2</td><td>210</td></tr><tr><td>Homa Bay</td><td>1</td><td>108</td><td>1</td><td>102</td></tr><tr><td>Kakamega</td><td>2</td><td>212</td><td>2</td><td>213</td></tr><tr><td>Kisii</td><td>1</td><td>105</td><td>1</td><td>103</td></tr><tr><td>Kisumu</td><td>3</td><td>312</td><td>3</td><td>313</td></tr><tr><td>Kwale</td><td>3</td><td>317</td><td>3</td><td>316</td></tr><tr><td>Mombasa</td><td>1</td><td>98</td><td>1</td><td>108</td></tr><tr><td>Narok</td><td>2</td><td>215</td><td>2</td><td>214</td></tr><tr><td>Taita Taveta</td><td>1</td><td>102</td><td>1</td><td>91</td></tr><tr><td>Overall</td><td>18</td><td>1899</td><td>18</td><td>1878</td></tr></table> |
2c0fdafc31416a8ee903f5d0c1b04ad424096b2f608a00351f985b23effdbdd2.png | simple | <table><tr><td></td><td>Patient 1</td><td>Patient 2</td><td>Patient 3</td></tr><tr><td>Origin</td><td>Dominican Republic</td><td>Haiti</td><td>Haiti</td></tr><tr><td>Age (years)</td><td>25</td><td>52</td><td>41</td></tr><tr><td>Sex (W/M)</td><td>W</td><td>W</td><td>M</td></tr><tr><td>Date of diagnosis (and onset of symptoms)</td><td>December 2014</td><td>January 2015</td><td>December 2014</td></tr><tr><td>Time in Guadeloupe</td><td>1 year</td><td>10 years</td><td>Several years</td></tr><tr><td>Initial symptoms</td><td>Generalized seizure</td><td>Generalized seizure</td><td>Ischemic stroke and tonic-clonic seizures<sup>a</sup></td></tr><tr><td>Number of colloidal cysts</td><td>1</td><td>5</td><td>0</td></tr><tr><td>Number of vesicular cysts</td><td>1</td><td>1</td><td>0</td></tr><tr><td>Number of calcified cerebral cysts</td><td>3</td><td>9</td><td>30</td></tr><tr><td><i>T. solium</i> antibodies in serum (ELISA)</td><td>Negative</td><td>Negative</td><td>Negative</td></tr><tr><td><i>T. solium</i> antibodies in CSF (EITB)</td><td>Negative</td><td>Positive</td><td>Not done</td></tr><tr><td>Screening for taeniasis in index case</td><td>Negative</td><td>Negative</td><td>Negative</td></tr><tr><td>Screening for taeniasis in household</td><td>Negative</td><td>Negative</td><td>Negative</td></tr><tr><td>Treatment</td><td>Albendazole + Steroids + Valproic acid</td><td>Albendazole + Praziquantel + Steroids + Levetiracetam</td><td>Surgical removal<sup>a</sup> + Albendazole + Steroids + Valproic acid</td></tr><tr><td>Seizure recurrence in the first 6 months after treatment</td><td>Several</td><td>Multiple episodes in the first months after tapering steroids</td><td>No recurrence</td></tr></table> |
545f8a9ff482173bc7bd2e568609d807dbdc5b6480bb0d8efa06ec8a539f9dea.png | complex | <table><tr><td>Domain</td><td>APH</td><td>PPH</td><td>Eclampsia</td></tr><tr><td rowspan="3">Initial assessment & diagnosis</td><td rowspan="3">Per vaginum examination (34%)</td><td rowspan="3">Exploring the uterus for blood clots (39%)</td><td>Weight (4%)</td></tr><tr><td>Swelling on body parts related to severe anemia (8%), blurred vision related to night blindness (1%)</td></tr><tr><td>Diagnosed eclampsia as pre eclampsia or pregnancy induced hypertension (26%)</td></tr><tr><td rowspan="8">First line management</td><td rowspan="2">Antibiotic (12%)</td><td>Alternate drugs mentioned:</td><td rowspan="2">Diazepam (5%)</td></tr><tr><td>Ergometrine (34%)</td></tr><tr><td>Iron folic acid (11%)</td><td>Misoprostol (15%)</td><td>Diazepam with MgSO4 (3%)</td></tr><tr><td rowspan="5">Misoprostol and ergometrine (<1%)</td><td>Unindicated drugs mentioned:</td><td>Antibiotics (5%)</td></tr><tr><td>Injection Tranexamic acid (1%),</td><td rowspan="4">Anti hypertensive (6%)</td></tr><tr><td>Antibiotics (21%)</td></tr><tr><td>Ironfolicacid (11%) Calcium and multivitamin (9%)</td></tr><tr><td>Vaginal packing (1%)</td></tr><tr><td>Advice</td><td>Dietary advice and regular ANC (12%)</td><td>Dietary advice and regular ANC (20%)</td><td>Regular ANC (3% )</td></tr><tr><td> </td><td>Perceived APH is caused by sexual activity or lifting weight; hence advised bed rest</td><td>New born care, Early breast feeding</td><td> </td></tr><tr><td> </td><td> </td><td>And Family planning (1%)</td><td> </td></tr></table> |
9f5329f3f783f64f8498a5e85e05656ad98514c0fa33e567ade50b60e871decb.png | simple | <table><tr><td>Pt nr.</td><td>Max IAP</td><td>Macroscopy</td><td>Microscopy</td><td>Outcome</td></tr><tr><td>1</td><td>22</td><td>Autopsy findings: Focal ischemia on serosal and mucosal side of small bowel</td><td>Mucosa of jejunum and colon almost completely disappeared</td><td>Died 2 days after admission to the ICU</td></tr><tr><td>7</td><td>24</td><td>Full necrosis of the sigmoid</td><td>Transmural ischemic necrosis sigmoid</td><td>Died 67 days after decompression due to bleeding complications caused by pancreatitis</td></tr><tr><td>8</td><td>26</td><td>Dubious signs of ischemia of terminal ileum</td><td>Segmental chronic and acute inflammation with perforation; concordant with ischemic enteritis</td><td>Died 40 days after decompression due to sepsis and MOF</td></tr><tr><td>9</td><td>27</td><td>Firm necrosis of the jejunum</td><td>Severe transmural ischemic enteritis</td><td>Discharge to ward 134 days after decompression</td></tr><tr><td>10</td><td>27</td><td>Only necrotic remains of the sigmoid colon</td><td>Transmural necrosis</td><td>Died 13 days after decompression due to sepsis and MOF</td></tr><tr><td>11</td><td>29</td><td>Full black necrosis of small and large intestine</td><td>Not available</td><td>Died several hours after decompression, after withdrawal of treatment</td></tr><tr><td>12</td><td>32</td><td>Marbled aspect of left liver lobe</td><td>Not available</td><td>Died 47 days after decompression, due to sepsis and MOF</td></tr><tr><td>13</td><td>32</td><td>Patchy and full ischemia of the terminal ileum; full ischemia of cecum and left colon</td><td>ischemia ileum, cecum and left colon</td><td>Discharge to ward 16 days after decompression</td></tr></table> |
409e0715612752730dc09a90bec367888cf0b4655b318dfe52f444f4e91f66ac.png | complex | <table><tr><td>Parameters</td><td>Score</td><td> </td></tr><tr><td rowspan="2">Acuteness of the first cry</td><td>Absent</td><td>0</td></tr><tr><td>Present</td><td>2</td></tr><tr><td rowspan="2">Burst rhythmicity</td><td>Absent</td><td>0</td></tr><tr><td>Present</td><td>2</td></tr><tr><td rowspan="3">Constancy of the crying intensity</td><td>Absent</td><td>0</td></tr><tr><td>Intermediate</td><td>1</td></tr><tr><td>Constant</td><td>2</td></tr></table> |
43f7300236f4d82723910113c4fd611177b1eaab613619144b85b581179cda8c.png | simple | <table><tr><td></td><td>Part 1 (<i>n</i> = 104)</td><td>Part 2 (<i>n</i> = 56)</td></tr><tr><td>Breed [number (%) of cats]</td><td></td><td></td></tr><tr><td>Domestic shorthair cat</td><td>85 (81.6)</td><td>46 (82.1)</td></tr><tr><td>Maine coon</td><td>6 (5.7)</td><td>3 (5.4)</td></tr><tr><td>Norwegian</td><td>4 (3.8)</td><td>3 (5.4)</td></tr><tr><td>Oriental</td><td>3 (2.9)</td><td>2 (3.6)</td></tr><tr><td>Chartreux</td><td>2 (2.8)</td><td>1 (1.8)</td></tr><tr><td>Birman</td><td>1 (0.9)</td><td>1 (1.8)</td></tr><tr><td>Siamese</td><td>1 (0.9)</td><td>–</td></tr><tr><td>Turkish Angora Cat</td><td>1 (0.9)</td><td>–</td></tr><tr><td>British Shorthair</td><td>1 (0.9)</td><td>–</td></tr><tr><td>Gender [number (%) of cats]</td><td></td><td></td></tr><tr><td>Sexually intact female</td><td>–</td><td>–</td></tr><tr><td>Spayed female</td><td>40 (38.8)</td><td>21 (37.5)</td></tr><tr><td>Sexually intact male</td><td>4 (3.8)</td><td>4 (7.1)</td></tr><tr><td>Castrated male</td><td>60 (57.6)</td><td>31 (55.4)</td></tr><tr><td>Age (in years)</td><td></td><td></td></tr><tr><td>Mean age ± SD</td><td>7.26 ± 4.0</td><td>7.47 ± 4.3</td></tr><tr><td>Viral status [number (%) of cats]</td><td></td><td></td></tr><tr><td>Tested for feline immunodeficiency virus (FIV)</td><td>89/104 (85.4)</td><td>49/56 (87.5)</td></tr><tr><td> FIV positive</td><td>12/89 (13.5)</td><td>6/49 (12.2)</td></tr><tr><td> Feline leukemia virus positive</td><td>0/89 (0)</td><td>0/49 (0)</td></tr><tr><td>Tested for FHV</td><td>80/104 (76.8)</td><td>43/56 (76.8)</td></tr><tr><td> FHV positive</td><td>14/80 (17.5)</td><td>7/43 (16.3)</td></tr></table> |
db39edbee9c25e77b4f67440a523c3840c8c4958d75c182a4842a7918551f474.png | complex | <table><tr><td rowspan="2">Feeding Practices</td><td colspan="2">Age of Introduction of Complementary Foods</td></tr><tr><td><17 Weeks <i>n</i> (%)</td><td>≥17 Weeks <i>n</i> (%)</td></tr><tr><td>Total</td><td>395 (62.5)</td><td>237 (37.5)</td></tr><tr><td colspan="3">Explanations given for introducing solid foods</td></tr><tr><td> Baby hungry</td><td>203 (51.4)</td><td>118 (49.8)</td></tr><tr><td> Baby old enough</td><td>105 (26.6)</td><td>56 (23.6)</td></tr><tr><td> Poor baby weight gain</td><td>50 (12.7)</td><td>35 (14.8)</td></tr><tr><td> Maternal illness</td><td>23 (5.8)</td><td>22 (9.3)</td></tr><tr><td> Other reason</td><td>14 (3.5)</td><td>6 (2.5)</td></tr><tr><td colspan="3">Type of food infant was initially given:</td></tr><tr><td> Baby cereal</td><td>244 (61.7)</td><td>145 (61.2)</td></tr><tr><td> Pureed or mashed fruit or vegetables</td><td>77 (19.5)</td><td>36 (15.2)</td></tr><tr><td> Pureed or mashed meat or fish</td><td>33 (8.4)</td><td>12 (5.1)</td></tr><tr><td> Baby food manufacturers</td><td>27 (6.8)</td><td>25 (10.5)</td></tr><tr><td> Yoghurt</td><td>5 (1.3)</td><td>11 (4.6)</td></tr><tr><td> Other food type</td><td>9 (2.3)</td><td>8 (3.4)</td></tr><tr><td colspan="3">Was it difficult to introduce solid foods?</td></tr><tr><td> Yes</td><td>298 (75.4)</td><td>115 (48.5)</td></tr><tr><td> No</td><td>97 (24.6)</td><td>122 (51.5)</td></tr><tr><td colspan="3">Explanations given for difficulty in introducing solid foods</td></tr><tr><td> Mother uncertain about weaning</td><td>34 (8.6)</td><td>29 (12.2)</td></tr><tr><td> Infant would only accept certain solids and not others</td><td>145 (36.7)</td><td>112 (47.3)</td></tr><tr><td> Infant preferred drinks to food</td><td>166 (42.0)</td><td>87 (36.7)</td></tr><tr><td> Infant experienced choking or vomiting</td><td>37 (9.3)</td><td>4 (1.7)</td></tr><tr><td> Other reason</td><td>13 (3.4)</td><td>5 (2.1)</td></tr><tr><td colspan="3">Infant took ≥30 min to finish a meal?</td></tr><tr><td> Yes</td><td>144 (36.5)</td><td>56 (23.6)</td></tr><tr><td> No</td><td>251 (63.5)</td><td>181 (76.4)</td></tr><tr><td colspan="3">Meals a day</td></tr><tr><td> 1</td><td>168 (42.5)</td><td>35 (14.8)</td></tr><tr><td> 2</td><td>147 (37.2)</td><td>138 (58.2)</td></tr><tr><td> 3 or more</td><td>80 (20.3)</td><td>64 (27.0)</td></tr><tr><td colspan="3">Was salt added to the infant’s solid food?</td></tr><tr><td> Yes</td><td>123 (31.1)</td><td>143 (60.3)</td></tr><tr><td> No</td><td>272 (68.9)</td><td>94 (39.7)</td></tr><tr><td colspan="3">Was sugar added to the infant’s solid food?</td></tr><tr><td> Yes</td><td>87 (22.0)</td><td>79 (33.3)</td></tr><tr><td> No</td><td>308 (78.0)</td><td>158 (66.7)</td></tr><tr><td colspan="3">Which foods did mothers avoid giving to their infants?</td></tr><tr><td> Any poultry, seafood or other meat</td><td>227 (57.5)</td><td>76 (32.1)</td></tr><tr><td> Eggs or other dairy products</td><td>104 (26.3)</td><td>37 (15.6)</td></tr><tr><td> Vegetables (salad)</td><td>387 (98.0)</td><td>188 (79.3)</td></tr><tr><td> Fruit (fresh)</td><td>338 (85.6)</td><td>201 (84.8)</td></tr><tr><td> Nuts</td><td>395 (100.0)</td><td>237 (100.0)</td></tr><tr><td> Honey</td><td>387 (98.0)</td><td>189 (79.7)</td></tr><tr><td> Processed foods</td><td>312 (79.0)</td><td>175 (73.8)</td></tr><tr><td> Chocolate or other sweets</td><td>277 (70.1)</td><td>107 (45.1)</td></tr><tr><td> High salt content foods</td><td>86 (21.8)</td><td>56 (23.6)</td></tr><tr><td> High sugar content foods</td><td>157 (39.7)</td><td>98 (41.4)</td></tr><tr><td> High fat content foods</td><td>203 (51.4)</td><td>186 (78.5)</td></tr><tr><td> Other foods</td><td>47 (11.9)</td><td>36 (15.2)</td></tr><tr><td colspan="3">Explanations given for not giving particular foods</td></tr><tr><td> The infant dislikes them</td><td>127 (32.2)</td><td>112 (47.3)</td></tr><tr><td> Heath reasons (allergies/adverse reactions)</td><td>91 (23.0)</td><td>23 (9.7)</td></tr><tr><td> Food was not cooked at home</td><td>47 (11.9)</td><td>41 (17.3)</td></tr><tr><td> Concern about choking</td><td>89 (22.5)</td><td>33 (13.9)</td></tr><tr><td> Infant is still too young</td><td>25 (6.3)</td><td>19 (8.0)</td></tr><tr><td> Other reason</td><td>16 (4.1)</td><td>9 (3.8)</td></tr></table> |
5d1e389cec720b66822eb8b0d59a66591621ea377ccded3b72d9792331884b98.png | complex | <table><tr><td> </td><td colspan="2">Right Knee</td><td> </td><td> </td><td colspan="2">Left Knee</td><td> </td><td> </td></tr><tr><td> </td><td>Before</td><td>After</td><td><i>P</i></td><td>Effect size</td><td>Before</td><td>After</td><td><i>P</i></td><td>Effect size</td></tr><tr><td>KIN (n = 16)</td><td>6.9 ± 1.9 (5.0 – 10.0)</td><td>2.3 ± 2.7<sup>a</sup> (0.0 – 8.0)</td><td>0.0001</td><td>0.70</td><td>7.0 ± 2.1 (4.0 – 10.0)</td><td>2.4 ± 2.8<sup>a</sup> (0.0 – 7.0)</td><td>0.0008</td><td>0.68</td></tr><tr><td>TENS (n = 12)</td><td>8.0 ± 1.5 (6.0 – 10.0)</td><td>2.6 ± 2.9<sup>a</sup> (0.0 – 7.5)</td><td>0.0001</td><td>0.76</td><td>5.6 ± 2.7 (0.0 – 10.0)</td><td>2.3 ± 2.5<sup>a</sup> (0.0 – 9.0)</td><td>0.004</td><td>0.53</td></tr><tr><td>US (n = 12)</td><td>6.6 ± 3.0 (0.0 – 10.0)</td><td>4.5 ± 3.7<sup>a</sup> (0.0 – 10.0)</td><td>0.009</td><td>0.41</td><td>7.3 ± 2.3 (4.0 – 10.0)</td><td>3.8 ± 3.1 (0.0 – 7.0)</td><td>0.054</td><td>0.54</td></tr></table> |
79c938375298aa138f1c58fddb5c402dfd06019b15b6fc62a4801bfa52ae2c22.png | simple | <table><tr><td></td><td>Positive keywords</td><td>Negative keywords</td></tr><tr><td>BTE</td><td>mould, be34, map, gp, 92, audio, inf, be52, ref, staff, reqd, be36, contact</td><td>fta, reshel, appt, it, nn, nfa, 2001, rev, lacquer, hn, km, imp, review, 2000</td></tr><tr><td>ITE</td><td>fta, reshel, appt, it, nn, nfa, 2001, rev, lacquer, hn, km, imp, review, 2000, nh, vent, progress, aid, dt, taken</td><td>mould, be34, map, gp, 92, audio, inf, be52, ref, staff, reqd, be36, contact, tri, n, order</td></tr></table> |
681d38e2c308825a62b0b547a3d6e519e686df060c63ebf681d673941d4dc637.png | complex | <table><tr><td colspan="10">A. Regions from first iteration analyses</td></tr><tr><td colspan="3">Degree of damage to each ROI</td><td colspan="3">Analysis with Fuzzy images</td><td colspan="4">Analysis with Binary images</td></tr><tr><td>Group</td><td>Temporal ROI</td><td>Frontal ROI</td><td>n</td><td>Impaired</td><td>Not impaired</td><td colspan="2">n</td><td>Impaired</td><td>Not impaired</td></tr><tr><td>Frontal (1)</td><td>≤ 25%</td><td>≥ 75%</td><td>68</td><td>18</td><td>50</td><td colspan="2">77</td><td>19</td><td>58</td></tr><tr><td>Temporal (2)</td><td>≥ 75%</td><td>≤ 25%</td><td>23</td><td>10</td><td>13</td><td colspan="2">25</td><td>11</td><td>14</td></tr><tr><td>Both (3)</td><td>≥ 75%</td><td>≥ 75%</td><td>71</td><td>48</td><td>23</td><td colspan="2">63</td><td>45</td><td>18</td></tr><tr><td>Partial (4)</td><td>74%−26%</td><td>74%−26%</td><td>70</td><td>13</td><td>57</td><td colspan="2">50</td><td>13</td><td>37</td></tr><tr><td>Neither (5)</td><td>≤ 25%</td><td>≤ 25%</td><td>127</td><td>9</td><td>118</td><td colspan="2">144</td><td>10</td><td>134</td></tr><tr><td colspan="10">B. Regions from second iteration analyses</td></tr><tr><td colspan="3"></td><td colspan="4">Analysis with Fuzzy images</td><td colspan="3">Analysis with Binary images</td></tr><tr><td colspan="3">Degree of damage of Putamen ROI</td><td>n</td><td>Impaired</td><td>Not Impaired</td><td colspan="2">n</td><td>Impaired</td><td>Not Impaired</td></tr><tr><td colspan="3">Putamen damaged (> 25%)</td><td>13</td><td>3</td><td>10</td><td colspan="2">26</td><td>5</td><td>21</td></tr><tr><td colspan="3">Putamen preserved (≤ 25%)</td><td>114</td><td>6</td><td>108</td><td colspan="2">118</td><td>5</td><td>113</td></tr></table> |
2ad758ee4e601bd0d564f58348e4245bd0cbca8c2565c18094b1d46dc0d97098.png | complex | <table><tr><td></td><td>Age</td><td colspan="3">Southern Coastal plain(Yoto)</td><td colspan="3">Central Plateaux(Ogou)</td><td colspan="3">Northern Savannah(Tone)</td></tr><tr><td></td><td>mo</td><td>2004%</td><td>2005%</td><td>RR (95%CI)</td><td>2004%</td><td>2005%</td><td>RR (95%CI)</td><td>2004%</td><td>2005%</td><td>RR (95%CI)</td></tr><tr><td>Hb <8 g/dL</td><td><18</td><td>23.9</td><td>24.3</td><td>1.01 (0.73-1.41)</td><td>35.0</td><td>16.2</td><td>0.46 (0.33-0.64)</td><td>38.8</td><td>31.7</td><td>0.82 (0.65-1.02)</td></tr><tr><td></td><td>≥18</td><td>15.2</td><td>9.4</td><td>0.62 (0.44-0.88)</td><td>17.4</td><td>9.4</td><td>0.54 (0.37-0.79)</td><td>14.5</td><td>15.7</td><td>1.08 (0.78-1.49)</td></tr><tr><td>Malarial anaemia</td><td><18</td><td>15.0</td><td>19.8</td><td>1.31 (0.86-2.01)</td><td>23.2</td><td>8.6</td><td>0.37 (0.24-0.58)</td><td>28.6</td><td>28.9</td><td>1.01 (0.75-1.37)</td></tr><tr><td></td><td>≥18</td><td>10.8</td><td>7.7</td><td>0.71 (0.48-1.05)</td><td>13.6</td><td>7.4</td><td>0.54 (0.33-0.90)</td><td>9.7</td><td>12.8</td><td>1.32 (0.89-1.95)</td></tr><tr><td>Clinical malaria</td><td><18</td><td>5.9</td><td>3.4</td><td>0.59 (0.27-1.27)</td><td>10.0</td><td>3.9</td><td>0.38 (0.19-0.76)</td><td>11.4</td><td>10.4</td><td>0.91 (0.62-1.34)</td></tr><tr><td></td><td>≥18</td><td>9.5</td><td>4.9</td><td>0.51 (0.35-0.75)</td><td>8.9</td><td>7.3</td><td>0.83 (0.54-1.28)</td><td>10.7</td><td>9.4</td><td>0.89 (0.59-1.33)</td></tr><tr><td>Any parasitaemia</td><td><18</td><td>39.6</td><td>50.4</td><td>1.27 (1.02-1.59)</td><td>49.1</td><td>44.1</td><td>0.90 (0.75-1.07)</td><td>39.4</td><td>49.0</td><td>1.24 (1.05-1.47)</td></tr><tr><td></td><td>≥18</td><td>64.1</td><td>71.3</td><td>1.11 (1.00-1.24)</td><td>71.1</td><td>68.1</td><td>0.96 (0.83-1.11)</td><td>70.7</td><td>74.5</td><td>1.05 (0.94-1.19)</td></tr><tr><td>High parasitaemia</td><td><18</td><td>32.2</td><td>24.8</td><td>0.77 (0.48-1.24)</td><td>45.5</td><td>22.2</td><td>0.49 (0.33-0.71)</td><td>43.2</td><td>40.1</td><td>0.93 (0.67-1.28)</td></tr><tr><td></td><td>≥18</td><td>30.4</td><td>26.4</td><td>0.87 (0.68-1.11)</td><td>36.0</td><td>28.0</td><td>0.78 (0.58-1.05)</td><td>31.5</td><td>36.2</td><td>1.15 (0.90-1.47)</td></tr></table> |
df44b013f80e6e277589ff1b0478e3a3d91132aba3d80da85315c04201443f91.png | complex | <table><tr><td></td><td>+</td><td>−</td></tr><tr><td colspan="3">NEURAL ACTIVITY</td></tr><tr><td>Spontaneous activity</td><td></td><td></td></tr><tr><td> Electro-physiology</td><td>Basta and Ernst (90), Jastreboff and Sasaki (87), and Manabe et al. (91)</td><td>Ma et al. (92)</td></tr><tr><td> Metabolicmarkers</td><td>Paul et al. (93)</td><td>Wallhausser-Franke et al. (94)</td></tr><tr><td>Burst firing</td><td>Chen and Jastreboff (88)</td><td></td></tr><tr><td>Auditory-evoked activity</td><td>Ma et al. (92) and Sun et al. (95)</td><td></td></tr><tr><td colspan="3">NEUROTRANSMISSION</td></tr><tr><td>Excitation</td></tr><tr><td> NMDA</td><td>Hu et al. (96) and Hwang et al. (97, 98)</td><td></td></tr><tr><td>Inhibition</td></tr><tr><td> GABA<sub>A</sub></td><td>Bauer et al. (99) (GABA<sub>A</sub> affinity)</td><td>Bauer et al. (99) (GABA<sub>A</sub> binding sites) and Zou and Shang (100)</td></tr><tr><td> GAD<sub>65</sub></td><td>Bauer et al. (99)</td><td></td></tr><tr><td> GAD<sub>67</sub></td><td></td><td>Zou and Shang (100)</td></tr><tr><td> GlyR</td><td></td><td>Lu et al. (102)</td></tr><tr><td> Serotonin</td><td>Liu et al. (101)</td><td>Wang et al. (103)</td></tr><tr><td colspan="3">GENE EXPRESSION</td></tr><tr><td> Arg3.1/arc</td><td></td><td>Hu et al. (96)</td></tr><tr><td> Egr-1</td><td></td><td>Hu et al. (96)</td></tr><tr><td> c-FOS</td><td>Wu et al. (104)</td><td>Mahlke and Wallhausser-Franke (105)</td></tr><tr><td colspan="3">INFLAMMATORY MARKERS</td></tr><tr><td> COX-2</td><td></td><td>Hwang et al. (97)</td></tr><tr><td> IL1β</td><td>Hwang et al. (98, 106)</td><td></td></tr><tr><td> TNFα</td><td>Hwang et al. (98, 106)</td><td></td></tr></table> |
b0bf5328cb063cfee409037e3fb9d9dde8c0aee4ff87f0c2d4ff688cab9fcf32.png | complex | <table><tr><td></td><td>Baseline</td><td colspan="2">HD</td><td colspan="2">H60</td><td colspan="2">S60</td></tr><tr><td></td><td></td><td>PEG-albumin</td><td>HES</td><td>PEG-albumin</td><td>HES</td><td>PEG-albumin</td><td>HES</td></tr><tr><td>Hematocrit (%)</td><td>46.4 ± 1.4</td><td>26.4 ± 0.9*<sup>b</sup></td><td>31.6 ± 1.1*</td><td>18.2 ± 0.4*<sup>†</sup></td><td>-</td><td>18.1 ± 0.5*<sup>†</sup></td><td>-</td></tr><tr><td>PaO<sub>2 </sub>(mmHg)</td><td>58.9 ± 8.7</td><td>59.5 ± 11.3<sup>b</sup></td><td>69.6 ± 7.0</td><td>100.0 ± 12.8*<sup>†</sup></td><td>-</td><td>121.0 ± 14.3*<sup>†‡</sup></td><td>-</td></tr><tr><td>PaCO<sub>2 </sub>(mmHg)</td><td>59.1 ± 10.1</td><td>59.7 ± 5.0</td><td>51.1 ± 5.3</td><td>45.3 ± 12.9</td><td>-</td><td>36.1 ± 8.1*<sup>†</sup></td><td>-</td></tr><tr><td>pH arterial</td><td>7.388 ± 0.030</td><td>7.387 ± 0.036</td><td>7.349 ± 0.025</td><td>7.251 ± 0.076*<sup>†</sup></td><td>-</td><td>7.109 ± 0.047*<sup>†‡</sup></td><td>-</td></tr><tr><td>BE (mmol/l)</td><td>5.5 ± 1.9</td><td>5.3 ± 2.3</td><td>1.8 ± 1.8*</td><td>-8.2 ± 2.8*<sup>†</sup></td><td>-</td><td>-18.0 ± 4.7*<sup>†</sup></td><td>-</td></tr></table> |
632719cc3d1a359e36170b4615329293200f40f91f48d96a914bc56cb693c9b7.png | simple | <table><tr><td></td><td>N = 134</td><td>(%)</td></tr><tr><td>Food reactions</td><td></td><td></td></tr><tr><td>Gastro-intestinal symptoms</td><td>67</td><td>(50)</td></tr><tr><td>OAS – Oral Allergy Syndrome</td><td>63</td><td>(47)</td></tr><tr><td>Difficulty breathing</td><td>53</td><td>(40)</td></tr><tr><td>Skin symptoms</td><td>50</td><td>(37)</td></tr><tr><td>Anaphylaxis</td><td>20</td><td>(15)</td></tr><tr><td>Eye-nose symptoms</td><td>19</td><td>(14)</td></tr><tr><td>Food reactions during the last 12 months</td><td>60</td><td>(45)</td></tr><tr><td>Allergic diseases</td><td>100</td><td>(75)</td></tr><tr><td>Rhino conjunctivitis</td><td>69</td><td>(52)</td></tr><tr><td>Eczema</td><td>64</td><td>(48)</td></tr><tr><td>Asthma</td><td>44</td><td>(33)</td></tr><tr><td>Additional allergy/hypersensitivity</td><td>95</td><td>(71)</td></tr><tr><td>Additional family member with food hypersensitivity</td><td>78</td><td>(58)</td></tr><tr><td>Parent(s)</td><td>49</td><td>(37)</td></tr><tr><td>Sibling(s)</td><td>45</td><td>(34)</td></tr></table> |
11bf9951ed5e1a7f6942e1921fc6304550ebb03f5086c42e30b0ec6e602e9ebf.png | complex | <table><tr><td></td><td></td><td>Cases (%)</td><td>Controls (%)</td></tr><tr><td colspan="4">Gender</td></tr><tr><td></td><td>Male</td><td>463 (58%)</td><td>423 (53%)</td></tr><tr><td></td><td>Female</td><td>334 (42%)</td><td>370 (47%)</td></tr><tr><td colspan="4">Age group (years)</td></tr><tr><td></td><td>20-49</td><td>150 (19%)</td><td>208 (26%)</td></tr><tr><td></td><td>50-59</td><td>194 (24%)</td><td>169 (21%)</td></tr><tr><td></td><td>60-69</td><td>214 (27%)</td><td>206 (26%)</td></tr><tr><td></td><td>70+</td><td>239 (30%)</td><td>210 (26%)</td></tr><tr><td colspan="4">Ethnicity</td></tr><tr><td></td><td>Caucasian</td><td>625 (78%)</td><td>613 (77%)</td></tr><tr><td></td><td>Asian</td><td>80 (10%)</td><td>90 (11%)</td></tr><tr><td></td><td>South Asian</td><td>29 (4%)</td><td>37 (5%)</td></tr><tr><td></td><td>Mixed/Other</td><td>36 (5%)</td><td>34 (4%)</td></tr><tr><td></td><td>Unknown/Refused</td><td>27 (3%)</td><td>19 (2%)</td></tr><tr><td colspan="4">Pathology</td></tr><tr><td colspan="4"> B-cell lymphomas</td></tr><tr><td></td><td>DLBCL</td><td>210 (26%)</td><td>-</td></tr><tr><td></td><td>FL1</td><td>138 (17%)</td><td>-</td></tr><tr><td></td><td>FL2/FL3</td><td>78 (10%)</td><td>-</td></tr><tr><td></td><td>MZL/MALT</td><td>92 (12%)</td><td>-</td></tr><tr><td></td><td>MCL</td><td>47 (6%)</td><td>-</td></tr><tr><td></td><td>SLL/CLL</td><td>43 (5%)</td><td>-</td></tr><tr><td></td><td>LPL</td><td>42 (5%)</td><td>-</td></tr><tr><td></td><td>MISC BCL</td><td>71 (9%)</td><td>-</td></tr><tr><td colspan="4"> T-cell lymphomas</td></tr><tr><td></td><td>MF</td><td>40 (5%)</td><td>-</td></tr><tr><td></td><td>PTCL</td><td>29 (4%)</td><td>-</td></tr><tr><td></td><td>MISC TCL</td><td>7 (1%)</td><td>-</td></tr><tr><td>Total</td><td></td><td>797 (100%)</td><td>793 (100%)</td></tr></table> |
6632dbe11832ab2bfb7f71c6f502a2b7c01efcf59e4c8bc368fd70b34022545f.png | complex | <table><tr><td></td><td>Number of airlines</td></tr><tr><td colspan="2">Pre-boarding arrangements</td></tr><tr><td>• Request a food “buffer zone”</td><td>5</td></tr><tr><td>• No “buffer zone”</td><td>3</td></tr><tr><td>• Request “allergen-free meal”</td><td>1</td></tr><tr><td rowspan="2">• Pre-boarding to wipe down seats and table trays</td><td>Yes 4</td></tr><tr><td>No 1</td></tr><tr><td>• Buffer zone for fragrance sensitivity</td><td>2</td></tr><tr><td rowspan="2">• Announcements to inform customers there is a peanut or tree-nut allergic passenger on board or that peanut products will not be served</td><td>Yes 4</td></tr><tr><td>No 7</td></tr><tr><td colspan="2">Free snack policy on peanut/nut/sesame</td></tr><tr><td rowspan="2">• Serving peanuts</td><td>Yes 2</td></tr><tr><td>No 11</td></tr><tr><td rowspan="2">• Serving nuts and sesameaw</td><td>Yes 8</td></tr><tr><td>No 1</td></tr><tr><td>• First class warmed nuts</td><td>3</td></tr><tr><td rowspan="2">Gluten-free meals</td><td>Yes 11</td></tr><tr><td>No 1</td></tr><tr><td>Lactose-free meals</td><td>1</td></tr><tr><td rowspan="2">Shellfish served</td><td>Yes 4</td></tr><tr><td>No 3</td></tr><tr><td rowspan="2">Fish served</td><td>Yes 6</td></tr><tr><td>No 1</td></tr><tr><td>Buffer zones for passengers allergic to pets</td><td>5</td></tr></table> |
f2f0112bcad693a028c723e4f298815614bd21d6c0ee02112455b220fd390312.png | complex | <table><tr><td>Risk category</td><td>Criteria</td><td>Age to commence screening</td><td>Screening Test</td><td>Screening frequency (years)</td></tr><tr><td rowspan="3">Average-risk(Age-only)</td><td rowspan="3">Age 50–74 years</td><td rowspan="3">50</td><td>FOBT</td><td>2</td></tr><tr><td>Sigmoidoscopy</td><td>5</td></tr><tr><td>Colonoscopy</td><td>10</td></tr><tr><td rowspan="3">Moderate-risk(FamilyHx)</td><td rowspan="3">Family history of CRC in 1 first-degree relative ≥60 years</td><td rowspan="3">40</td><td>FOBT</td><td>2</td></tr><tr><td>Sigmoidoscopy</td><td>5</td></tr><tr><td>Colonoscopy</td><td>10</td></tr><tr><td rowspan="2"></td><td>Family history of CRC in 1 first-degree relative < 60 years</td><td rowspan="2">40<sup>b</sup></td><td rowspan="2">Colonoscopy</td><td rowspan="2">5</td></tr><tr><td>Family history of CRC in 2 or more relatives</td></tr><tr><td>High-risk (PersonalHx)</td><td>Personal history of a bowel condition<sup>c</sup></td><td rowspan="2">40<sup>d</sup></td><td rowspan="2">Colonoscopy</td><td rowspan="2">5</td></tr><tr><td>Highest-risk (Family/PersonalHx)</td><td>Personal history of a bowel condition and family history of CRC</td></tr></table> |
11514fae5f9423d893e803a6cf7a0eafbce74345556a552f492cca2c181a8aa0.png | complex | <table><tr><td>Targeted Gene</td><td>Primer</td><td>Sequence (5′–3′)</td></tr><tr><td rowspan="2">ALDOA</td><td>Forward</td><td>ATGCCCTACCAATATCCAGC</td></tr><tr><td>Reverse</td><td>GACAGCCCATCCAACCCT</td></tr><tr><td rowspan="2">CDC20</td><td>Forward</td><td>GGCACCAGTGATCGACACATTCGCAT</td></tr><tr><td>Reverse</td><td>GCCATAGCCTCAGGGTCTCATCTGCT</td></tr><tr><td rowspan="2">CCNB2</td><td>Forward</td><td>GCGTTGGCATTATGGATCG</td></tr><tr><td>Reverse</td><td>TCTTCCGGGAAACTGGCTG</td></tr><tr><td rowspan="2">CDC45</td><td>Forward</td><td>TGGACTGCACACGGATCT</td></tr><tr><td>Reverse</td><td>AACCTGGCTGCGGTATAG</td></tr><tr><td rowspan="2">TK1</td><td>Forward</td><td>TGGCTGTCATAGGCATCGAC</td></tr><tr><td>Reverse</td><td>CCAGTGCAGCCACAATTACG</td></tr><tr><td rowspan="2">β-Actin</td><td>Forward</td><td>AGCGAGCATCCCCCAAAGTT</td></tr><tr><td>Reverse</td><td>GGGCACGAAGGCTCATCATT</td></tr></table> |
a270f231ac307b3e481e762cbd4de0bcc73ec2472e01530dbbbbdfd21a4f2a72.png | simple | <table><tr><td>Resistance pattern to the NARMS antimicrobial panel</td><td>% of isolates with resistance profile (no.)</td><td>Plasmid profile groups detected (no.)<sup>a</sup></td><td>Species of isolates with plasmids (no.)</td><td>PFGE patterns</td></tr><tr><td>STR, FIS, TET, SXT</td><td>33% (14)</td><td>II, X(3), VIII</td><td><i>S. sonnei </i>(4), S. <i>flexneri</i></td><td>III, V, VI, IX, X</td></tr><tr><td>AMP, STR, FIS, TET, SXT</td><td>14% (6)</td><td>II(4), VI</td><td><i>S. sonnei </i>(5)</td><td>I, IV, VII, VIII, XI, XII</td></tr><tr><td>AMP, CHL, STR, FIS, TET</td><td>10% (4)</td><td>none</td><td>none</td><td></td></tr><tr><td>AMP, CHL, TET</td><td>7% (3)</td><td>VII</td><td><i>S. flexneri </i>3a</td><td>XX, XXIII, XV</td></tr><tr><td>AMP, CHL, STR, FIS, TET, SXT</td><td>7% (3)</td><td>IV(2), V</td><td><i>S. flexneri </i>3a (2), <i>S. sonnei</i></td><td></td></tr><tr><td>TET</td><td>5% (2)</td><td>I, IV</td><td><i>S. flexneri </i>1b (2)</td><td>XIX</td></tr><tr><td>AMP, CHL, FIS, TET</td><td>5% (2)</td><td>IV(2)</td><td><i>S. flexneri </i>2a (2)</td><td>XVII</td></tr><tr><td>CHL, STR, FIS, TET, SXT</td><td>5% (2)</td><td>V(2)</td><td><i>S. flexneri </i>1c (2)</td><td>XV</td></tr><tr><td>AMP, CHL, FIS, TET, SXT</td><td>2% (1)</td><td>IV</td><td><i>S. flexneri </i>2a</td><td>XVIII</td></tr><tr><td>AMP, KAN, STR, FIS</td><td>2% (1)</td><td>IV</td><td><i>S. sonnei</i></td><td>XIII</td></tr><tr><td>CHL, FIS, TET, SXT</td><td>2% (1)</td><td>III</td><td><i>S. flexneri </i>Y var.</td><td>XXIV</td></tr><tr><td>AMP, CHL, STR, TET</td><td>2% (1)</td><td>IX</td><td><i>S. flexneri </i>1b</td><td>XIV</td></tr><tr><td>AMP, STR, FIS, SXT</td><td>2% (1)</td><td>IX</td><td><i>S. sonnei</i></td><td></td></tr><tr><td>AMC, AMP, GEN, STR, FIS</td><td>2% (1)</td><td>IV</td><td><i>S. flexneri</i></td><td></td></tr></table> |
7c76b8a59b7a860439ce9a9521cbba8fa3d773cdb5f545d589e99629573744b7.png | complex | <table><tr><td rowspan="3"></td><td colspan="5">Disability in 2012 (%)</td></tr><tr><td rowspan="2">All <i>n</i> (%)</td><td colspan="2">No FOF in 2012</td><td colspan="2">Having FOF in 2012</td></tr><tr><td>No FOF in 2010</td><td>Having FOF in 2010</td><td>No FOF in 2010</td><td>Having FOF in 2010</td></tr><tr><td>Prevalence of Disability in 2012<sup>††</sup></td><td>21.2</td><td>7.1</td><td>21.1</td><td>24.7</td><td>49.0</td></tr><tr><td>Age group</td><td></td><td>**</td><td>*</td><td>**</td><td>**</td></tr><tr><td>70–74</td><td>7.6</td><td>2.9</td><td>8.6</td><td>8.9</td><td>28.9</td></tr><tr><td>75–79</td><td>18.3</td><td>6.9</td><td>27.8</td><td>23.4</td><td>38.4</td></tr><tr><td>80–84</td><td>32.9</td><td>14.3</td><td>19.1</td><td>36.2</td><td>53.8</td></tr><tr><td>85 and over</td><td>56.0</td><td>30.0</td><td>42.9</td><td>58.6</td><td>73.1</td></tr><tr><td>Marital status and living arrangement</td><td>**</td><td>*</td><td>*</td><td></td><td>**</td></tr><tr><td>No spouse & Living alone</td><td>17.1</td><td>4.8</td><td>9.2</td><td>26.1</td><td>37.5</td></tr><tr><td>No spouse & living with others</td><td>35.1</td><td>13.6</td><td>37.7</td><td>33.9</td><td>63.0</td></tr><tr><td>Living with spouse only</td><td>14.0</td><td>4.3</td><td>18.8</td><td>16.7</td><td>42.5</td></tr><tr><td>Living with spouse & others</td><td>16.2</td><td>7.5</td><td>16.0</td><td>17.4</td><td>46.2</td></tr><tr><td>Education</td><td>**</td><td></td><td></td><td></td><td></td></tr><tr><td>Elementary school or less</td><td>22.8</td><td>7.8</td><td>21.7</td><td>25.9</td><td>50.5</td></tr><tr><td>Middle school</td><td>11.1</td><td>3.1</td><td>22.2</td><td>20.0</td><td>28.6</td></tr><tr><td>High school or more</td><td>8.5</td><td>3.8</td><td>0</td><td>9.1</td><td>33.3</td></tr><tr><td>Having disability in 2010 <sup>††</sup></td><td>**</td><td>**</td><td>**</td><td>**</td><td>**</td></tr><tr><td>No</td><td>11.4</td><td>4.6</td><td>13.1</td><td>15.2</td><td>28.4</td></tr><tr><td>Yes</td><td>64.4</td><td>33.8</td><td>47.8</td><td>74.4</td><td>81.3</td></tr><tr><td>Having fall history in 2010</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>20.4</td><td>6.9</td><td>20.1</td><td>25.0</td><td>49.2</td></tr><tr><td>Yes</td><td>38.0</td><td>22.2</td><td>33.3</td><td>14.3</td><td>47.5</td></tr><tr><td>Number of chronic disease in 2010</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>None</td><td>21.2</td><td>6.9</td><td>22.0</td><td>26.7</td><td>50.9</td></tr><tr><td>One or more</td><td>21.2</td><td>8.6</td><td>16.1</td><td>17.3</td><td>41.9</td></tr><tr><td>Cognitive function in 2010 <sup>††</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Normal (K-MMSE ≥ 24)</td><td>9.4 **</td><td>6.2</td><td>2.9</td><td>9.6</td><td>32.1</td></tr><tr><td>Mild impairment (18 ≤ K-MMSE ≤ 23)</td><td>15.4</td><td>4.3</td><td>13.8</td><td>20.8</td><td>36.5</td></tr><tr><td>Severe impairment (K-MMSE ≤ 17)</td><td>38.1</td><td>12.5</td><td>35.7</td><td>44.6</td><td>61.8</td></tr><tr><td>Visual function in 2010 <sup>†</sup></td><td>**</td><td></td><td></td><td>*</td><td></td></tr><tr><td>Good</td><td>16.7</td><td>7.2</td><td>16.2</td><td>17.4</td><td>49.4</td></tr><tr><td>Bad</td><td>28.1</td><td>6.9</td><td>26.0</td><td>35.4</td><td>48.7</td></tr><tr><td>Auditory function in 2010</td><td></td><td>*</td><td></td><td></td><td>**</td></tr><tr><td>Good</td><td>17.4</td><td>6.2</td><td>17.9</td><td>21.8</td><td>43.4</td></tr><tr><td>Bad</td><td>43.4</td><td>18.5</td><td>32.6</td><td>39.0</td><td>65.6</td></tr><tr><td>Fear-induce activity avoidance <sup>††</sup></td><td>**</td><td></td><td></td><td>*</td><td>*</td></tr><tr><td>No</td><td>11.3</td><td>6.5</td><td>19.6</td><td>13.0</td><td>34.8</td></tr><tr><td>Yes</td><td>34.1</td><td>9.4</td><td>25.0</td><td>29.3</td><td>52.4</td></tr><tr><td>Frequency of meeting friends</td><td>**</td><td></td><td>*</td><td>*</td><td>**</td></tr><tr><td>Less than several times a year or none</td><td>41.4</td><td>13.0</td><td>36.4</td><td>40.5</td><td>66.3</td></tr><tr><td>Once or twice a month</td><td>21.2</td><td>6.7</td><td>15.8</td><td>39.1</td><td>57.6</td></tr><tr><td>Everyday</td><td>16.5</td><td>6.4</td><td>16.9</td><td>19.1</td><td>40.3</td></tr><tr><td>Depressive symptoms <sup>††</sup></td><td>**</td><td></td><td>*</td><td>*</td><td>**</td></tr><tr><td>No</td><td>12.6</td><td>6.2</td><td>14.7</td><td>15.9</td><td>33.3</td></tr><tr><td>Yes (CES-D10 score ≥ 10)</td><td>34.6</td><td>9.7</td><td>30.1</td><td>34.2</td><td>59.6</td></tr></table> |
b03c671653f44c48a83b4e8791e5c4e90016519c5ac2f0417420bf69e511bbaf.png | complex | <table><tr><td></td><td colspan="2">Putative fox feces</td><td colspan="2">Locations</td></tr><tr><td></td><td>Number of samples</td><td>Positive samples (%)</td><td>Number of locations</td><td>Positive locations (%)</td></tr><tr><td>Anatolia</td><td>186</td><td>7 (3.8)</td><td>59</td><td>3 (5.1)</td></tr><tr><td>Thrace</td><td>219</td><td>1 (0.5)</td><td>114</td><td>1 (0.9)</td></tr><tr><td>Total</td><td>405</td><td>8 (1.9)</td><td>173</td><td>4 (2.3)</td></tr></table> |
ef90399023416d0219564f3273e662220ccb1d94fd7f309022532ee0de951e7e.png | complex | <table><tr><td>Characteristics</td><td>No. of patients</td><td colspan="2">Expression of CIP2A</td><td><i>P</i>value</td></tr><tr><td> </td><td> </td><td>Low, n (%)</td><td>High, n (%)</td><td> </td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≤45</td><td>130</td><td>48 (50)</td><td>82 (45)</td><td>0.39</td></tr><tr><td>>45</td><td>150</td><td>48 (50)</td><td>102 (55)</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>208</td><td>72 (75)</td><td>136 (74)</td><td>0.84</td></tr><tr><td>Female</td><td>72</td><td>24 (25)</td><td>48 (26)</td><td> </td></tr><tr><td>WHO type</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>I + II</td><td>10</td><td>2 (2)</td><td>8 (6)</td><td>0.50</td></tr><tr><td>III</td><td>270</td><td>94 (98)</td><td>176 (94)</td><td> </td></tr><tr><td>VCA-IgA</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>< 1:80</td><td>41</td><td>16 (17)</td><td>25 (14)</td><td>0.49</td></tr><tr><td>≥ 1:80</td><td>239</td><td>80 (83)</td><td>159 (86)</td><td> </td></tr><tr><td>EA-IgA</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>< 1:10</td><td>68</td><td>24 (25)</td><td>44 (24)</td><td>0.84</td></tr><tr><td>≥ 1:10</td><td>212</td><td>72 (75)</td><td>140 (76)</td><td> </td></tr><tr><td>T Stage</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>T1-T2</td><td>137</td><td>55 (57)</td><td>82 (45)</td><td>0.04</td></tr><tr><td>T3-T4</td><td>143</td><td>41 (43)</td><td>102 (55)</td><td> </td></tr><tr><td>N Stage</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>N0-N1</td><td>173</td><td>61 (64)</td><td>112 (61)</td><td>0.66</td></tr><tr><td>N2-N3</td><td>107</td><td>35 (36)</td><td>72 (39)</td><td> </td></tr><tr><td>TNM Stage</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>I-II</td><td>86</td><td>40 (42)</td><td>46 (25)</td><td><0.01</td></tr><tr><td>III-IV</td><td>194</td><td>56 (58)</td><td>138 (75)</td><td> </td></tr><tr><td>Locoregional failure</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>38</td><td>11 (11)</td><td>27 (15)</td><td>0.46</td></tr><tr><td>No</td><td>242</td><td>85 (89)</td><td>157 (85)</td><td> </td></tr><tr><td>Distant metastasis</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>63</td><td>11 (11)</td><td>52 (28)</td><td><0.01</td></tr><tr><td>No</td><td>217</td><td>85 (89)</td><td>132 (72)</td><td> </td></tr><tr><td>Death</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>67</td><td>14 (15)</td><td>53 (29)</td><td>0.01</td></tr><tr><td>No</td><td>213</td><td>82 (85)</td><td>131 (71)</td><td> </td></tr></table> |
0065bcbd987c65f4941e449b9083469577f34870a6b3f8839911bb1c97eabce7.png | complex | <table><tr><td></td><td>Early differentiation</td><td>Intermediate differentiation</td><td>Terminal differentiation</td></tr><tr><td colspan="4">Phenotypic markers</td></tr><tr><td>CD28</td><td>++</td><td>+/−</td><td>–</td></tr><tr><td>CD27</td><td>++</td><td>+/−</td><td>–</td></tr><tr><td>CD45RA</td><td>++</td><td>+/−</td><td>+/−</td></tr><tr><td>CCR7</td><td>++</td><td>+</td><td>–</td></tr><tr><td>CD62L</td><td>++</td><td>+</td><td>–</td></tr><tr><td>CD57</td><td>–</td><td>+/−</td><td>++</td></tr><tr><td>KLRG1</td><td>–</td><td>+/−</td><td>++</td></tr><tr><td>Other NKR (KIR, NKG2, and CD56)</td><td>–</td><td>+/−</td><td>++</td></tr><tr><td colspan="4">Functional features</td></tr><tr><td>Proliferation</td><td>++</td><td>+</td><td>–</td></tr><tr><td>Telomerase activity</td><td>++</td><td>+</td><td>–</td></tr><tr><td>Telomeres</td><td>+++</td><td>++</td><td>+</td></tr><tr><td>Cytotoxicity</td><td>–</td><td>+</td><td>++</td></tr><tr><td>Cytokine secretion (TNF-α, IFN-γ)</td><td>–</td><td>+</td><td>++</td></tr><tr><td colspan="4">Signaling pathways</td></tr><tr><td>TCR signaling</td><td>+</td><td>++</td><td>+/−</td></tr><tr><td>IL-2 signaling</td><td>+</td><td>++</td><td>+/−</td></tr><tr><td>Pi3K–AKT–mTOR signaling</td><td>+</td><td>++</td><td>+/−</td></tr><tr><td>p38MAPK activation</td><td>–</td><td>–</td><td>+</td></tr></table> |
4f32026ce8c83dab76977e207c1724e23b8c1663d4f2469139d4b7ba4bc8f61b.png | complex | <table><tr><td>Amendment</td><td>Concentration</td><td>m<sub>N</sub><sup>a</sup></td><td>Effectiveness</td></tr><tr><td rowspan="3">Aldrich Humic Acid</td><td>1 mg C L<sup>-1</sup></td><td>0.7(0)</td><td>LS</td></tr><tr><td>5 mg C L<sup>-1</sup></td><td>0.3(6)</td><td>LS</td></tr><tr><td>10 mg C L<sup>-1</sup></td><td>0.3(7)</td><td>LS</td></tr><tr><td rowspan="3">IHSS Humic Acid</td><td>1 mg C L<sup>-1</sup></td><td>0.8(4)</td><td>LS</td></tr><tr><td>5 mg C L<sup>-1</sup></td><td>0.1(7)</td><td>LS</td></tr><tr><td>10 mg C L<sup>-1</sup></td><td>0.1(9)</td><td>LS</td></tr><tr><td rowspan="3">IHSS Fulvic Acid</td><td>1 mg C L<sup>-1</sup></td><td>0.7(7)</td><td>LS</td></tr><tr><td>5 mg C L<sup>-1</sup></td><td>0.1(9)</td><td>LS</td></tr><tr><td>10 mg C L<sup>-1</sup></td><td>0.1(7)</td><td>LS</td></tr><tr><td>MCC water</td><td>∼ 5 mg C L<sup>-1</sup>*</td><td><0.1</td><td>NR</td></tr><tr><td>SR lake water</td><td>∼ 10 mg C L<sup>-1</sup>*</td><td>0.8(6)</td><td>LS</td></tr></table> |
95598a4906a9f2c28b112b5dc5e76dbaacc3482b41f077e1ab5c1bb3baa54f89.png | complex | <table><tr><td>Variable</td><td>HBV</td><td>%</td><td><i>Odds ratio</i></td><td><i>p</i></td></tr><tr><td>Year</td><td>Positive/Total</td><td> </td><td>(95% CI)</td><td> </td></tr><tr><td>2001*</td><td>52/552</td><td>9.42</td><td rowspan="2">3.31 (2.40-4.57)</td><td rowspan="2">< 0.01</td></tr><tr><td>2010</td><td>269/8,840</td><td>3.04</td></tr></table> |
dc5f675f4652ba6ae5481e47b21a80c122a7fdb6148f8729afb7260178fba33c.png | simple | <table><tr><td>Chromosome</td><td>AntiSMASH</td><td>SMURF</td><td>Unique NP</td></tr><tr><td>I</td><td>1</td><td>1</td><td>1</td></tr><tr><td>II</td><td>3</td><td>1</td><td>4</td></tr><tr><td>III</td><td>4</td><td>4</td><td>5</td></tr><tr><td>IV</td><td>3</td><td>1</td><td>4</td></tr><tr><td>V</td><td>6</td><td>6</td><td>7</td></tr><tr><td>VI</td><td>8</td><td>6</td><td>8</td></tr><tr><td>VII</td><td>7</td><td>6</td><td>7</td></tr><tr><td>Total</td><td>32</td><td>25</td><td>36</td></tr></table> |
8732a491314a5b2c62f2b500a195bcbc0d6fe51f048273e065e58829c489ca92.png | complex | <table><tr><td></td><td>n (%)</td></tr><tr><td colspan="2">Primary clinical composite diagnoses</td></tr><tr><td> Anterior cruciate ligament injury</td><td>8 (5)</td></tr><tr><td> Meniscal injury</td><td>36 (20)</td></tr><tr><td> Patellofemoral Pain Syndrome</td><td>45 (25)</td></tr><tr><td> Osteoarthritis</td><td>79 (44)</td></tr><tr><td> Other knee diagnoses</td><td>11 (6)</td></tr><tr><td colspan="2">Imaging findings and diagnoses</td></tr><tr><td> Osteoarthritis</td><td>96 (56)</td></tr><tr><td>K-L Grade 1</td><td>14 (15)</td></tr><tr><td>K-L Grade 2</td><td>36 (38)</td></tr><tr><td>K-L Grade 3</td><td>19 (20)</td></tr><tr><td>K-L Grade 4</td><td>13 (14)</td></tr><tr><td> Meniscal tears (n)</td><td>54 (32)</td></tr><tr><td>Medial meniscus</td><td>49 (91)</td></tr><tr><td>Lateral meniscus</td><td>8 (15)</td></tr><tr><td> Anterior cruciate ligament tears</td><td>16 (9)</td></tr><tr><td>Complete</td><td>6 (37)</td></tr><tr><td>Partial</td><td>8 (50)</td></tr><tr><td>Unclear</td><td>2 (13)</td></tr><tr><td> Posterior cruciate ligament tear</td><td>1 (1)</td></tr><tr><td> Soleus tear</td><td>1 (1)</td></tr><tr><td> Hamstring tendinopathy</td><td>2 (1)</td></tr><tr><td> Medial collateral ligament tear</td><td>1 (1)</td></tr></table> |
e5c92916e322f51d50e3ee07a141fd653d793e92a556cf59be026ed562606f01.png | simple | <table><tr><td></td><td>0d</td><td>3d</td><td>6d</td><td>9d</td><td>12d</td><td>15d</td><td>18d</td><td>21d</td><td>24d</td><td>27d</td><td>30d</td><td>33d</td><td>36d</td><td>39d</td><td>42d</td><td>45d</td><td>48d</td><td>51d</td><td>54d</td><td>57d</td><td>60d</td><td>63d</td><td>≥ 66d</td></tr><tr><td># of CTGR-SPs</td><td>214</td><td>211</td><td>221</td><td>194</td><td>154</td><td>135</td><td>131</td><td>127</td><td>125</td><td>128</td><td>125</td><td>127</td><td>136</td><td>157</td><td>157</td><td>163</td><td>163</td><td>163</td><td>163</td><td>187</td><td>190</td><td>198</td><td>217</td></tr><tr><td># of longest CTGR-SPs</td><td>28</td><td>25</td><td>25</td><td>82</td><td>37</td><td>17</td><td>17</td><td>14</td><td>10</td><td>13</td><td>13</td><td>7</td><td>10</td><td>157</td><td>157</td><td>163</td><td>163</td><td>163</td><td>163</td><td>187</td><td>190</td><td>198</td><td>217</td></tr><tr><td>Maximal length of CTGR-SPs</td><td>4</td><td>4</td><td>4</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>2</td><td>2</td><td>2</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td># of genes in CTGR-SPs</td><td>136</td><td>134</td><td>136</td><td>134</td><td>127</td><td>124</td><td>123</td><td>121</td><td>120</td><td>121</td><td>119</td><td>121</td><td>125</td><td>132</td><td>132</td><td>132</td><td>132</td><td>132</td><td>132</td><td>136</td><td>136</td><td>136</td><td>136</td></tr><tr><td># of genes in longest CTGR-SPs</td><td>3</td><td>3</td><td>3</td><td>15</td><td>10</td><td>9</td><td>9</td><td>9</td><td>7</td><td>8</td><td>5</td><td>5</td><td>4</td><td>7</td><td>7</td><td>7</td><td>7</td><td>7</td><td>7</td><td>7</td><td>7</td><td>7</td><td>7</td></tr><tr><td># of gene pairs in lonest CTGR-SPs</td><td>21</td><td>19</td><td>19</td><td>59</td><td>26</td><td>16</td><td>16</td><td>14</td><td>10</td><td>12</td><td>10</td><td>10</td><td>12</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>-Log(p-value)<sup>††</sup></td><td>1.26</td><td>1.37</td><td>1.37</td><td>0.70</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.86</td><td>0.86</td><td>0.65</td><td>0.53</td><td>0.40</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> |
6924d401fd0b856d3b289ec313931fbf18aba667109ab648748c653444575e97.png | complex | <table><tr><td rowspan="3">Part of Intestine</td><td colspan="2">Control group</td><td colspan="2">Pomegranate treated group</td><td colspan="2">Sodium.butyrate treated group</td></tr><tr><td>Non-everted (μg)</td><td>Everted (μg)</td><td>Non-everted (μg)</td><td>Everted (μg)</td><td>Non-everted (μg)</td><td>Everted (μg)</td></tr><tr><td>Duodenum</td><td>12.4±0.14</td><td>13.1±0.2</td><td>7.07± 1.0</td><td>12.29±0 .7</td><td>11.9±1.0 †</td><td>15.5±0.3</td></tr><tr><td>Jejunum</td><td>13.3±0.66</td><td>15.2±0.2</td><td>8.96±0 .32</td><td>11.87±0.3</td><td>13.4±0 .4†</td><td>14.3±0.3</td></tr><tr><td>Ileum</td><td>9.97±0.77</td><td>17.1±0.3</td><td>7.97±0.05</td><td>14.82 ±0.4</td><td>10.3±0.8</td><td>16.8±0.8†</td></tr><tr><td>Colon</td><td>9.57±0.48</td><td>14.0±0.2</td><td>6.85±0.7</td><td>9.89±0.1</td><td>9.7±1.2†</td><td>14.5±0.3†</td></tr></table> |
a309c6393b5461670b9ec048aa56a98d53815eb0322080d5df2287b6280252e7.png | simple | <table><tr><td></td><td>Discharged</td><td>Expired</td></tr><tr><td></td><td>32</td><td>18</td></tr><tr><td>Tracheostomy</td><td>26.5</td><td>23.5</td></tr><tr><td></td><td>1.141</td><td>1.30</td></tr><tr><td></td><td>21</td><td>29</td></tr><tr><td>Non Tracheostomy</td><td>26.5</td><td>23.5</td></tr><tr><td></td><td>1.141</td><td>1.30</td></tr></table> |
6f6adfe73321e5611bfa59a161cb2012a61f77c5576d7196431723a739c49a34.png | simple | <table><tr><td> </td><td>BRCA1</td><td>BRCA2</td><td>Non-BRCA1/2</td></tr><tr><td>All males in kConFab registry</td><td>429</td><td>339</td><td>19137</td></tr><tr><td>Breast Cancers</td><td>5 (1.2%)</td><td>35 (10.3%)</td><td>78 (0.4%)</td></tr><tr><td>Pathology Available</td><td>3</td><td>25</td><td>32</td></tr></table> |
2464281b7e42f8d8c51dcb219b3896d4f3f43b65f3da349a9e6c734c7d9a1f24.png | simple | <table><tr><td>Patients with HPA</td><td>Gender</td><td>Age</td><td>Mechanism of trauma</td><td>Liver injury grade*</td><td>Symptoms of HPA</td><td>Blood transfusion</td></tr><tr><td>1</td><td>Female</td><td>25</td><td>Blunt</td><td>2</td><td>No</td><td>No</td></tr><tr><td>2</td><td>Male</td><td>20</td><td>Blunt</td><td>2</td><td>Yes</td><td>Yes</td></tr><tr><td>3</td><td>Male</td><td>45</td><td>Blunt</td><td>2</td><td>No</td><td>No</td></tr><tr><td>4</td><td>Male</td><td>9</td><td>Blunt</td><td>3</td><td>No</td><td>No</td></tr><tr><td>5</td><td>Male</td><td>30</td><td>Blunt</td><td>3</td><td>Yes</td><td>Yes</td></tr><tr><td>6</td><td>Female</td><td>42</td><td>Blunt</td><td>4</td><td>No</td><td>No</td></tr><tr><td>7</td><td>Male</td><td>42</td><td>Blunt</td><td>4</td><td>No</td><td>No</td></tr></table> |
0cd07bfd47076ea2d32ce6e52a11eba8e6155b4c2743aa9aad0f840ba470b286.png | simple | <table><tr><td>Age groups of Males/females </td><td>Quantity of interviewees</td></tr><tr><td>50-60 (10 males)</td><td>10</td></tr><tr><td>63-69 (20 males/5 females)</td><td>25</td></tr><tr><td>70-75 (10 male hakims/7 females)</td><td>17</td></tr><tr><td>75-80 (8 female)</td><td>8</td></tr></table> |
da1454e4a51c2473b02bc0994f853e83fda54124b2f2a6b0fa59377c1236bfc7.png | simple | <table><tr><td>Gene <sup>a</sup></td><td>Region</td><td>Size</td><td>Inc <sup>b</sup></td><td>AT%</td><td>AT-Skew <sup>c</sup></td><td>GC-Skew</td><td>Start Codon</td><td>Stop Codon</td><td>Anticodon</td></tr><tr><td><i>cox1</i></td><td>1–1539</td><td>1539</td><td>1</td><td>64.39</td><td>−0.322</td><td>0.263</td><td>ATG</td><td>TAA</td><td>-</td></tr><tr><td><i>trnL<sub>2</sub></i></td><td>1542–1606</td><td>65</td><td>2</td><td>70.77</td><td>−0.087</td><td>0.474</td><td>-</td><td>-</td><td>TAA</td></tr><tr><td><i>cox2</i></td><td>1607–2270</td><td>664</td><td>0</td><td>68.67</td><td>−0.197</td><td>0.202</td><td>ATT</td><td>T- <sup>e</sup></td><td>-</td></tr><tr><td><i>trnK</i></td><td>2271–2340</td><td>70</td><td>0</td><td>71.43</td><td>0.000</td><td>−0.100</td><td>-</td><td>-</td><td>CTT</td></tr><tr><td><i>trnD</i></td><td>2347–2408</td><td>62</td><td>6</td><td>66.13</td><td>−0.171</td><td>0.333</td><td>-</td><td>-</td><td>GTC</td></tr><tr><td><i>atp8</i></td><td>2418–2564</td><td>147</td><td>9</td><td>62.59</td><td>−0.217</td><td>0.273</td><td>ATA</td><td>TAA</td><td>-</td></tr><tr><td><i>atp6</i></td><td>2558–3208</td><td>651</td><td>−7</td><td>71.27</td><td>−0.388</td><td>0.241</td><td>ATT</td><td>TAG</td><td>-</td></tr><tr><td><i>trnE</i></td><td>3233–3293</td><td>61</td><td>24</td><td>72.13</td><td>0.000</td><td>0.059</td><td>-</td><td>-</td><td>TTC</td></tr><tr><td><i>trnF</i></td><td>3301–3363</td><td>63</td><td>7</td><td>76.19</td><td>0.292</td><td>0.067</td><td>-</td><td>-</td><td>GAA</td></tr><tr><td><i>nad5</i></td><td>3364–5023</td><td>1660</td><td>0</td><td>73.13</td><td>0.137</td><td>−0.166</td><td>ATA</td><td>T-</td><td>-</td></tr><tr><td><i>trnH</i></td><td>5024–5084</td><td>61</td><td>0</td><td>81.97</td><td>0.040</td><td>0.455 </td><td>-</td><td>-</td><td>GTG</td></tr><tr><td><i>nad4</i></td><td>5086–6366</td><td>1281</td><td>1</td><td>69.95</td><td>−0.007</td><td>−0.179</td><td>ATA</td><td>TAG</td><td>-</td></tr><tr><td><i>nad4L</i></td><td>6363–6659</td><td>297</td><td>−4</td><td>76.77</td><td>−0.018</td><td>−0.246</td><td>ATG</td><td>TAA</td><td>-</td></tr><tr><td><i>trnT</i></td><td>6661–6724</td><td>64</td><td>1</td><td>76.56</td><td>−0.102</td><td>0.333</td><td>-</td><td>-</td><td>TGT</td></tr><tr><td><i>trnP</i></td><td>6723–6784</td><td>62</td><td>−2</td><td>72.58</td><td>0.111</td><td>−0.059</td><td>-</td><td>-</td><td>TGG</td></tr><tr><td><i>nad6</i></td><td>6816–7250</td><td>435</td><td>31</td><td>70.57</td><td>−0.270</td><td>0.328</td><td>ATA</td><td>TAA</td><td>-</td></tr><tr><td><i>cob</i></td><td>7250–8383</td><td>1134</td><td>−1</td><td>64.90</td><td>−0.351</td><td>0.186</td><td>ATG</td><td>TAA</td><td>-</td></tr><tr><td><i>trnS<sub>2</sub></i></td><td>8384–8439</td><td>56</td><td>0</td><td>80.36</td><td>−0.067</td><td>0.273</td><td>-</td><td>-</td><td>TGA</td></tr><tr><td><i>nad1</i></td><td>8450–9359</td><td>910</td><td>10</td><td>72.86</td><td>0.005</td><td>−0.198</td><td>ATT</td><td>T-</td><td>-</td></tr><tr><td><i>trnL<sub>1</sub></i></td><td>9360–9422</td><td>63</td><td>0</td><td>84.13</td><td>0.132</td><td>0.200</td><td>-</td><td>-</td><td>TAG</td></tr><tr><td><i>rrnL</i></td><td>9423–10612</td><td>1190</td><td>0</td><td>77.23</td><td>0.134</td><td>−0.055</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>rrnS</i></td><td>10707–11435</td><td>729</td><td>94</td><td>75.99</td><td>0.022</td><td>0.074</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>trnN</i></td><td>11483–11548</td><td>66</td><td>47</td><td>78.79</td><td>0.115</td><td>0.143</td><td>-</td><td>-</td><td>ATT</td></tr><tr><td><i>trnQ</i></td><td>11553–11623</td><td>71</td><td>4</td><td>87.32</td><td>0.000</td><td>−0.111</td><td>-</td><td>-</td><td>TTG</td></tr><tr><td><i>trnV</i></td><td>11617–11680</td><td>64</td><td>−7</td><td>73.44</td><td>−0.021</td><td>0.059</td><td>-</td><td>-</td><td>TAC</td></tr><tr><td><i>trnR</i></td><td>11678–11742</td><td>65</td><td>−3</td><td>73.85</td><td>−0.042</td><td>0.059</td><td>-</td><td>-</td><td>TCG</td></tr><tr><td><i>trnA</i></td><td>11744–11805</td><td>62</td><td>1</td><td>75.81</td><td>−0.021</td><td>0.200</td><td>-</td><td>-</td><td>TGC</td></tr><tr><td><i>nad3</i></td><td>11806–12159</td><td>354</td><td>0</td><td>72.60</td><td>−0.276</td><td>0.052</td><td>ATT</td><td>TAA</td><td>-</td></tr><tr><td><i>trnG</i></td><td>12161–12222</td><td>63</td><td>1</td><td>82.54</td><td>−0.038</td><td>0.273</td><td>-</td><td>-</td><td>TCC</td></tr><tr><td><i>cox3</i></td><td>12223–13009</td><td>786</td><td>0</td><td>66.92</td><td>−0.198</td><td>0.115</td><td>ATG</td><td>TAA</td><td>-</td></tr><tr><td><i>trnS<sub>1</sub></i></td><td>13025–13086</td><td>62</td><td>15</td><td>61.29</td><td>−0.263</td><td>0.083</td><td>-</td><td>-</td><td>TCT</td></tr><tr><td>CR <sup>d</sup></td><td>13087–13961</td><td>875</td><td>0</td><td>66.86</td><td>−0.050</td><td>0.117</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>trnM</i></td><td>13962–14028</td><td>67</td><td>0</td><td>77.61</td><td>0.077</td><td>−0.067</td><td>-</td><td>-</td><td>CAT</td></tr><tr><td><i>nad2</i></td><td>14029–15003</td><td>975</td><td>0</td><td>68.72</td><td>−0.287</td><td>0.279</td><td>ATA</td><td>TAA</td><td>-</td></tr><tr><td><i>trnW</i></td><td>15002–15064</td><td>63</td><td>−2</td><td>82.54</td><td>0.077</td><td>0.091</td><td>-</td><td>-</td><td>TCA</td></tr><tr><td><i>trnY</i></td><td>15063–15124</td><td>60</td><td>−2</td><td>86.67</td><td>0.154</td><td>0.500</td><td>-</td><td>-</td><td>GTA</td></tr><tr><td><i>trnC</i></td><td>15125–15187</td><td>63</td><td>0</td><td>92.06</td><td>0.138</td><td>0.200</td><td>-</td><td>-</td><td>GCA</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.